Difference between revisions of "HAEM5:Volunteer Assignments and Opportunities"

From Compendium of Cancer Genome Aberrations
Jump to navigation Jump to search
VisualWikitext
[unchecked revision][checked revision]
 
(182 intermediate revisions by 7 users not shown)
Line 1: Line 1:
−
{| class="wikitable" style="margin:auto"
+
Welcome!
−
|+WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues (4th Edition) Content
+
 
 +
'''A new version of the Heme/Lymphoid book (5th edition) is in beta form on the WHO website with publication of a final form anticipated in 2024; we're aligning the related CCGA content to the new structure.'''
 +
 
 +
*For assignments, please see the "Author" column below (highlighted blue).
 +
 
 +
*If empty (no name is present), please volunteer to create content for that disease!
 +
*If "PENDING" is present, the original author of that disease page is currently being contacted about revising the content.
 +
 
 +
*To volunteer, please '''[[Mailto:CCGA@cancergenomics.org <u>Contact us</u>]]''' with your page of interest.
 +
*Note - "NEW (No Prior)" in the 4th edition columns means either the disease is a new entity in the 5th edition or the disease was present in the 4th edition without content previously added.
 +
 
 +
__TOC__
 +
 
 +
<br />
 +
{| class="wikitable sortable" style="margin:auto"
 +
|+<big>WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues (5th Edition) Content</big>
 +
|-
 +
!Disease (5th Edition)!!Page Type!!<span style="color:#0070C0">Author (5th Edition) (Note: please indicate trainees in parentheses)!!Date Assigned to Author (5th Edition)
 +
!Target Completion Date (5th Edition)!!Content Status (5th Edition)(Pending or Complete)!!Date Completed by Author (5th Edition)!!Associate Editor!!Date of Last Editor Review (5th Edition)!!Notes (5th Edition)
 +
!Correlated Prior Disease Name (4th Edition)
 +
!Correlated Prior Author (4th Edition)
 +
!Prior Content Status (4th Edition)(Pending or Complete)
 +
!Prior Date of Last Editor Review (4th Edition)
 +
!Prior Notes (4th Edition)
 
|-
 
|-
−
!Disease (5th Edition)!!Page Type!!Author!!Date Assigned to Author!!Target Completion Date!!Author Content (Pending or Complete)!!Date Completed by Author!!Associate Editor!!Date of Last Editor Review
+
|
−
!Correlated Prior Disease Name (4th Edition)!!Notes
+
====CHAPTER 2 (MYELOID PROLIFERATIONS AND NEOPLASMS)====
 +
|
 +
----<br />
 +
|
 +
----<br />
 +
|
 +
----<br />
 +
|
 +
----<br />
 +
|
 +
----<br />
 +
|
 +
----<br />
 +
|
 +
----<br />
 +
|
 +
----<br />
 +
|
 +
----<br />
 +
|
 +
----<br />
 +
|
 +
----<br />
 +
|
 +
----<br />
 +
|
 +
----<br />
 +
|
 +
----<br />
 +
|-
 +
|[[HAEM5:Clonal haematopoiesis|Clonal haematopoiesis]]||Disease||Meenakshi Mehrotra
 +
|4/8/24
 +
| ||Pending|| ||Fabiola Quintero-Rivera (FQR)|| ||
 +
|NEW (No Prior)
 +
|NEW (No Prior)
 +
|NEW (No Prior)
 +
|NEW (No Prior)
 +
|NEW (No Prior)
 +
|-
 +
|[[HAEM5:Clonal cytopenias of undetermined significance|Clonal cytopenias of undetermined significance]]||Disease|| || || || || ||FQR|| ||
 +
|NEW (No Prior)
 +
|NEW (No Prior)
 +
|NEW (No Prior)
 +
|NEW (No Prior)
 +
|NEW (No Prior)
 +
|-
 +
|[[HAEM5:Chronic myeloid leukaemia|Chronic myeloid leukaemia]]||Disease||PENDING|| || || || ||FQR|| ||
 +
|Chronic Myeloid Leukemia (CML), BCR-ABL1 Positive
 +
|Jack Reid, MD (University of California, Irvine)  Mark Evans, MD (University of California, Irvine)  Fabiola Quintero-Rivera, MD (University of California, Irvine)
 +
|Complete
 +
|Date page was created
 +
|
 +
|-
 +
|[[HAEM5:Chronic neutrophilic leukaemia|Chronic neutrophilic leukaemia]]||Disease||PENDING
 +
| || || || ||FQR|| ||
 +
|Chronic Neutrophilic Leukemia (CNL)
 +
|Anamaria Munteanu, MD, Ph.D**, Harbor-UCLA Medical Center, Joseph J. Merlo Jr, MD. Ph.D**, Ashion Analytics, Fabiola Quintero-Rivera, University of California Irvine  <nowiki>**</nowiki>contributed equally
 +
|Complete
 +
|Date page was created
 +
|
 +
|-
 +
|[[HAEM5:Chronic eosinophilic leukaemia|Chronic eosinophilic leukaemia]]||Disease||PENDING
 +
| || || || ||FQR|| ||
 +
|Chronic Eosinophilic Leukemia, Not Otherwise Specified
 +
|Chelsea D. Kramish; Daynna J.Wolff
 +
|complete/pending faculty review
 +
|
 +
|
 +
|-
 +
|[[HAEM5:Polycythaemia vera|Polycythaemia vera]]||Disease||PENDING
 +
| || || || ||FQR|| ||
 +
|Polycythemia Vera (PV)
 +
|Gokce A. Toruner, MD, PhD  UT MD Anderson Cancer Center
 +
|Complete
 +
|
 +
|
 +
|-
 +
|[[HAEM5:Essential thrombocythaemia|Essential thrombocythaemia]]||Disease||PENDING
 +
| || || || ||FQR|| ||
 +
|Essential Thrombocythemia (ET)
 +
|Rebecca Smith, PhD, Director, Genetics Associates, Nashville, TN
 +
|Complete
 +
|
 +
|
 +
|-
 +
|[[HAEM5:Primary myelofibrosis|Primary myelofibrosis]]||Disease||PENDING
 +
| || || || ||FQR|| ||
 +
|Primary Myelofibrosis (PMF)
 +
|T. Niroshi Senaratne, UCLA
 +
|Complete
 +
|8/4/2020 before submission<br />
 +
|
 +
|-
 +
|[[HAEM5:Juvenile myelomonocytic leukaemia|Juvenile myelomonocytic leukaemia]]||Disease|| '''Sarah Rapisardo, PhD, FACMG''' |PENDING
 +
| || || || ||FQR|| ||
 +
|Juvenile Myelomonocytic Leukemia (JMML)
 +
|<nowiki>Sarah Rapisardo, PhD, FACMG | Assistant Professor, Pathology</nowiki>
 +
 
 +
Associate Director | Division of Molecular Pathology, Genetics and Genomics
  
 +
Duke University Health System Clinical Laboratories
 +
|PENDING importing content and reference formatting
 +
|
 +
|FQR has emailed SR several times, last 4/20/22
 +
|-
 +
!Disease (5th Edition)
 +
!Page Type
 +
!<span style="color:#0070C0">Author (5th Edition) (Note: please indicate trainees in parentheses)
 +
!Date Assigned to Author (5th Edition)
 +
!Target Completion Date (5th Edition)
 +
!Content Status (5th Edition)(Pending or Complete)
 +
!Date Completed by Author (5th Edition)
 +
!Associate Editor
 +
!Date of Last Editor Review (5th Edition)
 +
!Notes (5th Edition)
 +
!Correlated Prior Disease Name (4th Edition)
 +
!Correlated Prior Author (4th Edition)
 +
!Prior Content Status (4th Edition)(Pending or Complete)
 +
!Prior Date of Last Editor Review (4th Edition)
 +
!Prior Notes (4th Edition)
 +
|-
 +
|[[HAEM5:Myeloproliferative neoplasm, NOS|Myeloproliferative neoplasm, NOS]]||Disease||PENDING
 +
| || || || ||FQR|| ||
 +
|Myeloproliferative Neoplasm (MPN), Unclassifiable
 +
|Thomas Lee, MD, PhD, University of California, Los Angeles
 +
|Complete
 +
|
 +
|
 +
|-
 +
|[[HAEM5:Cutaneous mastocytosis|Cutaneous mastocytosis]]||Disease||PENDING
 +
| || || || ||FQR|| ||
 +
|Cutaneous Mastocytosis
 +
|S. Shawn Liu, MD, PhD and Thuy Phung, MD, PhD
 +
|Complete
 +
|
 +
|
 
|-
 
|-
−
|Clonal haematopoiesis||Disease|| || || || || ||Fabiola Quintero-Rivera (FQR)||
+
|[[HAEM5:Systemic mastocytosis|Systemic mastocytosis]]||Disease||PENDING|| || || || ||FQR|| ||
−
| ||
+
|Systemic Mastocytosis
 +
|Abdullah Osme, MD, University Hospitals Cleveland Medical Center, Case Western Reserve University  Shashi Shetty, Ph.D. FACMG, FCCMG, University Hospitals Cleveland Medical Center, Case Western Reserve University
 +
|Complete
 +
|
 +
|
 
|-
 
|-
−
|Clonal cytopenias of undetermined significance||Disease|| || || || || ||FQR||
+
|[[HAEM5:Mast cell sarcoma|Mast cell sarcoma]]||Disease||PENDING
−
| ||
+
| || || || ||FQR|| ||
 +
|Mast Cell Sarcoma
 +
|Jordan Lowery, MD and Thuy Phung, MD, PhD  Department of Pathology, University of South Alabama, Mobile, AL
 +
|Complete
 +
|
 +
|
 
|-
 
|-
−
|Chronic myeloid leukaemia||Disease||Jack Reid, MD (University of California, Irvine)  Mark Evans, MD (University of California, Irvine)  Fabiola Quintero-Rivera, MD (University of California, Irvine)|| || || || ||FQR||
+
|[[HAEM5:Myelodysplastic neoplasm with low blasts and 5q deletion|Myelodysplastic neoplasm with low blasts and 5q deletion]]||Disease||PENDING
−
| ||
+
| || || || ||FQR|| ||
 +
|Myelodysplastic Syndrome (MDS) with Isolated del(5q)
 +
|Xiaolin Hu, Ph.D; Teresa Smolarek, Ph.D, FACMG
 +
|Complete
 +
|
 +
|
 
|-
 
|-
−
|Chronic neutrophilic leukaemia||Disease||Anamaria Munteanu, MD, Ph.D**, Harbor-UCLA Medical Center, Joseph J. Merlo Jr, MD. Ph.D**, Ashion Analytics, Fabiola Quintero-Rivera, University of California Irvine  <nowiki>**</nowiki>contributed equally|| || || || ||FQR||
+
|[[HAEM5:Myelodysplastic neoplasm with low blasts and SF3B1 mutation|Myelodysplastic neoplasm with low blasts and SF3B1 mutation]]||Disease||PENDING
−
| ||
+
| || || || ||FQR|| ||
 +
|NEW (No Prior)
 +
|NEW (No Prior)
 +
|NEW (No Prior)
 +
|NEW (No Prior)
 +
|NEW (No Prior)
 
|-
 
|-
−
|Chronic eosinophilic leukaemia||Disease||Chelsea D. Kramish; Daynna J.Wolff  Pending Review*|| || || || ||FQR||
+
|[[HAEM5:Myelodysplastic neoplasm with biallelic TP53 inactivation|Myelodysplastic neoplasm with biallelic TP53 inactivation]]||Disease||Eric McGinnis (assigned to new 5th edition page - FQR is this reviewed?)|| || || || ||FQR|| ||
−
| ||
+
|NEW (No Prior)
 +
|NEW (No Prior)
 +
|NEW (No Prior)
 +
|NEW (No Prior)
 +
|NEW (No Prior)
 
|-
 
|-
−
|Polycythaemia vera||Disease||Gokce A. Toruner, MD, PhD  UT MD Anderson Cancer Center|| || || || ||FQR||
+
|[[HAEM5:Myelodysplastic neoplasm with low blasts|Myelodysplastic neoplasm with low blasts]]||Disease|| || || || || ||FQR|| ||
−
| ||
+
|NEW (No Prior)
 +
|NEW (No Prior)
 +
|NEW (No Prior)
 +
|NEW (No Prior)
 +
|NEW (No Prior)
 
|-
 
|-
−
|Essential thrombocythaemia||Disease||Rebecca Smith, PhD, Director, Genetics Associates, Nashville, TN|| || || || ||FQR||
+
|[[HAEM5:Myelodysplastic neoplasm, hypoplastic|Myelodysplastic neoplasm, hypoplastic]]||Disease|| || || || || ||FQR|| ||
−
| ||
+
|NEW (No Prior)
 +
|NEW (No Prior)
 +
|NEW (No Prior)
 +
|NEW (No Prior)
 +
|NEW (No Prior)
 
|-
 
|-
−
|Primary myelofibrosis||Disease||T. Niroshi Senaratne, UCLA|| || || || ||FQR||
+
|[[HAEM5:Myelodysplastic neoplasm with increased blasts|Myelodysplastic neoplasm with increased blasts]]||Disease||PENDING
−
| ||
+
| || || || ||FQR|| ||
 +
|Myelodysplastic Syndrome (MDS) with Excess Blasts
 +
|Xiaoli Du, Ph.D; Teresa A. Smolarek, Ph.D, FACMG  Division of Human Genetics, Cincinnati Children's Hospital Medical Center
 +
|Complete
 +
|
 +
|
 
|-
 
|-
−
|Juvenile myelomonocytic leukaemia||Disease|| '''Sarah Rapisardo, PhD, FACMG''' |Assistant Professor, Pathology  Associate Director | Division of Molecular Pathology, Genetics and Genomics  Duke University Health System Clinical Laboratories|| || || || ||FQR||
+
!Disease (5th Edition)
−
| ||
+
!Page Type
 +
!<span style="color:#0070C0">Author (5th Edition) (Note: please indicate trainees in parentheses)
 +
!Date Assigned to Author (5th Edition)
 +
!Target Completion Date (5th Edition)
 +
!Content Status (5th Edition)(Pending or Complete)
 +
!Date Completed by Author (5th Edition)
 +
!Associate Editor
 +
!Date of Last Editor Review (5th Edition)
 +
!Notes (5th Edition)
 +
!Correlated Prior Disease Name (4th Edition)
 +
!Correlated Prior Author (4th Edition)
 +
!Prior Content Status (4th Edition)(Pending or Complete)
 +
!Prior Date of Last Editor Review (4th Edition)
 +
!Prior Notes (4th Edition)
 
|-
 
|-
−
|Myeloproliferative neoplasm, NOS||Disease||Thomas Lee, MD, PhD, University of California, Los Angeles|| || || || ||FQR||
+
|[[HAEM5:Childhood myelodysplastic neoplasm with low blasts|Childhood myelodysplastic neoplasm with low blasts]]||Disease||PENDING
−
| ||
+
| || || || ||FQR|| ||
 +
|Refractory Cytopenia of Childhood
 +
|Xiaoli Du, Ph.D; Teresa A. Smolarek, Ph.D, FACMG  Division of Human Genetics, Cincinnati Children's Hospital Medical Center
 +
|Complete
 +
|
 +
|
 
|-
 
|-
−
|Cutaneous mastocytosis||Disease||S. Shawn Liu, MD, PhD and Thuy Phung, MD, PhD|| || || || ||FQR||
+
|[[HAEM5:Childhood myelodysplastic neoplasm with increased blasts|Childhood myelodysplastic neoplasm with increased blasts]]||Disease||PENDING
−
| ||
+
| || || || ||FQR|| ||
 +
|Refractory Cytopenia of Childhood
 +
|Xiaoli Du, Ph.D; Teresa A. Smolarek, Ph.D, FACMG  Division of Human Genetics, Cincinnati Children's Hospital Medical Center
 +
|Complete
 +
|
 +
|
 
|-
 
|-
−
|Systemic mastocytosis||Disease||'''Abdullah Osme, MD,''' University Hospitals Cleveland Medical Center, Case Western Reserve University  '''Shashi Shetty, Ph.D. FACMG, FCCMG,''' University Hospitals Cleveland Medical Center, Case Western Reserve University|| || || || ||FQR||
+
|[[HAEM5:Chronic myelomonocytic leukaemia|Chronic myelomonocytic leukaemia]]||Disease||PENDING
−
| ||
+
| || || || ||FQR|| ||
 +
|Chronic Myelomonocytic Leukemia (CMML)
 +
|Linsheng Zhang, MD, PhD
 +
|Complete
 +
|
 +
|
 
|-
 
|-
−
|Mast cell sarcoma||Disease||Jordan Lowery, MD and Thuy Phung, MD, PhD  Department of Pathology, University of South Alabama, Mobile, AL|| || || || ||FQR||
+
|[[HAEM5:Myelodysplastic/myeloproliferative neoplasm with neutrophilia|Myelodysplastic/myeloproliferative neoplasm with neutrophilia]]||Disease||PENDING
−
| ||
+
| || || || ||FQR|| ||
 +
|Atypical Chronic Myeloid Leukemia (aCML), BCR-ABL1 Negative
 +
|Linsheng Zhang, MD, PhD
 +
|Complete
 +
|
 +
|
 
|-
 
|-
−
|Myelodysplastic neoplasm with low blasts and 5q deletion||Disease|| || || || || ||FQR||
+
|[[HAEM5:Myelodysplastic/myeloproliferative neoplasm with SF3B1 mutation and thrombocytosis|Myelodysplastic/myeloproliferative neoplasm with SF3B1 mutation and thrombocytosis]]||Disease||PENDING
−
| ||
+
| || || || ||FQR|| ||
 +
|Myelodysplastic/Myeloproliferative Neoplasms with Ring Sideroblasts and Thrombocytosis (MDS/MPN-RS-T)
 +
|Anamaria Munteanu, MD, Ph.D, Harbor-UCLA Medical Center, Fabiola Quintero-Rivera, University of California Irvine
 +
|Complete
 +
|Date page was created
 +
|
 
|-
 
|-
−
|Myelodysplastic neoplasm with low blasts and SF3B1 mutation||Disease|| || || || || ||FQR||
+
|[[HAEM5:Myelodysplastic/myeloproliferative neoplasm, NOS|Myelodysplastic/myeloproliferative neoplasm, NOS]]||Disease||PENDING
−
| ||
+
| || || || ||FQR|| ||
 +
|Myelodysplastic/Myeloproliferative Neoplasms (MDS/MPN), Unclassifiable
 +
|Ruth MacKinnon PhD  Victorian Cancer Cytogenetics Service  Melbourne, Australia
 +
|Complete
 +
|
 +
|
 
|-
 
|-
−
|Myelodysplastic neoplasm with biallelic TP53 inactivation||Disease|| || || || || ||FQR||
+
|[[HAEM5:Acute promyelocytic leukaemia with PML::RARA fusion|Acute promyelocytic leukaemia with PML::RARA fusion]]
−
| ||
+
|Disease
 +
|(Rabail Aslam, MD)
 +
Shashi Shetty, Ph.D.
 +
|7/1/24
 +
|
 +
|
 +
|
 +
|Jennelle Hodge (JH)/ Malini Sathanoori (MS)
 +
|
 +
|
 +
|Acute Promyelocytic Leukemia (APL) with PML-RARA
 +
|Yiming Zhong, Ph.D., Megan Piazza, Ph.D., and Shashi Shetty, Ph.D.
 +
|Complete
 +
|03/01/2021-MS (re-review)
 +
|
 
|-
 
|-
−
|Myelodysplastic neoplasm with low blasts||Disease|| || || || || ||FQR||
+
|[[HAEM5:Acute myeloid leukaemia with RUNX1::RUNX1T1 fusion|Acute myeloid leukaemia with RUNX1::RUNX1T1 fusion]]
−
| ||
+
|Disease
 +
|Mayuri Shende (trainee) and Scott Turner (mentor)<br />
 +
|9/22/24
 +
|
 +
|Pending
 +
|
 +
|JH_MS
 +
|
 +
|
 +
|Acute Myeloid Leukemia (AML) with t(8;21)(q22;q22.1); RUNX1-RUNX1T1
 +
|Christine Bryke, MD<br>Beth Israel Deaconess Medical Center, Boston, MA
 +
|Complete
 +
|04/26/2021-MS (re-review)
 +
|
 
|-
 
|-
−
|Myelodysplastic neoplasm, hypoplastic||Disease|| || || || || ||FQR||
+
|[[HAEM5:Acute myeloid leukaemia with CBFB::MYH11 fusion|Acute myeloid leukaemia with CBFB::MYH11 fusion]]
−
| ||
+
|Disease
 +
|Mayuri Shende (trainee) and Scott Turner (mentor)<br />
 +
|9/22/24
 +
|
 +
|Pending
 +
|
 +
|JH_MS
 +
|
 +
|
 +
|Acute Myeloid Leukemia (AML) with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11
 +
|Christine Bryke, MD <br> Beth Israel Deaconess Medical Center, Boston, MA
 +
|Complete
 +
|03/01/2021-MS (re-review)
 +
|
 
|-
 
|-
−
|Myelodysplastic neoplasm with increased blasts||Disease||Xiaoli Du, Ph.D; Teresa A. Smolarek, Ph.D, FACMG  Division of Human Genetics, Cincinnati Children's Hospital Medical Center, 3333 Burnet Avenue, Cincinnati, OH, 45229, USA.|| || || || ||FQR||
+
|[[HAEM5:Acute myeloid leukaemia with DEK::NUP214 fusion|Acute myeloid leukaemia with DEK::NUP214 fusion]]
−
| ||
+
|Disease
 +
|PENDING
 +
|
 +
|
 +
|
 +
|
 +
|JH_MS
 +
|
 +
|
 +
|Acute Myeloid Leukemia (AML) with t(6;9)(p23;q34.1); DEK-NUP214
 +
|Jennelle C. Hodge, PhD, FACMG
 +
|Complete
 +
|02/24/2021-MS (re-review)
 +
|
 
|-
 
|-
−
|Childhood myelodysplastic neoplasm with low blasts||Disease||Xiaoli Du, Ph.D; Teresa A. Smolarek, Ph.D, FACMG  Division of Human Genetics, Cincinnati Children's Hospital Medical Center, 3333 Burnet Avenue, Cincinnati, OH, 45229, USA.|| || || || ||FQR||
+
!Disease (5th Edition)
−
| ||
+
!Page Type
 +
!<span style="color:#0070C0">Author (5th Edition) (Note: please indicate trainees in parentheses)
 +
!Date Assigned to Author (5th Edition)
 +
!Target Completion Date (5th Edition)
 +
!Content Status (5th Edition)(Pending or Complete)
 +
!Date Completed by Author (5th Edition)
 +
!Associate Editor
 +
!Date of Last Editor Review (5th Edition)
 +
!Notes (5th Edition)
 +
!Correlated Prior Disease Name (4th Edition)
 +
!Correlated Prior Author (4th Edition)
 +
!Prior Content Status (4th Edition)(Pending or Complete)
 +
!Prior Date of Last Editor Review (4th Edition)
 +
!Prior Notes (4th Edition)
 
|-
 
|-
−
|Childhood myelodysplastic neoplasm with increased blasts||Disease||Xiaoli Du, Ph.D; Teresa A. Smolarek, Ph.D, FACMG  Division of Human Genetics, Cincinnati Children's Hospital Medical Center, 3333 Burnet Avenue, Cincinnati, OH, 45229, USA.|| || || || ||FQR||
+
|[[HAEM5:Acute myeloid leukaemia with RBM15::MRTFA fusion|Acute myeloid leukaemia with RBM15::MRTFA fusion]]
−
| ||
+
|Disease
 +
|PENDING
 +
|
 +
|
 +
|
 +
|
 +
|JH_MS
 +
|
 +
|
 +
|Acute Myeloid Leukemia (AML) Megakaryoblastic with t(1;22)(p13.3;q13.1);RBM15-MKL1
 +
|Jennelle C. Hodge, PhD, FACMG
 +
|Complete
 +
|
 +
|
 
|-
 
|-
−
|Chronic myelomonocytic leukaemia||Disease||Linsheng Zhang, MD, PhD|| || || || ||FQR||
+
|[[HAEM5:Acute myeloid leukaemia with BCR::ABL1 fusion|Acute myeloid leukaemia with BCR::ABL1 fusion]]
−
| ||
+
|Disease
 +
|
 +
|
 +
|
 +
|
 +
|
 +
|JH_MS
 +
|
 +
|
 +
|Acute Myeloid Leukemia (AML) with BCR-ABL1
 +
|Kay Weng Choy MBBS, Monash Medical Centre
 +
|Complete
 +
|
 +
|
 
|-
 
|-
−
|Myelodysplastic/myeloproliferative neoplasm with neutrophilia||Disease||Linsheng Zhang, MD, PhD|| || || || ||FQR||
+
|[[HAEM5:Acute myeloid leukaemia with KMT2A rearrangement|Acute myeloid leukaemia with KMT2A rearrangement]]
−
| ||
+
|Disease
 +
|(Rabail Aslam, MD)
 +
Shashi Shetty, Ph.D.
 +
|7/1/24
 +
|
 +
|
 +
|
 +
|JH_MS
 +
|
 +
|
 +
|Acute Myeloid Leukemia (AML) with t(9;11)(p21.3;q23.3); KMT2A-MLLT3
 +
|Megan Piazza, Ph.D., Yiming Zhong, Ph.D., Shashi Shetty, Ph.D.
 +
|Complete
 +
|03/01/2021-MS (re-review)
 +
|
 
|-
 
|-
−
|Myelodysplastic/myeloproliferative neoplasm with SF3B1 mutation and thrombocytosis||Disease||Anamaria Munteanu, MD, Ph.D, Harbor-UCLA Medical Center, Fabiola Quintero-Rivera, University of California Irvine|| || || || ||FQR||
+
|[[HAEM5:Acute myeloid leukaemia with MECOM rearrangement|Acute myeloid leukaemia with MECOM rearrangement]]
−
| ||
+
|Disease
 +
|PENDING
 +
|
 +
|
 +
|
 +
|
 +
|JH_MS
 +
|
 +
|
 +
|Acute Myeloid Leukemia (AML) with inv(3)(q21.3q26.2) or t(3;3)(q21.3;q26.2);GATA2, MECOM
 +
|Gordana Raca MD PhD, University of Southern California, Los Angeles
 +
|Complete
 +
|
 +
|Need permission for figure? Update WHO?
 
|-
 
|-
−
|Myelodysplastic/myeloproliferative neoplasm, NOS||Disease||Ruth MacKinnon PhD  Victorian Cancer Cytogenetics Service  Melbourne, Australia|| || || || ||FQR||
+
|[[HAEM5:Acute myeloid leukaemia with NUP98 rearrangement|Acute myeloid leukaemia with NUP98 rearrangement]]
−
| ||
+
|Disease
 +
|Eric McGinnis, MD, Fatma Al-Bulushi (trannee)
 +
|12/20/23
 +
|
 +
|
 +
|
 +
|JH_MS
 +
|
 +
|
 +
|NEW (No Prior)
 +
|NEW (No Prior)
 +
|NEW (No Prior)
 +
|NEW (No Prior)
 +
|NEW (No Prior)
 
|-
 
|-
−
|Myeloid/lymphoid neoplasm with PDGFRA rearrangement||Disease||Jay Alden, DO|| || || || ||FQR||
+
|[[HAEM5:Acute myeloid leukaemia with NPM1 mutation|Acute myeloid leukaemia with NPM1 mutation]]
−
| ||
+
|Disease
 +
|PENDING
 +
|
 +
|
 +
|
 +
|
 +
|JH_MS
 +
|
 +
|
 +
|Acute Myeloid Leukemia (AML) with Mutated NPM1
 +
|Xinjie Xu, PhD, FACMG
 +
|Complete
 +
|
 +
|Add WHO reference
 
|-
 
|-
−
|Myeloid/lymphoid neoplasm with PDGFRB rearrangement||Disease||Christopher Sullivan, MD, MPH and Daynna J. Wolff, PhD|| || || || ||FQR||
+
|[[HAEM5:Acute myeloid leukaemia with CEBPA mutation|Acute myeloid leukaemia with CEBPA mutation]]
−
| ||
+
|Disease
 +
|
 +
|
 +
|
 +
|
 +
|
 +
|JH_MS
 +
|
 +
|
 +
|Acute Myeloid Leukemia (AML) with Biallelic Mutations of CEBPA
 +
|Paul Defazio, MSc, Monash Health
 +
|Complete
 +
|
 +
|
 
|-
 
|-
−
|Myeloid/lymphoid neoplasm with FGFR1 rearrangement||Disease||Yanna Ding, MD PhD|| || || || ||FQR||
+
|[[HAEM5:Acute myeloid leukaemia, myelodysplasia-related|Acute myeloid leukaemia, myelodysplasia-related]]
−
| ||
+
|Disease
 +
|PENDING
 +
|
 +
|
 +
|
 +
|
 +
|JH_MS
 +
|
 +
|
 +
|Acute Myeloid Leukemia (AML) with Myelodysplasia-Related Changes
 +
|Fei Yang, MD, FACMG  <br> Oregon Health & Science University
 +
|Complete
 +
|
 +
|
 
|-
 
|-
−
|Myeloid/lymphoid neoplasm with JAK2 rearrangement||Disease||Jessica Snider, M.D. and Daynna J. Wolff, PhD|| || || || ||FQR||
+
|[[HAEM5:Acute myeloid leukaemia with other defined genetic alterations|Acute myeloid leukaemia with other defined genetic alterations]]
−
| ||
+
|Disease
 +
|
 +
|
 +
|
 +
|
 +
|
 +
|JH_MS
 +
|
 +
|
 +
|NEW (No Prior)
 +
|NEW (No Prior)
 +
|NEW (No Prior)
 +
|NEW (No Prior)
 +
|NEW (No Prior)
 
|-
 
|-
−
|Myeloid/lymphoid neoplasm with FLT3 rearrangement||Disease|| || || || || ||FQR||
+
|[[HAEM5:Acute myeloid leukaemia with minimal differentiation|Acute myeloid leukaemia with minimal differentiation]]
−
| ||
+
|Disease
 +
|
 +
|
 +
|
 +
|
 +
|
 +
|JH_MS
 +
|
 +
|
 +
|Acute Myeloid Leukemia (AML) with Minimal Differentiation
 +
|Celeste Eno, PhD, Cedars Sinai Medical Center, Los Angeles,  Fabiola Quintero-Rivera, MD, FACMG, University of California Irvine
 +
|Complete
 +
|
 +
|
 
|-
 
|-
−
|Myeloid/lymphoid neoplasm with ETV6::ABL1 fusion||Disease|| || || || || ||FQR||
+
!Disease (5th Edition)
−
| ||
+
!Page Type
 +
!<span style="color:#0070C0">Author (5th Edition) (Note: please indicate trainees in parentheses)
 +
!Date Assigned to Author (5th Edition)
 +
!Target Completion Date (5th Edition)
 +
!Content Status (5th Edition)(Pending or Complete)
 +
!Date Completed by Author (5th Edition)
 +
!Associate Editor
 +
!Date of Last Editor Review (5th Edition)
 +
!Notes (5th Edition)
 +
!Correlated Prior Disease Name (4th Edition)
 +
!Correlated Prior Author (4th Edition)
 +
!Prior Content Status (4th Edition)(Pending or Complete)
 +
!Prior Date of Last Editor Review (4th Edition)
 +
!Prior Notes (4th Edition)
 
|-
 
|-
−
|Myeloid/lymphoid neoplasms with other tyrosine kinase fusion genes||Disease|| || || || || ||FQR||
+
|[[HAEM5:Acute myeloid leukaemia without maturation|Acute myeloid leukaemia without maturation]]
−
| ||
+
|Disease
 +
|PENDING
 +
|
 +
|
 +
|
 +
|
 +
|JH_MS
 +
|
 +
|
 +
|Acute Myeloid Leukemia (AML) without Maturation
 +
|Jennelle C. Hodge, PhD, FACMG
 +
|Complete
 +
|
 +
|
 
|-
 
|-
 +
|[[HAEM5:Acute myeloid leukaemia with maturation|Acute myeloid leukaemia with maturation]]
 +
|Disease
 +
|PENDING
 +
|
 +
|
 +
|
 +
|
 +
|JH_MS
 
|
 
|
 
|
 
|
 +
|Acute Myeloid Leukemia (AML) with Maturation
 +
|Jennelle C. Hodge, PhD, FACMG
 +
|Complete
 
|
 
|
 
|
 
|
 +
|-
 +
|[[HAEM5:Acute basophilic leukaemia|Acute basophilic leukaemia]]
 +
|Disease
 +
|Ashwini Yenamandra PhD FACMG
 +
|5/1/24
 
|
 
|
 
|
 
|
 
|
 
|
 +
|JH_MS
 
|
 
|
 
|
 
|
 +
|Acute Basophilic Leukemia
 +
|Ashwini Yenamandra PhD FACMG
 +
|Complete
 
|
 
|
 
|
 
|
 
|-
 
|-
 +
|[[HAEM5:Acute myelomonocytic leukaemia|Acute myelomonocytic leukaemia]]
 +
|Disease
 +
|PENDING
 
|
 
|
 
|
 
|
 
|
 
|
 
|
 
|
 +
|JH_MS
 
|
 
|
 
|
 
|
 +
|Acute Myelomonocytic Leukemia
 +
|Fei Yang, MD, FACMG <br> Oregon Health & Science University
 +
|Complete
 
|
 
|
 
|
 
|
 +
|-
 +
|[[HAEM5:Acute monocytic leukaemia|Acute monocytic leukaemia]]
 +
|Disease
 +
|PENDING
 
|
 
|
 +
|
 +
|
 +
|
 +
|JH_MS
 +
|
 +
|
 +
|Acute Monoblastic and Monocytic Leukemia
 +
|Fei Yang, MD, FACMG <br> Oregon Health & Science University
 +
|Complete
 
|
 
|
 
|
 
|
 
|-
 
|-
 +
|[[HAEM5:Acute erythroid leukaemia|Acute erythroid leukaemia]]
 +
|Disease
 +
|Ashwini Yenamandra PhD FACMG
 +
|5/1/24
 +
|
 +
|
 +
|
 +
|JH_MS
 +
|
 
|
 
|
 +
|Pure Erythroid Leukemia
 +
|Ashwini Yenamandra PhD FACMG
 +
|Complete
 
|
 
|
 
|
 
|
 +
|-
 +
|[[HAEM5:Acute megakaryoblastic leukaemia|Acute megakaryoblastic leukaemia]]
 +
|Disease
 +
|PENDING
 
|
 
|
 
|
 
|
 
|
 
|
 
|
 
|
 +
|JH_MS
 
|
 
|
 
|
 
|
 +
|Acute Megakaryoblastic Leukemia (AMKL)
 +
|Fei Yang, MD, FACMG <br> Oregon Health & Science University
 +
|Complete
 
|
 
|
 
|
 
|
 
|-
 
|-
−
|Langerhans cell histiocytosis||Disease||Dr Malaika Perchard BSci(MedSci), MBBS, FRACP, FRCPA, (Paediatric Haematologist) Pathology Queensland|| || || || ||GC||
+
|[[HAEM5:Myeloid sarcoma|Myeloid sarcoma]]
−
| ||
+
|Disease
 +
|Yalda Naeini
 +
|6/11/24
 +
|
 +
|
 +
|
 +
|JH_MS
 +
|
 +
|
 +
|Myeloid Sarcoma
 +
|Yalda Naeini, MD, School of Medicine at University of California Los Angeles Fabiola Quintero-Rivera, MD, FACMG, School of Medicine at University of California Irvine
 +
|Complete
 +
|
 +
|
 
|-
 
|-
−
|Langerhans cell sarcoma||Disease||Dr Malaika Perchard BSci(MedSci), MBBS, FRACP, FRCPA, (Paediatric Haematologist) Pathology Queensland|| || || || ||GC||
+
|RESOLVE 4th edition AML-Related NON-WHO entities content
−
| ||
+
|[[HAEM4:Acute Myeloid Leukemia (AML) with Mutated FLT3|Acute Myeloid Leukemia (AML) with Mutated FLT3]] + [[HAEM4:Acute Myeloid Leukemia (AML) with NUP214-ABL1|Acute Myeloid Leukemia (AML) with NUP214-ABL1]] + [[HAEM4:Acute Myeloid Leukemia (AML) with t(4;12)(q12;p13); CHIC2-ETV6|Acute Myeloid Leukemia (AML) with t(4;12)(q12;p13); CHIC2-ETV6]]
 +
|ISSUE- FIX
 +
 
 +
 
 +
Resolve Non-WHO entities
 +
|
 +
|
 +
|
 +
|
 +
|
 +
|
 +
|
 +
|
 +
|
 +
|
 +
|
 +
|
 
|-
 
|-
−
|Indeterminate dendritic cell tumour||Disease|| || || || || ||GC||
+
|[[HAEM5:Myeloid neoplasm post cytotoxic therapy|Myeloid neoplasm post cytotoxic therapy]]
−
| ||
+
|Disease
 +
|(Rabail Aslam, MD)
 +
Shashi Shetty, Ph.D.
 +
|7/1/24
 +
|
 +
|
 +
|
 +
|JH_MS
 +
|
 +
|
 +
|Therapy-Related Myeloid Neoplasms
 +
|Shawn A. Silver, DO, Shashi Shetty, Ph.D.
 +
|Complete
 +
|
 +
|Check reference format
 
|-
 
|-
−
|Interdigitating dendritic cell sarcoma||Disease|| || || || || ||GC||
+
!Disease (5th Edition)
−
| ||
+
!Page Type
 +
!<span style="color:#0070C0">Author (5th Edition) (Note: please indicate trainees in parentheses)
 +
!Date Assigned to Author (5th Edition)
 +
!Target Completion Date (5th Edition)
 +
!Content Status (5th Edition)(Pending or Complete)
 +
!Date Completed by Author (5th Edition)
 +
!Associate Editor
 +
!Date of Last Editor Review (5th Edition)
 +
!Notes (5th Edition)
 +
!Correlated Prior Disease Name (4th Edition)
 +
!Correlated Prior Author (4th Edition)
 +
!Prior Content Status (4th Edition)(Pending or Complete)
 +
!Prior Date of Last Editor Review (4th Edition)
 +
!Prior Notes (4th Edition)
 
|-
 
|-
−
|Juvenile xanthogranuloma||Disease|| || || || || ||GC||
+
|[[HAEM5:Myeloid neoplasms associated with germline predisposition|Myeloid neoplasms associated with germline predisposition]]
−
| ||
+
|Disease
 +
|PENDING
 +
|
 +
|
 +
|
 +
|
 +
|JH_MS
 +
|
 +
|
 +
|Multiple pages including overview page ([[Myeloid Neoplasms with Germline Predisposition|Myeloid Neoplasms with Germline Predisposition - Compendium of Cancer Genome Aberrations (ccga.io)]]) and 6 disease pages ( [[HAEM4:Acute Myeloid Leukaemia with Germline CEBPA Mutation]], [[HAEM4:Myeloid Neoplasms with Germline DDX41 Mutation]], [[HAEM4:Myeloid Neoplasms with Germline ETV6 Mutation]], [[HAEM4:Myeloid Neoplasms with Germline GATA2 Mutation]], [[HAEM4:Myeloid Neoplasms with Germline RUNX1 Mutation]], [[HAEM4:Myeloid Neoplasms with Germline ANKRD26 Mutation]])
 +
|See links from instructions on the 5th edition page
 +
|Complete
 +
|Most were re-reviewed by MS on 03/02/2021
 +
|For page Acute Myeloid Leukaemia with Germline CEBPA Mutation - Note by MS of "Review completed, awaiting some clarification from JH - 07/04/2022"
 
|-
 
|-
−
|Erdheim-Chester disease||Disease|| || || || || ||GC||
+
|[[HAEM5:Myeloid proliferations associated with Down syndrome|Myeloid proliferations associated with Down syndrome]]
−
| ||
+
|Disease
 +
|PENDING
 +
|
 +
|
 +
|
 +
|
 +
|JH_MS
 +
|
 +
|
 +
|MERGE 3 PAGES --> Transient Abnormal Myelopoiesis (TAM) Associated with Down Syndrome  +  Transient Abnormal Myelopoiesis (TAM) Associated with Down Syndrome + Myeloid Leukemia Associated with Down Syndrome
 +
|Linda D Cooley, MD, MBA, Children's Mercy Hospital, Kansas City, MO
 +
|Complete (all three pages)
 +
|
 +
|
 
|-
 
|-
−
|Rosai-Dorfman Disease||Disease|| || || || || ||GC||
+
|[[HAEM5:Myeloid/lymphoid neoplasm with PDGFRA rearrangement|Myeloid/lymphoid neoplasm with PDGFRA rearrangement]]
−
| ||
+
|Disease
 +
|PENDING
 +
|
 +
|
 +
|
 +
|
 +
|FQR
 +
|
 +
|
 +
|Myeloid/Lymphoid Neoplasms with PDGFRA Rearrangement
 +
|Jay Alden, DO
 +
|Complete
 +
|
 +
|
 
|-
 
|-
−
|ALK-positive histiocytosis||Disease|| || || || || ||GC||
+
|[[HAEM5:Myeloid/lymphoid neoplasm with PDGFRB rearrangement|Myeloid/lymphoid neoplasm with PDGFRB rearrangement]]
−
| ||
+
|Disease
 +
|PENDING
 +
|
 +
|
 +
|
 +
|
 +
|FQR
 +
|
 +
|
 +
|Myeloid/Lymphoid Neoplasms with PDGFRB Rearrangement
 +
|Christopher Sullivan, MD, MPH and Daynna J. Wolff, PhD
 +
|Complete
 +
|
 +
|
 
|-
 
|-
−
|Histiocytic sarcoma||Disease||Marie-France Gagnon, MD, Mayo Clinic, Xinjie Xu, PhD FACMG, Mayo Clinic|| || || || ||GC||
+
|[[HAEM5:Myeloid/lymphoid neoplasm with FGFR1 rearrangement|Myeloid/lymphoid neoplasm with FGFR1 rearrangement]]
−
| ||
+
|Disease
 +
|PENDING
 +
|
 +
|
 +
|
 +
|
 +
|FQR
 +
|
 +
|
 +
|Myeloid/Lymphoid Neoplasms with FGFR1 Rearrangement
 +
|Yanna Ding, MD PhD
 +
|Complete
 +
|
 +
|
 
|-
 
|-
−
|Reactive B-cell rich lymphoid proliferations that can mimic lymphoma||Disease|| || || || || ||GC||
+
|[[HAEM5:Myeloid/lymphoid neoplasm with JAK2 rearrangement|Myeloid/lymphoid neoplasm with JAK2 rearrangement]]
−
| ||
+
|Disease
 +
|ISSUE- FIX
 +
 
 +
 
 +
Resolve Non-WHO entities
 +
|
 +
|
 +
|
 +
|
 +
|FQR
 +
|
 +
|
 +
|Myeloid/Lymphoid Neoplasms with PCM1-JAK2 + consider a non-WHO page Myeloid/Lymphoid Neoplasms with ETV6-JAK2 ([[HAEM4:Myeloid/Lymphoid Neoplasms with ETV6-JAK2|Myeloid/Lymphoid Neoplasms with ETV6-JAK2 - Compendium of Cancer Genome Aberrations (ccga.io)]])  + another non-WHO page Myeloid/Lymphoid Neoplasms with BCR-JAK2 ([[HAEM4:Myeloid/Lymphoid Neoplasms with BCR-JAK2|Myeloid/Lymphoid Neoplasms with BCR-JAK2 - Compendium of Cancer Genome Aberrations (ccga.io)]] )  - both non-WHO pages are authored by trainee Lauren Crowson-Hindman and Daynna Wolff
 +
|Jessica Snider, M.D. and Daynna J. Wolff, PhD + non-WHO pages by trainee Lauren Crowson-Hindman and Daynna Wolff
 +
|Complete
 +
|
 +
|
 
|-
 
|-
−
|IgG4-related disease||Disease|| || || || || ||GC||
+
|[[HAEM5:Myeloid/lymphoid neoplasm with FLT3 rearrangement|Myeloid/lymphoid neoplasm with FLT3 rearrangement]]
−
| ||
+
|Disease
 +
|
 +
|
 +
|
 +
|
 +
|
 +
|FQR
 +
|
 +
|
 +
|NEW (No Prior)
 +
|NEW (No Prior)
 +
|NEW (No Prior)
 +
|NEW (No Prior)
 +
|NEW (No Prior)
 
|-
 
|-
−
|Unicentric Castleman disease||Disease|| || || || || ||GC||
+
|[[HAEM5:Myeloid/lymphoid neoplasm with ETV6::ABL1 fusion|Myeloid/lymphoid neoplasm with ETV6::ABL1 fusion]]
−
| ||
+
|Disease
 +
|Mayuri Shende (trainee) and Scott Turner (mentor)<br />
 +
|9/22/24
 +
|
 +
|Pending
 +
|
 +
|FQR
 +
|
 +
|
 +
|NEW (No Prior)
 +
|NEW (No Prior)
 +
|NEW (No Prior)
 +
|NEW (No Prior)
 +
|NEW (No Prior)
 
|-
 
|-
−
|Idiopathic multicentric Castleman disease||Disease|| || || || || ||GC||
+
|[[HAEM5:Myeloid/lymphoid neoplasms with other tyrosine kinase fusion genes|Myeloid/lymphoid neoplasms with other tyrosine kinase fusion genes]]
−
| ||
+
|Disease
 +
|
 +
|
 +
|
 +
|
 +
|
 +
|FQR
 +
|
 +
|
 +
|NEW (No Prior)
 +
|NEW (No Prior)
 +
|NEW (No Prior)
 +
|NEW (No Prior)
 +
|NEW (No Prior)
 
|-
 
|-
−
|KSHV/HHV8-associated multicentric Castleman disease||Disease||Sudha Arumugam, MD|| || || || ||GC||
+
|[[HAEM5:Mixed-phenotype acute leukaemia with BCR::ABL1 fusion|Mixed-phenotype acute leukaemia with BCR::ABL1 fusion]]
−
| ||
+
|Disease
 +
|Tracy Tucker, PhD, FCCMG
 +
|4/6/24
 +
|
 +
|Pending
 +
|
 +
|JH_MS
 +
|
 +
|
 +
|Mixed Phenotype Acute Leukemia (MPAL) with t(9;22)(q34.1;q11.2); BCR-ABL1
 +
|Tracy Tucker, PhD, FCCMG
 +
|Complete
 +
|
 +
|
 
|-
 
|-
−
|Diffuse large B-cell lymphoma, NOS||Disease||Ashwini Yenamandra, PhD FACMG, Vanderbilt University Medical Center|| || || || ||GC||
+
!Disease (5th Edition)
−
| ||
+
!Page Type
 +
!<span style="color:#0070C0">Author (5th Edition) (Note: please indicate trainees in parentheses)
 +
!Date Assigned to Author (5th Edition)
 +
!Target Completion Date (5th Edition)
 +
!Content Status (5th Edition)(Pending or Complete)
 +
!Date Completed by Author (5th Edition)
 +
!Associate Editor
 +
!Date of Last Editor Review (5th Edition)
 +
!Notes (5th Edition)
 +
!Correlated Prior Disease Name (4th Edition)
 +
!Correlated Prior Author (4th Edition)
 +
!Prior Content Status (4th Edition)(Pending or Complete)
 +
!Prior Date of Last Editor Review (4th Edition)
 +
!Prior Notes (4th Edition)
 
|-
 
|-
−
|T-cell/histiocyte-rich large B-cell lymphoma||Disease|| || || || || ||GC||
+
|[[HAEM5:Mixed-phenotype acute leukaemia with KMT2A rearrangement|Mixed-phenotype acute leukaemia with KMT2A rearrangement]]
−
| ||
+
|Disease
 +
|Tracy Tucker, PhD, FCCMG
 +
|4/6/24
 +
|
 +
|Pending
 +
|
 +
|JH_MS
 +
|
 +
|
 +
|Mixed Phenotype Acute Leukemia (MPAL) with t(v;11q23.3); KMT2A Rearranged
 +
|Tracy Tucker, PhD, FCCMG
 +
|Complete
 +
|
 +
|
 
|-
 
|-
−
|Diffuse large B-cell lymphoma / high grade B-cell lymphoma with MYC and BCL2 rearrangements||Disease||Kate Berry, MBBS, BBus (Hons), Pathology Queensland|| || || || ||GC||
+
|[[HAEM5:Acute leukaemia of ambiguous lineage with other defined genetic alterations|Acute leukaemia of ambiguous lineage with other defined genetic alterations]]
−
| ||
+
|Disease
 +
|
 +
|
 +
|
 +
|
 +
|
 +
|JH_MS
 +
|
 +
|
 +
|NEW (No Prior)
 +
|NEW (No Prior)
 +
|NEW (No Prior)
 +
|NEW (No Prior)
 +
|NEW (No Prior)
 
|-
 
|-
−
|ALK-positive large B-cell lymphoma||Disease||Manando Nakasaki, MD, PhD (University of California, Irvine) Fabiola Quintero-Rivera, MD, FACMG (University of California, Irvine)|| || || || ||GC||
+
|[[HAEM5:Mixed-phenotype acute leukaemia, B/myeloid|Mixed-phenotype acute leukaemia, B/myeloid]]
−
| ||
+
|Disease
 +
|(Rabail Aslam, MD)
 +
Shashi Shetty, Ph.D.
 +
|7/1/24
 +
|
 +
|
 +
|
 +
|JH_MS
 +
|
 +
|
 +
|Mixed Phenotype Acute Leukemia (MPAL), B/Myeloid, Not Otherwise Specified
 +
|Priyatharsini Nirmalanantham, MD and  Shashi Shetty, PhD
 +
|Complete
 +
|
 +
|
 
|-
 
|-
−
|Large B-cell lymphoma with IRF4 rearrangement||Disease||*Afia Hasnain, MBBS, PhD|| || || || ||GC||
+
|[[HAEM5:Mixed-phenotype acute leukaemia, T/myeloid|Mixed-phenotype acute leukaemia, T/myeloid]]
−
| ||
+
|Disease
 +
|PENDING
 +
|
 +
|
 +
|
 +
|
 +
|JH_MS
 +
|
 +
|
 +
|Mixed Phenotype Acute Leukemia (MPAL), T/Myeloid, Not Otherwise Specified
 +
|Narsis Attar, MD, PhD, Fabiola Quintero-Rivera, MD University of California, Irvine
 +
|Complete
 +
|
 +
|
 
|-
 
|-
−
|High grade B-cell lymphoma with 11q aberrations||Disease||Lauren Shealy, MD, Medical University of South Carolina  Daynna Wolff, PhD, Medical University of South Carolina|| || || || ||GC||
+
|[[HAEM5:Mixed-phenotype acute leukaemia, rare types|Mixed-phenotype acute leukaemia, rare types]]
−
| ||
+
|Disease
 +
|Daynna Wolff, PhD
 +
|5/9/24
 +
|
 +
|
 +
|
 +
|JH_MS
 +
|
 +
|
 +
|Mixed-Phenotype Acute Leukemia, Not Otherwise Specified (NOS), Rare Types
 +
|Elicia Goodale, MD, Medical University of South Carolina  Daynna Wolff, PhD, Medical University of South Carolina
 +
|PENDING
 +
|
 +
|
 
|-
 
|-
−
|Lymphomatoid granulomatosis||Disease|| || || || || ||GC||
+
|[[HAEM5:Acute leukaemia of ambiguous lineage, NOS|Acute leukaemia of ambiguous lineage, NOS]]
−
| ||
+
|Disease
 +
|
 +
|
 +
|
 +
|
 +
|
 +
|JH_MS
 +
|
 +
|
 +
|NEW (No Prior)
 +
|NEW (No Prior)
 +
|NEW (No Prior)
 +
|NEW (No Prior)
 +
|NEW (No Prior)
 
|-
 
|-
−
|EBV-positive diffuse large B-cell lymphoma||Disease|| || || || || ||GC||
+
|[[HAEM5:Acute undifferentiated leukaemia|Acute undifferentiated leukaemia]]
−
| ||
+
|Disease
 +
|(Rabail Aslam, MD)
 +
Shashi Shetty, Ph.D.
 +
|7/1/24
 +
|
 +
|
 +
|
 +
|JH_MS
 +
|
 +
|
 +
|Acute Undifferentiated Leukemia
 +
|Amelia Nakanishi, MD and Shashi Shetty, PhD
 +
|Complete
 +
|
 +
|Check reference format
 
|-
 
|-
−
|Diffuse large B-cell lymphoma associated with chronic inflammation||Disease|| || || || || ||GC||
+
|
−
| ||
+
====CHAPTER 3 (HISTIOCYTIC/DENRITIC CELL NEOPLASMS)====
 +
|
 +
----<br />
 +
|
 +
----<br />
 +
|
 +
----<br />
 +
|
 +
----<br />
 +
|
 +
----<br />
 +
|
 +
----<br />
 +
|
 +
----<br />
 +
|
 +
----<br />
 +
|
 +
----<br />
 +
|
 +
----<br />
 +
|
 +
----<br />
 +
|
 +
----<br />
 +
|
 +
----<br />
 +
|
 +
----<br />
 
|-
 
|-
−
|Fibrin-associated large B-cell lymphoma||Disease|| || || || || ||GC||
+
|[[HAEM5:Mature plasmacytoid dendritic cell proliferation associated with myeloid neoplasm|Mature plasmacytoid dendritic cell proliferation associated with myeloid neoplasm]]
−
| ||
+
|Disease
 +
|
 +
|
 +
|
 +
|
 +
|
 +
|Greg Corboy (GC)
 +
|
 +
|
 +
|NEW (No Prior)
 +
|NEW (No Prior)
 +
|NEW (No Prior)
 +
|NEW (No Prior)
 +
|NEW (No Prior)
 
|-
 
|-
−
|Fluid overload-associated large B-cell lymphoma||Disease|| || || || || ||GC||
+
|[[HAEM5:Blastic plasmacytoid dendritic cell neoplasm|Blastic plasmacytoid dendritic cell neoplasm]]
−
| ||
+
|Disease
 +
|PENDING
 +
|
 +
|
 +
|
 +
|
 +
|GC
 +
|
 +
|
 +
|Blastic Plasmacytoid Dendritic Cell Neoplasm
 +
|Hao Liu, MD and Daynna J. Wolff, PhD
 +
|Complete
 +
|
 +
|Previously within myeloid section under JH/MS editors
 
|-
 
|-
−
|Plasmablastic lymphoma||Disease||Mark Evans, MD (University of California, Irvine) Fabiola Quintero-Rivera, MD (University of California, Irvine)|| || || || ||GC||
+
!Disease (5th Edition)
−
| ||
+
!Page Type
 +
!<span style="color:#0070C0">Author (5th Edition) (Note: please indicate trainees in parentheses)
 +
!Date Assigned to Author (5th Edition)
 +
!Target Completion Date (5th Edition)
 +
!Content Status (5th Edition)(Pending or Complete)
 +
!Date Completed by Author (5th Edition)
 +
!Associate Editor
 +
!Date of Last Editor Review (5th Edition)
 +
!Notes (5th Edition)
 +
!Correlated Prior Disease Name (4th Edition)
 +
!Correlated Prior Author (4th Edition)
 +
!Prior Content Status (4th Edition)(Pending or Complete)
 +
!Prior Date of Last Editor Review (4th Edition)
 +
!Prior Notes (4th Edition)
 
|-
 
|-
−
|Primary large B-cell lymphoma of immune-privileged sites||Disease||Ashwini Yenamandra, PhD FACMG, Vanderbilt University Medical Center|| || || || ||GC||
+
|[[HAEM5:Langerhans cell histiocytosis|Langerhans cell histiocytosis]]
−
| ||
+
|Disease
 +
|PENDING
 +
|
 +
|
 +
|
 +
|
 +
|GC
 +
|
 +
|
 +
|Langerhans Cell Histiocytosis
 +
|Dr Malaika Perchard BSci(MedSci), MBBS, FRACP, FRCPA, (Paediatric Haematologist) Pathology Queensland
 +
|Complete
 +
|5/19/2022<br />
 +
|Date completed by author: 04/28/2022
 
|-
 
|-
−
|Primary cutaneous diffuse large B-cell lymphoma, leg type||Disease|| || || || || ||GC||
+
|[[HAEM5:Langerhans cell sarcoma|Langerhans cell sarcoma]]
−
| ||
+
|Disease
 +
|PENDING
 +
|
 +
|
 +
|
 +
|
 +
|GC
 +
|
 +
|
 +
|Langerhans Cell Sarcoma
 +
|Dr Malaika Perchard BSci(MedSci), MBBS, FRACP, FRCPA, (Paediatric Haematologist) Pathology Queensland
 +
|Complete
 +
|5/19/2022<br />
 +
|Date completed by author: 04/28/2022
 
|-
 
|-
−
|Intravascular large B-cell lymphoma||Disease||Kate Berry, MBBS, BBus (Hons), Pathology Queensland|| || || || ||GC||
+
|[[HAEM5:Indeterminate dendritic cell tumour|Indeterminate dendritic cell tumour]]
−
| ||
+
|Disease
 +
|
 +
|
 +
|
 +
|
 +
|
 +
|GC
 +
|
 +
|
 +
|NEW (No Prior)
 +
|NEW (No Prior)
 +
|NEW (No Prior)
 +
|NEW (No Prior)
 +
|NEW (No Prior)
 
|-
 
|-
−
|Primary mediastinal large B-cell lymphoma||Disease|| || || || || ||GC||
+
|[[HAEM5:Interdigitating dendritic cell sarcoma|Interdigitating dendritic cell sarcoma]]
−
| ||
+
|Disease
 +
|
 +
|
 +
|
 +
|
 +
|
 +
|GC
 +
|
 +
|
 +
|NEW (No Prior)
 +
|NEW (No Prior)
 +
|NEW (No Prior)
 +
|NEW (No Prior)
 +
|NEW (No Prior)
 
|-
 
|-
−
|Mediastinal grey zone lymphoma||Disease|| || || || || ||GC||
+
|[[HAEM5:Juvenile xanthogranuloma|Juvenile xanthogranuloma]]
−
| ||
+
|Disease
 +
|Mayuri Shende (trainee) and Scott Turner (mentor)<br />
 +
|9/22/24
 +
|
 +
|Pending
 +
|
 +
|GC
 +
|
 +
|
 +
|NEW (No Prior)
 +
|NEW (No Prior)
 +
|NEW (No Prior)
 +
|NEW (No Prior)
 +
|NEW (No Prior)
 
|-
 
|-
−
|High-grade B-cell lymphoma, NOS||Disease||Aiko Otsubo, PhD, Indiana University|| || || || ||GC||
+
|[[HAEM5:Erdheim-Chester disease|Erdheim-Chester disease]]
−
| ||
+
|Disease
 +
|Mayuri Shende (trainee) and Scott Turner (mentor)<br />
 +
|9/22/24
 +
|
 +
|Pending
 +
|
 +
|GC
 +
|
 +
|
 +
|NEW (No Prior)
 +
|NEW (No Prior)
 +
|NEW (No Prior)
 +
|NEW (No Prior)
 +
|NEW (No Prior)
 
|-
 
|-
−
|Burkitt lymphoma||Disease||Becky Leung, MBBS (Hons), BSc, Pathology Queensland|| || || || ||GC||
+
|[[HAEM5:Rosai-Dorfman Disease|Rosai-Dorfman Disease]]
−
| ||
+
|Disease
 +
|Mayuri Shende (trainee) and Scott Turner (mentor)<br />
 +
|9/22/24
 +
|
 +
|Pending
 +
|
 +
|GC
 +
|
 +
|
 +
|NEW (No Prior)
 +
|NEW (No Prior)
 +
|NEW (No Prior)
 +
|NEW (No Prior)
 +
|NEW (No Prior)
 
|-
 
|-
−
|Primary effusion lymphoma||Disease|| || || || || ||GC||
+
|[[HAEM5:ALK-positive histiocytosis|ALK-positive histiocytosis]]
−
| ||
+
|Disease
 +
|
 +
|
 +
|
 +
|
 +
|
 +
|GC
 +
|
 +
|
 +
|NEW (No Prior)
 +
|NEW (No Prior)
 +
|NEW (No Prior)
 +
|NEW (No Prior)
 +
|NEW (No Prior)
 
|-
 
|-
−
|KSHV/HHV8-positive diffuse large B-cell lymphoma||Disease|| || || || || ||GC||
+
|[[HAEM5:Histiocytic sarcoma|Histiocytic sarcoma]]
−
| ||
+
|Disease
 +
|PENDING
 +
|
 +
|
 +
|
 +
|
 +
|GC
 +
|
 +
|
 +
|Histiocytic Sarcoma
 +
|Marie-France Gagnon, MD, Mayo Clinic, Xinjie Xu, PhD FACMG, Mayo Clinic
 +
|Complete
 +
|10/01/2021
 +
|Date completed by author: 10/01/2021
 
|-
 
|-
−
|KSHV/HHV8-positive germinotropic lymphoproliferative disorder||Disease|| || || || || ||GC||
+
!Disease (5th Edition)
−
| ||
+
!Page Type
 +
!<span style="color:#0070C0">Author (5th Edition) (Note: please indicate trainees in parentheses)
 +
!Date Assigned to Author (5th Edition)
 +
!Target Completion Date (5th Edition)
 +
!Content Status (5th Edition)(Pending or Complete)
 +
!Date Completed by Author (5th Edition)
 +
!Associate Editor
 +
!Date of Last Editor Review (5th Edition)
 +
!Notes (5th Edition)
 +
!Correlated Prior Disease Name (4th Edition)
 +
!Correlated Prior Author (4th Edition)
 +
!Prior Content Status (4th Edition)(Pending or Complete)
 +
!Prior Date of Last Editor Review (4th Edition)
 +
!Prior Notes (4th Edition)
 
|-
 
|-
−
|Hyperplasias arising in immune deficiency/dysregulation||Disease|| || || || || ||GC||
+
|
−
| ||
+
====CHAPTER 4 (B-CELL LYMPHOID PROLIFERATIONS AND LYMPHOMAS)====
 +
|
 +
----<br />
 +
|
 +
----<br />
 +
|
 +
----<br />
 +
|
 +
----<br />
 +
|
 +
----<br />
 +
|
 +
----<br />
 +
|
 +
----<br />
 +
|
 +
----<br />
 +
|
 +
----<br />
 +
|
 +
----<br />
 +
|
 +
----<br />
 +
|
 +
----<br />
 +
|
 +
----<br />
 +
|
 +
----<br />
 
|-
 
|-
−
|Polymorphic lymphoproliferative disorders arising in immune deficiency / dysregulation||Disease||Anna Shestakova, MD, PhD, Fellow, University of Utah/ARUP Laboratories  Fabiola Quintero-Rivera, MD, Professor, University of California Irvine (UCI)|| || || || ||GC||
+
|[[HAEM5:Reactive B-cell rich lymphoid proliferations that can mimic lymphoma|Reactive B-cell rich lymphoid proliferations that can mimic lymphoma]]
−
| ||
+
|Disease
 +
|
 +
|
 +
|
 +
|
 +
|
 +
|GC
 +
|
 +
|
 +
|NEW (No Prior)
 +
|NEW (No Prior)
 +
|NEW (No Prior)
 +
|NEW (No Prior)
 +
|NEW (No Prior)
 
|-
 
|-
−
|EBV-positive mucocutaneous ulcer||Disease|| || || || || ||GC||
+
|[[HAEM5:IgG4-related disease|IgG4-related disease]]
−
| ||
+
|Disease
 +
|
 +
|
 +
|
 +
|
 +
|
 +
|GC
 +
|
 +
|
 +
|NEW (No Prior)
 +
|NEW (No Prior)
 +
|NEW (No Prior)
 +
|NEW (No Prior)
 +
|NEW (No Prior)
 
|-
 
|-
−
|Lymphomas arising in immune deficiency / dysregulation||Disease|| || || || || ||GC||
+
|[[HAEM5:Unicentric Castleman disease|Unicentric Castleman disease]]
−
| ||
+
|Disease
 +
|
 +
|
 +
|
 +
|
 +
|
 +
|GC
 +
|
 +
|
 +
|NEW (No Prior)
 +
|NEW (No Prior)
 +
|NEW (No Prior)
 +
|NEW (No Prior)
 +
|NEW (No Prior)
 
|-
 
|-
−
|Inborn error of immunity-associated lymphoid proliferations and lymphomas||Disease|| || || || || ||GC||
+
|[[HAEM5:Idiopathic multicentric Castleman disease|Idiopathic multicentric Castleman disease]]
−
| ||
+
|Disease
 +
|
 +
|
 +
|
 +
|
 +
|
 +
|GC
 +
|
 +
|
 +
|NEW (No Prior)
 +
|NEW (No Prior)
 +
|NEW (No Prior)
 +
|NEW (No Prior)
 +
|NEW (No Prior)
 
|-
 
|-
−
|Classic Hodgkin lymphoma||Disease||Patricia V. Hernandez, M.D., Washington University School of Medicine|| || || || ||GC||
+
|[[HAEM5:KSHV/HHV8-associated multicentric Castleman disease|KSHV/HHV8-associated multicentric Castleman disease]]
−
| ||
+
|Disease
 +
|PENDING
 +
|
 +
|
 +
|
 +
|
 +
|GC
 +
|
 +
|
 +
|Multicentric Castleman Disease
 +
|Sudha Arumugam, MD
 +
|Complete
 +
|01/24/2022
 +
|Date completed by author: 01/24/2022
 
|-
 
|-
−
|Nodular lymphocyte predominant Hodgkin lymphoma||Disease|| || || || || ||GC||
+
|[[HAEM5:B-lymphoblastic leukaemia/lymphoma|B-lymphoblastic leukaemia/lymphoma]]
−
| ||
+
|Disease
 +
|PENDING
 +
|
 +
|
 +
|
 +
|
 +
|Holli Drendel (HD)
 +
|
 +
|
 +
|B-Lymphoblastic Leukemia/Lymphoma, Not Otherwise Specified
 +
|Holli Drendel
 +
|PENDING
 +
|
 +
|
 
|-
 
|-
 +
|[[HAEM5:B-lymphoblastic leukaemia/lymphoma with high hyperdiploidy|B-lymphoblastic leukaemia/lymphoma with high hyperdiploidy]]
 +
|Disease
 +
|PENDING
 +
|
 +
|
 +
|
 
|
 
|
 +
|HD
 
|
 
|
 
|
 
|
 +
|B-Lymphoblastic Leukemia/Lymphoma with Hyperdiploidy
 +
|Afia Hasnain, MBBS, PhD; Yassmine Akkari, PhD, FACMG
 +
|PENDING
 
|
 
|
 
|
 
|
 +
|-
 +
|[[HAEM5:B-lymphoblastic leukaemia/lymphoma with hypodiploidy|B-lymphoblastic leukaemia/lymphoma with hypodiploidy]]
 +
|Disease
 +
|PENDING
 
|
 
|
 
|
 
|
 
|
 
|
 
|
 
|
 +
|HD
 +
|
 +
|
 +
|B-Lymphoblastic Leukemia/Lymphoma with Hypodiploidy
 +
|Ashwini Yenamandra PhD FACMG  Lisa Smith PhD FACMG  Yassmine Akkari PhD FACMG
 +
|Complete
 
|
 
|
 
|
 
|
 
|-
 
|-
−
|Acute promyelocytic leukaemia with PML::RARA fusion||Disease||Yiming Zhong, Ph.D., Megan Piazza, Ph.D., and Shashi Shetty, Ph.D.|| || || || ||JH_MS||
+
|[[HAEM5:B-lymphoblastic leukaemia/lymphoma with iAMP21|B-lymphoblastic leukaemia/lymphoma with iAMP21]]
−
| ||
+
|Disease
 +
|Holli Drendel
 +
|
 +
|
 +
|?Complete? Looks like tables need more editing.
 +
|
 +
|HD
 +
|
 +
|
 +
|B-Lymphoblastic Leukemia/Lymphoma with iAMP21 [but was completed as a 5th edition page by Holli]
 +
|Holli M. Drendel, PhD, FACMGG, Carolinas Pathology Group, Charlotte
 +
|?Complete
 +
|
 +
|
 
|-
 
|-
−
|Acute myeloid leukaemia with RUNX1::RUNX1T1 fusion||Disease||Christine Bryke, MD<br>Beth Israel Deaconess Medical Center, Boston, MA|| || || || ||JH_MS||
+
!Disease (5th Edition)
−
| ||
+
!Page Type
 +
!<span style="color:#0070C0">Author (5th Edition) (Note: please indicate trainees in parentheses)
 +
!Date Assigned to Author (5th Edition)
 +
!Target Completion Date (5th Edition)
 +
!Content Status (5th Edition)(Pending or Complete)
 +
!Date Completed by Author (5th Edition)
 +
!Associate Editor
 +
!Date of Last Editor Review (5th Edition)
 +
!Notes (5th Edition)
 +
!Correlated Prior Disease Name (4th Edition)
 +
!Correlated Prior Author (4th Edition)
 +
!Prior Content Status (4th Edition)(Pending or Complete)
 +
!Prior Date of Last Editor Review (4th Edition)
 +
!Prior Notes (4th Edition)
 
|-
 
|-
−
|Acute myeloid leukaemia with CBFB::MYH11 fusion||Disease||Christine Bryke, MD <br> Beth Israel Deaconess Medical Center, Boston, MA|| || || || ||JH_MS||
+
|[[HAEM5:B-lymphoblastic leukaemia/lymphoma with BCR::ABL1 fusion|B-lymphoblastic leukaemia/lymphoma with BCR::ABL1 fusion]]
−
| ||
+
|Disease
 +
|PENDING
 +
|
 +
|
 +
|
 +
|
 +
|HD
 +
|
 +
|
 +
|B-Lymphoblastic Leukemia/Lymphoma with t(9;22)(q34.1;q11.2); BCR-ABL1
 +
|Afia Hasnain, MBBS, PhD; Yassmine Akkari, PhD, FACMG
 +
|PENDING
 +
|
 +
|
 
|-
 
|-
−
|Acute myeloid leukaemia with DEK::NUP214 fusion||Disease|| || || || || ||JH_MS||
+
|[[HAEM5:B-lymphoblastic leukaemia/lymphoma with BCR::ABL1-like features|B-lymphoblastic leukaemia/lymphoma with BCR::ABL1-like features]]
−
| ||
+
|Disease
 +
|PENDING
 +
|
 +
|
 +
|
 +
|
 +
|HD
 +
|
 +
|
 +
|B-Lymphoblastic Leukemia/Lymphoma, BCR-ABL1-Like
 +
|Mark G. Evans, MD, University of California, Irvine  Fabiola Quintero-Rivera, MD, University of California, Irvine
 +
|Complete
 +
|
 +
|
 
|-
 
|-
−
|Acute myeloid leukaemia with RBM15::MRTFA fusion||Disease||Jennelle C. Hodge, PhD, FACMG|| || || || ||JH_MS||
+
|[[HAEM5:B lymphoblastic leukaemia/lymphoma with KMT2A rearrangement|B lymphoblastic leukaemia/lymphoma with KMT2A rearrangement]]
−
| ||
+
|Disease
 +
|PENDING
 +
|
 +
|
 +
|
 +
|
 +
|HD
 +
|
 +
|
 +
|B-Lymphoblastic Leukemia/Lymphoma with t(v;11q23.3); KMT2A-Rearranged
 +
|Yassmine Akkari  Nicolas Millan
 +
|PENDING
 +
|
 +
|
 
|-
 
|-
−
|Acute myeloid leukaemia with BCR::ABL1 fusion||Disease||Kay Weng Choy MBBS, Monash Medical Centre|| || || || ||JH_MS||
+
|[[HAEM5:B lymphoblastic leukaemia/lymphoma with ETV6::RUNX1 fusion|B lymphoblastic leukaemia/lymphoma with ETV6::RUNX1 fusion]]
−
| ||
+
|Disease
 +
|PENDING
 +
|
 +
|
 +
|
 +
|
 +
|HD
 +
|
 +
|
 +
|B lymphoblastic leukaemia/lymphoma with ETV6::RUNX1 fusion
 +
|Marilena Melas, PhD; Yassmine Akkari, PhD, FACMG  Cancer Category/Type    B-Lymphoblastic Leukemia/Lymphoma
 +
|PENDING
 +
|
 +
|
 
|-
 
|-
−
|Acute myeloid leukaemia with KMT2A rearrangement||Disease||Megan Piazza, Ph.D., Yiming Zhong, Ph.D., Shashi Shetty, Ph.D.|| || || || ||JH_MS||
+
|[[HAEM5:B-lymphoblastic leukaemia/lymphoma with ETV6::RUNX1-like features|B-lymphoblastic leukaemia/lymphoma with ETV6::RUNX1-like features]]
−
| ||
+
|Disease
 +
|Lei Zhang and Michelle Fan (trainee)
 +
|8/8/2024
 +
|
 +
|Pending
 +
|
 +
|HD
 +
|
 +
|
 +
|NEW (No Prior)
 +
|NEW (No Prior)
 +
|NEW (No Prior)
 +
|NEW (No Prior)
 +
|NEW (No Prior)
 
|-
 
|-
−
|Acute myeloid leukaemia with MECOM rearrangement||Disease|| || || || || ||JH_MS||
+
|[[HAEM5:B lymphoblastic leukaemia/lymphoma with TCF3::PBX1 fusion|B lymphoblastic leukaemia/lymphoma with TCF3::PBX1 fusion]]
−
| ||
+
|Disease
 +
|PENDING
 +
|
 +
|
 +
|
 +
|
 +
|HD
 +
|
 +
|
 +
|B-Lymphoblastic Leukemia/Lymphoma with t(1;19)(q23;p13.3); TCF3-PBX1
 +
|Binu Porath, PhD. Vanderbilt University Medical Center, Nashville, TN  Linda D. Cooley, MD, MBA. Children's Mercy Kansas City, Kansas City, MO
 +
|PENDING
 +
|
 +
|
 
|-
 
|-
−
|Acute myeloid leukaemia with NUP98 rearrangement||Disease|| || || || || ||JH_MS||
+
|[[HAEM5:B lymphoblastic leukaemia/lymphoma with IGH::IL3 fusion|B lymphoblastic leukaemia/lymphoma with IGH::IL3 fusion]]
−
| ||
+
|Disease
 +
|PENDING
 +
|
 +
|
 +
|
 +
|
 +
|HD
 +
|
 +
|
 +
|B-Lymphoblastic Leukemia/Lymphoma with t(5;14)(q31.1;q32.1); IGH/IL3
 +
|Binu Porath, PhD. Vanderbilt University Medical Center, Nashville, TN  Linda D. Cooley, MD, MBA. Children's Mercy Kansas City, Kansas City, MO
 +
|PENDING
 +
|
 +
|
 
|-
 
|-
−
|Acute myeloid leukaemia with NPM1 mutation||Disease||Xinjie Xu, PhD, FACMG|| || || || ||JH_MS||
+
|[[HAEM5:B lymphoblastic leukaemia/lymphoma with TCF3::HLF fusion|B lymphoblastic leukaemia/lymphoma with TCF3::HLF fusion]]
−
| ||
+
|Disease
 +
|Aiko Otsubo
 +
|6/25/2024
 +
|
 +
|Pending
 +
|
 +
|HD
 +
|
 +
|
 +
|NEW (No Prior)
 +
|NEW (No Prior)
 +
|NEW (No Prior)
 +
|NEW (No Prior)
 +
|NEW (No Prior)
 
|-
 
|-
−
|Acute myeloid leukaemia with CEBPA mutation||Disease||Paul Defazio, MSc, Monash Health|| || || || ||JH_MS||
+
|[[HAEM5:B-lymphoblastic leukaemia/lymphoma with other defined genetic alterations|B-lymphoblastic leukaemia/lymphoma with other defined genetic alterations]]
−
| ||
+
|Disease
 +
|Lei Zhang and Michelle Fan (trainee)
 +
|8/8/2024
 +
|
 +
|Pending
 +
|
 +
|HD
 +
|
 +
|
 +
|NEW (No Prior)
 +
|NEW (No Prior)
 +
|NEW (No Prior)
 +
|NEW (No Prior)
 +
|NEW (No Prior)
 
|-
 
|-
−
|Acute myeloid leukaemia, myelodysplasia-related||Disease||Fei Yang, MD, FACMG  <br> Oregon Health & Science University, Portland, OR|| || || || ||JH_MS||
+
|[[HAEM5:B-lymphoblastic leukaemia/lymphoma, NOS|B-lymphoblastic leukaemia/lymphoma, NOS]]
−
| ||
+
|Disease
 +
|
 +
|
 +
|
 +
|
 +
|
 +
|HD
 +
|
 +
|
 +
|NEW (No Prior)
 +
|NEW (No Prior)
 +
|NEW (No Prior)
 +
|NEW (No Prior)
 +
|NEW (No Prior)
 
|-
 
|-
−
|Acute myeloid leukaemia with other defined genetic alterations||Disease|| || || || || ||JH_MS||
+
!Disease (5th Edition)
−
| ||
+
!Page Type
 +
!<span style="color:#0070C0">Author (5th Edition) (Note: please indicate trainees in parentheses)
 +
!Date Assigned to Author (5th Edition)
 +
!Target Completion Date (5th Edition)
 +
!Content Status (5th Edition)(Pending or Complete)
 +
!Date Completed by Author (5th Edition)
 +
!Associate Editor
 +
!Date of Last Editor Review (5th Edition)
 +
!Notes (5th Edition)
 +
!Correlated Prior Disease Name (4th Edition)
 +
!Correlated Prior Author (4th Edition)
 +
!Prior Content Status (4th Edition)(Pending or Complete)
 +
!Prior Date of Last Editor Review (4th Edition)
 +
!Prior Notes (4th Edition)
 
|-
 
|-
−
|Acute myeloid leukaemia with minimal differentiation||Disease||Celeste Eno, PhD, Cedars Sinai Medical Center, Los Angeles,  Fabiola Quintero-Rivera, MD, FACMG, University of California Irvine|| || || || ||JH_MS||
+
|RESOLVE 4th edition ALL-Related NON-WHO entities content
−
| ||
+
|B-Lymphoblastic Leukemia/Lymphoma with t(4;14)(q35.2;q32); IGH/DUX4 + B-Lymphoblastic Leukemia/Lymphoma with dic(9;12)(p13;p13); PAX5/ETV6 + B-Lymphoblastic Leukemia/Lymphoma with ZNF384 Rearrangements + B-Lymphoblastic Leukemia/Lymphoma with IKZF1 Deletions + B-Lymphoblastic Leukemia/Lymphoma with TCF3 Rearrangements - Excluding t(1;19) and t(12;19) + B-Lymphoblastic Leukemia/Lymphoma with dic(9;20)(p13;q11)
 +
|ISSUE- FIX
 +
 
 +
 
 +
Resolve Non-WHO entities
 +
|
 +
|
 +
|
 +
|
 +
|
 +
|
 +
|
 +
|
 +
|ISSUE - FIX
 +
|
 +
|
 +
|
 
|-
 
|-
−
|Acute myeloid leukaemia without maturation||Disease||Jennelle C. Hodge, PhD, FACMG|| || || || ||JH_MS||
+
|[[HAEM5:Monoclonal B-cell lymphocytosis|Monoclonal B-cell lymphocytosis]]||Disease||PENDING; Shashirekha Shetty
 +
| || || || ||Shivani Golem (SG)
 
| ||
 
| ||
 +
|Monoclonal B-cell Lymphocytosis
 +
|Tsigab Bahta Hagos (trainee) / Shashirekha Shetty
 +
|PENDING, 4/30/2024
 +
|
 +
|Assigned 12/19/2022 with completion date of 1/19/2023
 
|-
 
|-
−
|Acute myeloid leukaemia with maturation||Disease||Jennelle C. Hodge, PhD, FACMG|| || || || ||JH_MS||
+
|[[HAEM5:Chronic lymphocytic leukaemia/small lymphocytic lymphoma|Chronic lymphocytic leukaemia/small lymphocytic lymphoma]]||Disease||Jaime Nagy, PhD, University of Iowa
−
| ||
+
 
 +
Renee Eigsti, MD, Pathology Services of Kalamazoo
 +
 
 +
Honey Reddi, PhD, Belay Diagnostics
 +
| || ||Complete|| ||SG|| ||
 +
|Already converted to 5th edition
 +
|Jamie Nagy, PhD, University of Iowa  Honey Reddi, PhD
 +
|
 +
|
 +
|
 
|-
 
|-
−
|Acute basophilic leukaemia||Disease||Ashwini Yenamandra PhD FACMG|| || || || ||JH_MS||
+
|[[HAEM5:Hairy cell leukaemia|Hairy cell leukaemia]]||Disease||Michael Lack, MD, KUMC (trainee)/Shivani Golem
−
| ||
+
|7/16/24|| ||PENDING|| ||SG|| ||Need new author to update latest content. Prior author cannot update the page.
 +
|Hairy Cell Leukemia
 +
|Snehal Patel, MD, PhD
 +
|Pending WHO 5th e. July 2024
 +
|
 +
|
 
|-
 
|-
−
|Acute myelomonocytic leukaemia||Disease||Fei Yang, MD, FACMG <br> Oregon Health & Science University, Portland, OR|| || || || ||JH_MS||
+
|[[HAEM5:Splenic marginal zone lymphoma|Splenic marginal zone lymphoma]]||Disease||
−
| ||
+
| || || || ||SG|| ||Need new author to update latest content. Prior author cannot update the page.
 +
|Splenic Marginal Zone Lymphoma
 +
|Snehal Patel, MD, PhD
 +
|Complete
 +
|
 +
|
 
|-
 
|-
−
|Acute monocytic leukaemia||Disease||Fei Yang, MD, FACMG  <br> Oregon Health & Science University, Portland, OR|| || || || ||JH_MS||
+
|[[HAEM5:Splenic diffuse red pulp small B-cell lymphoma|Splenic diffuse red pulp small B-cell lymphoma]]||Disease||
−
| ||
+
| || || || ||SG|| ||Need new author to update latest content. Prior author cannot update the page.
 +
|Splenic Diffuse Red Pulp Small B-cell Lymphoma
 +
|Snehal Patel, MD, PhD
 +
|Complete
 +
|
 +
|
 
|-
 
|-
−
|Acute erythroid leukaemia||Disease||Ashwini Yenamandra PhD FACMG|| || || || ||JH_MS||
+
|[[HAEM5:Splenic B-cell lymphoma/leukaemia with prominent nucleoli|Splenic B-cell lymphoma/leukaemia with prominent nucleoli]]
−
| ||
+
|Disease
 +
|
 +
|
 +
|
 +
|
 +
|
 +
|SG
 +
|
 +
|Need new author to update latest content. Prior author cannot update the page.
 +
|Hairy Cell Leukemia Variant
 +
|Snehal Patel, MD, PhD
 +
|Complete
 +
|
 +
|
 
|-
 
|-
−
|Acute megakaryoblastic leukaemia||Disease||Fei Yang, MD, FACMG  <br> Oregon Health & Science University, Portland, OR|| || || || ||JH_MS||
+
|[[HAEM5:Lymphoplasmacytic lymphoma|Lymphoplasmacytic lymphoma]]
−
| ||
+
|Disease
 +
|PENDING
 +
|
 +
|
 +
|
 +
|
 +
|SG
 +
|
 +
|Email sent to request to update 2024
 +
|(1) Lymphoplasmacytic Lymphoma + (2) Waldenstrom Macroglobulinemia
 +
|(1 and 2) Kapitolina Semenova, MD, Jack Reid, MD, Fabiola Quintero-Rivera, MD  Departments of Pathology, Laboratory Medicine, and Pediatrics, Division of Genetic and Genomic Medicine, University of California, Irvine (UCI)
 +
|Complete
 +
|4/12/2023 by FQR
 +
|
 
|-
 
|-
−
|Myeloid sarcoma||Disease||Yalda Naeini, MD, School of Medicine at University of California Los Angeles Fabiola Quintero-Rivera, MD, FACMG, School of Medicine at University of California Irvine|| || || || ||JH_MS||
+
|[[HAEM5:Extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue|Extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue]]
−
| ||
+
|Disease
 +
|PENDING
 +
|
 +
|
 +
|
 +
|
 +
|SG
 +
|
 +
|Email sent to request to update 2024
 +
|Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue (MALT Lymphoma)
 +
|Whayoung Lee, MD (trainee), Fabiola Quintero-Rivera, MD, FACMG*
 +
 
 +
Department of Pathology and Laboratory Medicine and *Pediatrics, School of Medicine, University of California Irvine (UCI)
 +
|Complete
 +
|4/12/23 by FQR
 +
|
 
|-
 
|-
−
|Myeloid neoplasm post cytotoxic therapy||Disease||Shawn A. Silver, DO, Shashi Shetty, Ph.D.|| || || || ||JH_MS||
+
|[[HAEM5:Primary cutaneous marginal zone lymphoma|Primary cutaneous marginal zone lymphoma]]
−
| ||
+
|Disease
 +
|
 +
|
 +
|
 +
|
 +
|
 +
|SG
 +
|
 +
|
 +
|NEW (No Prior)
 +
|NEW (No Prior)
 +
|NEW (No Prior)
 +
|NEW (No Prior)
 +
|NEW (No Prior)
 
|-
 
|-
−
|Myeloid neoplasms associated with germline predisposition||Disease|| || || || || ||JH_MS||
+
!Disease (5th Edition)
−
| ||
+
!Page Type
 +
!<span style="color:#0070C0">Author (5th Edition) (Note: please indicate trainees in parentheses)
 +
!Date Assigned to Author (5th Edition)
 +
!Target Completion Date (5th Edition)
 +
!Content Status (5th Edition)(Pending or Complete)
 +
!Date Completed by Author (5th Edition)
 +
!Associate Editor
 +
!Date of Last Editor Review (5th Edition)
 +
!Notes (5th Edition)
 +
!Correlated Prior Disease Name (4th Edition)
 +
!Correlated Prior Author (4th Edition)
 +
!Prior Content Status (4th Edition)(Pending or Complete)
 +
!Prior Date of Last Editor Review (4th Edition)
 +
!Prior Notes (4th Edition)
 
|-
 
|-
−
|Myeloid proliferations associated with Down syndrome||Disease||Linda D Cooley, MD, MBA, Children's Mercy Hospital, Kansas City, MO|| || || || ||JH_MS||
+
|[[HAEM5:Nodal marginal zone lymphoma|Nodal marginal zone lymphoma]]
−
| ||
+
|Disease
 +
|PENDING
 +
|
 +
|
 +
|
 +
|
 +
|SG
 +
|
 +
|
 +
|Nodal Marginal Zone Lymphoma
 +
|Andrew Ly, DO and Shivani Golem, PhD, FACMG
 +
|Complete
 +
|5/28/2021
 +
|
 
|-
 
|-
 +
|[[HAEM5:Paediatric nodal marginal zone lymphoma|Paediatric nodal marginal zone lymphoma]]
 +
|Disease
 +
|PENDING
 +
|
 
|
 
|
 
|
 
|
 
|
 
|
 +
|SG
 
|
 
|
 +
|Need new author to update latest content. Prior authors cannot update the page.
 +
|Paediatric Nodal Marginal Zone Lymphoma
 +
|* Kathleen M. Schieffer, PhD * Ruthann Pfau, PhD
 +
|Complete; Need new author to update latest content. Primary author cannot update the page.
 +
|11/11/2020
 
|
 
|
 +
|-
 +
|[[HAEM5:In situ follicular B-cell neoplasm|In situ follicular B-cell neoplasm]]
 +
|Disease
 +
|Rachel D. Burnside, PhD, MBA, FACMGG
 +
|7/28/2023
 
|
 
|
 +
|Pending
 
|
 
|
 +
|SG
 
|
 
|
 
|
 
|
 +
|In Situ Follicular Neoplasia
 +
|Rachel D. Burnside, PhD, MBA, FACMGG
 +
|Pending
 
|
 
|
 
|
 
|
 
|-
 
|-
−
|Mixed-phenotype acute leukaemia with BCR::ABL1 fusion||Disease||Tracy Tucker, PhD, FCCMG|| || || || ||JH_MS||
+
|[[HAEM5:Follicular lymphoma|Follicular lymphoma]]
−
| ||
+
|Disease
 +
|Rachel D. Burnside, PhD, MBA, FACMGG
 +
|7/28/2023
 +
|
 +
|Pending
 +
|
 +
|SG
 +
|
 +
|Author also needs to correlate with 4th edition disease "Testicular Follicular Lymphoma", which is no longer a separate entity
 +
|(1) Follicular Lymphoma + (2) Testicular Follicular Lymphoma
 +
|(1 and 2) Ruthann Pfau, PhD, FACMG, Nationwide Children's Hospital  Rachel D. Burnside, PhD, MBA, FACMG, University of Florida
 +
|Pending
 +
|
 +
|
 
|-
 
|-
−
|Mixed-phenotype acute leukaemia with KMT2A rearrangement||Disease||Tracy Tucker, PhD, FCCMG|| || || || ||JH_MS||
+
|[[HAEM5:Paediatric-type follicular lymphoma|Paediatric-type follicular lymphoma]]
−
| ||
+
|Disease
 +
|PENDING
 +
|
 +
|
 +
|
 +
|
 +
|SG
 +
|
 +
|Need new author to update latest content. Prior authors cannot update the page.
 +
|Paediatric-Type Follicular Lymphoma
 +
|*Kathleen M. Schieffer, PhD *Ruthann Pfau, PhD, FACMG
 +
|Complete; Need new author to update latest content. Primary author  cannot update the page.
 +
|8/16/2020
 +
|
 
|-
 
|-
−
|Acute leukaemia of ambiguous lineage with other defined genetic alterations||Disease|| || || || || ||JH_MS||
+
|[[HAEM5:Duodenal-type follicular lymphoma|Duodenal-type follicular lymphoma]]
−
| ||
+
|Disease
 +
|Rachel D. Burnside, PhD, MBA, FACMGG
 +
|7/28/2023
 +
|
 +
|Pending
 +
|
 +
|SG
 +
|
 +
|
 +
|Duodenal-Type Follicular Lymphoma
 +
|No prior content
 +
|
 +
|
 +
|
 
|-
 
|-
−
|Mixed-phenotype acute leukaemia, B/myeloid||Disease||Priyatharsini Nirmalanantham, MD and  Shashi Shetty, PhD|| || || || ||JH_MS||
+
|[[HAEM5:Primary cutaneous follicle centre lymphoma|Primary cutaneous follicle centre lymphoma]]
−
| ||
+
|Disease
 +
|PENDING
 +
|
 +
|
 +
|
 +
|
 +
|SG
 +
|
 +
|
 +
|Primary Cutaneous Follicle Centre Lymphoma
 +
|Linlin Gao, MD, PhD and Shivani Golem, PhD, FACMG
 +
|Complete
 +
|09/10/2022
 +
|
 
|-
 
|-
−
|Mixed-phenotype acute leukaemia, T/myeloid||Disease||Narsis Attar, MD, PhD, Fabiola Quintero-Rivera, MD University of California, Irvine|| || || || ||JH_MS||
+
|[[HAEM5:In situ mantle cell neoplasm|In situ mantle cell neoplasm]]
−
| ||
+
|Disease
 +
|PENDING
 +
|
 +
|
 +
|
 +
|
 +
|SG
 +
|
 +
|
 +
|In Situ Mantle Cell Neoplasia
 +
|Rina Kansal, MD; Versiti Blood Center of Wisconsin
 +
|Complete
 +
|7/26/2022
 +
|
 
|-
 
|-
−
|Mixed-phenotype acute leukaemia, rare types||Disease||Elicia Goodale, MD, Medical University of South Carolina  Daynna Wolff, PhD, Medical University of South Carolina|| || || || ||JH_MS||
+
|[[HAEM5:Mantle cell lymphoma|Mantle cell lymphoma]]
−
| ||
+
|Disease
 +
|PENDING
 +
|
 +
|
 +
|
 +
|
 +
|SG
 +
|
 +
|
 +
|Mantle Cell Lymphoma
 +
|Mahsa Khanlari, MD and  Zhenya Tang, MD, PhD  The University Of Texas MD Anderson Cancer Center, Department of Hematopathology, Houston, Texas
 +
|Pending
 +
|
 +
|Target completion date 8/15/20
 
|-
 
|-
−
|Acute leukaemia of ambiguous lineage, NOS||Disease|| || || || || ||JH_MS||
+
|[[HAEM5:Leukaemic non-nodal mantle cell lymphoma|Leukaemic non-nodal mantle cell lymphoma]]
−
| ||
+
|Disease
 +
|
 +
|
 +
|
 +
|
 +
|
 +
|SG
 +
|
 +
|
 +
|NEW (No Prior)
 +
|NEW (No Prior)
 +
|NEW (No Prior)
 +
|NEW (No Prior)
 +
|NEW (No Prior)
 
|-
 
|-
−
|Acute undifferentiated leukaemia||Disease||Amelia Nakanishi, MD and Shashi Shetty, PhD|| || || || ||JH_MS||
+
!Disease (5th Edition)
−
| ||
+
!Page Type
 +
!<span style="color:#0070C0">Author (5th Edition) (Note: please indicate trainees in parentheses)
 +
!Date Assigned to Author (5th Edition)
 +
!Target Completion Date (5th Edition)
 +
!Content Status (5th Edition)(Pending or Complete)
 +
!Date Completed by Author (5th Edition)
 +
!Associate Editor
 +
!Date of Last Editor Review (5th Edition)
 +
!Notes (5th Edition)
 +
!Correlated Prior Disease Name (4th Edition)
 +
!Correlated Prior Author (4th Edition)
 +
!Prior Content Status (4th Edition)(Pending or Complete)
 +
!Prior Date of Last Editor Review (4th Edition)
 +
!Prior Notes (4th Edition)
 
|-
 
|-
 +
|[[HAEM5:Transformations of indolent B-cell lymphomas|Transformations of indolent B-cell lymphomas]]
 +
|Disease
 
|
 
|
 
|
 
|
Line 395: Line 1,953:
 
|
 
|
 
|
 
|
 +
|SG
 
|
 
|
 +
|Include content on chronic myelomonocytic leukemia in transformation and refractory anaemia with excess blasts in transformation
 +
|NEW (No Prior)
 +
|NEW (No Prior)
 +
|NEW (No Prior)
 +
|NEW (No Prior)
 +
|NEW (No Prior)
 +
|-
 +
|[[HAEM5:Diffuse large B-cell lymphoma, NOS|Diffuse large B-cell lymphoma, NOS]]||Disease||PENDING
 +
| || || || ||GC|| ||
 +
|Diffuse Large B-cell Lymphoma, Not Otherwise Specified
 +
|Ashwini Yenamandra, PhD FACMG, Vanderbilt University Medical Center
 +
|Pending
 
|
 
|
 +
|Requested to update 14022022
 +
|-
 +
|[[HAEM5:T-cell/histiocyte-rich large B-cell lymphoma|T-cell/histiocyte-rich large B-cell lymphoma]]||Disease|| || || || || ||GC|| ||
 +
|NEW (No Prior)
 +
|NEW (No Prior)
 +
|NEW (No Prior)
 +
|NEW (No Prior)
 +
|NEW (No Prior)
 +
|-
 +
|[[HAEM5:Diffuse large B-cell lymphoma / high grade B-cell lymphoma with MYC and BCL2 rearrangements|Diffuse large B-cell lymphoma / high grade B-cell lymphoma with MYC and BCL2 rearrangements]]||Disease||PENDING
 +
| || || || ||GC|| ||
 +
|High-Grade B-cell Lymphoma with MYC and BCL2 and/or BCL6 Rearrangements
 +
|Kate Berry, MBBS, BBus (Hons), Pathology Queensland
 +
|Complete
 +
|24/02/2022
 
|
 
|
 +
|-
 +
|[[HAEM5:ALK-positive large B-cell lymphoma|ALK-positive large B-cell lymphoma]]||Disease||PENDING
 +
| || || || ||GC|| ||
 +
|ALK-Positive Large B-cell Lymphoma
 +
|Manando Nakasaki, MD, PhD (University of California, Irvine)  Fabiola Quintero-Rivera, MD, FACMG (University of California, Irvine)
 +
|Pending
 
|
 
|
 +
|Nakasaki Manando removed March 2022 due to no progress/contact 1y. Added Nakasaki Manando back n 8/29/22 based on newer email communication (Jennelle's note). 2021 template added. FQR emailed Manando on 4/12/23
 +
|-
 +
|[[HAEM5:Large B-cell lymphoma with IRF4 rearrangement|Large B-cell lymphoma with IRF4 rearrangement]]||Disease||PENDING
 +
| || || || ||GC|| ||
 +
|Large B-cell Lymphoma with IRF4 Rearrangement
 +
|Afia Hasnain, MBBS, PhD
 +
|Complete
 +
|5/26/2021
 
|
 
|
 +
|-
 +
|[[HAEM5:High grade B-cell lymphoma with 11q aberrations|High grade B-cell lymphoma with 11q aberrations]]||Disease||PENDING
 +
| || || || ||GC|| ||
 +
|Burkitt-Like Lymphoma with 11q Aberration
 +
|Lauren Shealy, MD, Medical University of South Carolina  Daynna Wolff, PhD, Medical University of South Carolina
 +
|Comlete
 +
|27/01/2022
 
|
 
|
 
|-
 
|-
−
|Mature plasmacytoid dendritic cell proliferation associated with myeloid neoplasm||Disease|| || || || || ||JH_MS||
+
|[[HAEM5:Lymphomatoid granulomatosis|Lymphomatoid granulomatosis]]||Disease|| || || || || ||GC|| ||
−
| ||
+
|NEW (No Prior)
 +
|NEW (No Prior)
 +
|NEW (No Prior)
 +
|NEW (No Prior)
 +
|NEW (No Prior)
 
|-
 
|-
−
|Blastic plasmacytoid dendritic cell neoplasm||Disease||Hao Liu, MD and Daynna J. Wolff, PhD|| || || || ||JH_MS||
+
|[[HAEM5:EBV-positive diffuse large B-cell lymphoma|EBV-positive diffuse large B-cell lymphoma]]||Disease||Fnu Monika (trainee) + Andrew Siref as mentor
−
| ||
+
|3/22/24|| ||Pending|| ||GC|| ||
 +
|NEW (No Prior)
 +
|NEW (No Prior)
 +
|NEW (No Prior)
 +
|NEW (No Prior)
 +
|NEW (No Prior)
 
|-
 
|-
−
|Monoclonal B-cell lymphocytosis||Disease|| || || || || ||SP||
+
|[[HAEM5:Diffuse large B-cell lymphoma associated with chronic inflammation|Diffuse large B-cell lymphoma associated with chronic inflammation]]||Disease|| || || || || ||GC|| ||
−
| ||
+
|NEW (No Prior)
 +
|NEW (No Prior)
 +
|NEW (No Prior)
 +
|NEW (No Prior)
 +
|NEW (No Prior)
 
|-
 
|-
−
|Chronic lymphocytic leukaemia/small lymphocytic lymphoma||Disease||Jamie Nagy, PhD, University of Iowa  Honey Reddi, PhD|| || || || ||SP||
+
!Disease (5th Edition)
−
| ||
+
!Page Type
 +
!<span style="color:#0070C0">Author (5th Edition) (Note: please indicate trainees in parentheses)
 +
!Date Assigned to Author (5th Edition)
 +
!Target Completion Date (5th Edition)
 +
!Content Status (5th Edition)(Pending or Complete)
 +
!Date Completed by Author (5th Edition)
 +
!Associate Editor
 +
!Date of Last Editor Review (5th Edition)
 +
!Notes (5th Edition)
 +
!Correlated Prior Disease Name (4th Edition)
 +
!Correlated Prior Author (4th Edition)
 +
!Prior Content Status (4th Edition)(Pending or Complete)
 +
!Prior Date of Last Editor Review (4th Edition)
 +
!Prior Notes (4th Edition)
 
|-
 
|-
−
|Hairy cell leukaemia||Disease||*Snehal Patel, MD, PhD|| || || || ||SP||
+
|[[HAEM5:Fibrin-associated large B-cell lymphoma|Fibrin-associated large B-cell lymphoma]]||Disease||PENDING
−
| ||
+
| || || || ||GC|| ||Note: previously a subset DLBCL assoc with chronic inflam
 +
|Originally called Fibrin-Associated Diffuse Large B-cell Lymphoma; NEW (No Prior)
 +
|NEW (No Prior)
 +
|NEW (No Prior)
 +
|NEW (No Prior)
 +
|NEW (No Prior)
 
|-
 
|-
−
|Splenic marginal zone lymphoma||Disease||*Snehal Patel, MD, PhD|| || || || ||SP||
+
|[[HAEM5:Fluid overload-associated large B-cell lymphoma|Fluid overload-associated large B-cell lymphoma]]||Disease|| || || || || ||GC|| ||
−
| ||
+
|NEW (No Prior)
 +
|NEW (No Prior)
 +
|NEW (No Prior)
 +
|NEW (No Prior)
 +
|NEW (No Prior)
 
|-
 
|-
−
|Splenic diffuse red pulp small B-cell lymphoma||Disease||*Snehal Patel, MD, PhD|| || || || ||SP||
+
|[[HAEM5:Plasmablastic lymphoma|Plasmablastic lymphoma]]||Disease||PENDING
−
| ||
+
| || || || ||GC|| ||
 +
|Plasmablastic Lymphoma
 +
|Mark Evans, MD (University of California, Irvine)  Fabiola Quintero-Rivera, MD (University of California, Irvine)
 +
|Complete
 +
|28/03/2022
 +
|
 
|-
 
|-
−
|Splenic B-cell lymphoma/leukaemia with prominent nucleoli||Disease||*Snehal Patel, MD, PhD|| || || || ||SP||
+
|[[HAEM5:Primary large B-cell lymphoma of immune-privileged sites|Primary large B-cell lymphoma of immune-privileged sites]]||Disease||PENDING
−
| ||
+
| || || || ||GC|| ||
 +
|(1) Diffuse Large B-cell Lymphoma, Not Otherwise Specified + (2) Primary Diffuse Large B-cell Lymphoma of the CNS
 +
|(1) Ashwini Yenamandra, PhD FACMG, Vanderbilt University Medical Center + (2) Laveniya Satgunaseelan, FRCPA, Department of Neuropathology, Royal Prince Alfred Hospital
 +
|(1) Pending + (2) Complete
 +
|(1) Not ready + (2) 03/28/22
 +
|For "Diffuse Large B-cell Lymphoma, Not Otherwise Specified" page from Ash, Greg requested to update 14022022
 
|-
 
|-
−
|Lymphoplasmacytic lymphoma||Disease||Kapitolina Semenova, MD, Jack Reid, MD, Fabiola Quintero-Rivera, MD  Departments of Pathology, Laboratory Medicine, and *Pediatrics, Division of Genetic and Genomic Medicine, University of California, Irvine (UCI)|| || || || ||SP||
+
|[[HAEM5:Primary cutaneous diffuse large B-cell lymphoma, leg type|Primary cutaneous diffuse large B-cell lymphoma, leg type]]||Disease|| || || || || ||GC|| ||
−
| ||
+
|NEW (No Prior)
 +
|NEW (No Prior)
 +
|NEW (No Prior)
 +
|NEW (No Prior)
 +
|NEW (No Prior)
 
|-
 
|-
−
|Extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue||Disease|| || || || || ||SP||
+
|[[HAEM5:Intravascular large B-cell lymphoma|Intravascular large B-cell lymphoma]]||Disease||PENDING
−
| ||
+
| || || || ||GC|| ||
 +
|Intravascular Large B-cell Lymphoma
 +
|Kate Berry, MBBS, BBus (Hons), Pathology Queensland, Greg Corboy
 +
|Complete
 +
|9/1/22
 +
|Emailed 28/3/2022 for progress update
 
|-
 
|-
−
|Primary cutaneous marginal zone lymphoma||Disease|| || || || || ||SP||
+
|[[HAEM5:Primary mediastinal large B-cell lymphoma|Primary mediastinal large B-cell lymphoma]]||Disease|| || || || || ||GC|| ||
−
| ||
+
|NEW (No Prior)
 +
|NEW (No Prior)
 +
|NEW (No Prior)
 +
|NEW (No Prior)
 +
|NEW (No Prior)
 
|-
 
|-
−
|Nodal marginal zone lymphoma||Disease||Andrew Ly, DO and Shivani Golem, PhD, FACMG|| || || || ||SP||
+
|[[HAEM5:Mediastinal grey zone lymphoma|Mediastinal grey zone lymphoma]]||Disease|| || || || || ||GC|| ||
−
| ||
+
|NEW (No Prior)
 +
|NEW (No Prior)
 +
|NEW (No Prior)
 +
|NEW (No Prior)
 +
|NEW (No Prior)
 
|-
 
|-
−
|Paediatric nodal marginal zone lymphoma||Disease||* Kathleen M. Schieffer, PhD * Ruthann Pfau, PhD|| || || || ||SP||
+
|[[HAEM5:High-grade B-cell lymphoma, NOS|High-grade B-cell lymphoma, NOS]]||Disease||PENDING
−
| ||
+
| || || || ||GC|| ||
 +
|High-Grade B-cell Lymphoma, Not Otherwise Specified (NOS)
 +
|Aiko Otsubo, PhD, Indiana University, Holli Drendel
 +
|Complete
 +
|16/11/2021
 +
|
 
|-
 
|-
−
|In situ follicular B-cell neoplasm||Disease||Rachel D. Burnside, PhD, MBA, FACMGG|| || || || ||SP||
+
|[[HAEM5:Burkitt lymphoma|Burkitt lymphoma]]||Disease||PENDING
−
| ||
+
| || || || ||GC|| ||
 +
|Burkitt Lymphoma
 +
|Becky Leung, MBBS (Hons), BSc, Pathology Queensland
 +
|Complete
 +
|28/06/2021
 +
|
 
|-
 
|-
−
|Follicular lymphoma||Disease||Ruthann Pfau, PhD, FACMG, Nationwide Children's Hospital  Rachel D. Burnside, PhD, MBA, FACMG, University of Florida|| || || || ||SP||
+
!Disease (5th Edition)
−
| ||
+
!Page Type
 +
!<span style="color:#0070C0">Author (5th Edition) (Note: please indicate trainees in parentheses)
 +
!Date Assigned to Author (5th Edition)
 +
!Target Completion Date (5th Edition)
 +
!Content Status (5th Edition)(Pending or Complete)
 +
!Date Completed by Author (5th Edition)
 +
!Associate Editor
 +
!Date of Last Editor Review (5th Edition)
 +
!Notes (5th Edition)
 +
!Correlated Prior Disease Name (4th Edition)
 +
!Correlated Prior Author (4th Edition)
 +
!Prior Content Status (4th Edition)(Pending or Complete)
 +
!Prior Date of Last Editor Review (4th Edition)
 +
!Prior Notes (4th Edition)
 
|-
 
|-
−
|Paediatric-type follicular lymphoma||Disease||*Kathleen M. Schieffer, PhD *Ruthann Pfau, PhD, FACMG|| || || || ||SP||
+
|[[HAEM5:Primary effusion lymphoma|Primary effusion lymphoma]]||Disease|| || || || || ||GC|| ||
−
| ||
+
|NEW (No Prior)
 +
|NEW (No Prior)
 +
|NEW (No Prior)
 +
|NEW (No Prior)
 +
|NEW (No Prior)
 
|-
 
|-
−
|Duodenal-type follicular lymphoma||Disease|| || || || || ||SP||
+
|[[HAEM5:KSHV/HHV8-positive diffuse large B-cell lymphoma|KSHV/HHV8-positive diffuse large B-cell lymphoma]]||Disease|| || || || || ||GC|| ||
−
| ||
+
|NEW (No Prior)
 +
|NEW (No Prior)
 +
|NEW (No Prior)
 +
|NEW (No Prior)
 +
|NEW (No Prior)
 
|-
 
|-
−
|Primary cutaneous follicle centre lymphoma||Disease||Linlin Gao, MD, PhD and Shivani Golem, PhD, FACMG|| || || || ||SP||
+
|[[HAEM5:KSHV/HHV8-positive germinotropic lymphoproliferative disorder|KSHV/HHV8-positive germinotropic lymphoproliferative disorder]]||Disease|| || || || || ||GC|| ||
−
| ||
+
|NEW (No Prior)
 +
|NEW (No Prior)
 +
|NEW (No Prior)
 +
|NEW (No Prior)
 +
|NEW (No Prior)
 
|-
 
|-
−
|In situ mantle cell neoplasm||Disease||Rina Kansal, MD; Versiti Blood Center of Wisconsin|| || || || ||SP||
+
|[[HAEM5:Hyperplasias arising in immune deficiency/dysregulation|Hyperplasias arising in immune deficiency/dysregulation]]||Disease||FIX ISSUE! (on 5th edition page instructions say "encompassing non-destructive post-transplant lymphoproliferative disorders, among others"). "Non-Destructive Post-Transplant Lymphoproliferative Disorders" was a HAME4 page but no content.  What are "among others" from HAEM4 to see if we need to pull prior content into 5th edition page.|| || || || ||GC|| ||
−
| ||
+
|
 +
|
 +
|
 +
|
 +
|
 
|-
 
|-
−
|Mantle cell lymphoma||Disease||* Mahsa Khanlari, MD * Zhenya Tang, MD, PhD  The University Of Texas MD Anderson Cancer Center, Department of Hematopathology, Houston, Texas|| || || || ||SP||
+
|[[HAEM5:Polymorphic lymphoproliferative disorders arising in immune deficiency / dysregulation|Polymorphic lymphoproliferative disorders arising in immune deficiency / dysregulation]]||Disease||FIX ISSUE! (on 5th edition page instructions say "This page was converted to the new template on 2023-12-07. The original page can be found at [[HAEM4:Polymorphic Post-Transplant Lymphoproliferative Disorders]].
−
| ||
+
Note: encompassing polymorphic PTLD, other iatrogenic immunodef-assoc lympho disorders, among others)"
 +
| || || || ||GC|| ||
 +
|Polymorphic Post-Transplant Lymphoproliferative Disorders
 +
|Anna Shestakova, MD, PhD, Fellow, University of Utah/ARUP Laboratories  Fabiola Quintero-Rivera, MD, Professor, University of California Irvine (UCI)
 +
|Completed
 +
|26/4/2022
 +
|
 
|-
 
|-
−
|Leukaemic non-nodal mantle cell lymphoma||Disease||<br />|| || || || ||SP||
+
|[[HAEM5:EBV-positive mucocutaneous ulcer|EBV-positive mucocutaneous ulcer]]||Disease|| || || || || ||GC|| ||
−
| ||
+
|NEW (No Prior)
 +
|NEW (No Prior)
 +
|NEW (No Prior)
 +
|NEW (No Prior)
 +
|NEW (No Prior)
 
|-
 
|-
−
|Transformations of indolent B-cell lymphomas||Disease|| || || || || ||SP||
+
|[[HAEM5:Lymphomas arising in immune deficiency / dysregulation|Lymphomas arising in immune deficiency / dysregulation]]||Disease||FIX ISSUE! (on 5th edition page instructions say "encompassing monomorphic PTLD, classic HL PTLD, lymphomas assoc with HIV infection, among others"|| || || || ||GC|| ||
−
| ||
+
|
 +
|
 +
|
 +
|
 +
|
 
|-
 
|-
−
|Cold agglutinin disease||Disease|| || || || || ||SP||
+
|[[HAEM5:Inborn error of immunity-associated lymphoid proliferations and lymphomas|Inborn error of immunity-associated lymphoid proliferations and lymphomas]]||Disease||FIX ISSUE! (on 5th edition page instructions say "Editor said this overview page is a match. [Immunodeficiency-Associated Lymphoproliferative Disorders] [Lymphoproliferative diseases associated with primary immune disorders]") - last link name above is not a known page in haem4 or haem5.|| || || || ||GC|| ||
−
| ||
+
|
 +
|
 +
|
 +
|
 +
|
 
|-
 
|-
−
|IgM monoclonal gammopathy of undetermined significance||Disease|| || || || || ||SP||
+
|[[HAEM5:Classic Hodgkin lymphoma|Classic Hodgkin lymphoma]]||Disease||PENDING
−
| ||
+
| || || ||
 +
|GC|| ||Note: author needs to merge Nodular Sclerosis Classic Hodgkin Lymphoma, Lymphocyte-Rich Classic Hodgkin Lymphoma, Mixed Cellularity Classic Hodgkin Lymphoma, Lymphocyte-Depleted Classic Hodgkin Lymphoma
 +
|(1) Lymphocyte-Rich Classic Hodgkin Lymphoma + (2) Nodular Sclerosis Classic Hodgkin Lymphoma + (3) Mixed Cellularity Classic Hodgkin Lymphoma + (4) Lymphocyte-Depleted Classic Hodgkin Lymphoma
 +
|(1) Patricia V. Hernandez, M.D., Washington University School of Medicine and Holli Drendel + (2) Xiaolin Hu, PhD, Sema4 OpCo Inc. + (3 and 4) Patricia V. Hernandez
 +
|Pending + Completed (03/21/22)
 +
|Not completed for checking (1, 3 and 4) + 03/21/22 (2)
 +
|
 
|-
 
|-
−
|Non-IgM monoclonal gammopathy of undetermined significance||Disease|| || || || || ||SP||
+
|[[HAEM5:Nodular lymphocyte predominant Hodgkin lymphoma|Nodular lymphocyte predominant Hodgkin lymphoma]]||Disease|| || || || || ||GC|| ||
−
| ||
+
|NEW (No Prior)
 +
|NEW (No Prior)
 +
|NEW (No Prior)
 +
|NEW (No Prior)
 +
|NEW (No Prior)
 
|-
 
|-
−
|Monoclonal gammopathy of renal significance||Disease|| || || || || ||SP||
+
!Disease (5th Edition)
−
| ||
+
!Page Type
 +
!<span style="color:#0070C0">Author (5th Edition) (Note: please indicate trainees in parentheses)
 +
!Date Assigned to Author (5th Edition)
 +
!Target Completion Date (5th Edition)
 +
!Content Status (5th Edition)(Pending or Complete)
 +
!Date Completed by Author (5th Edition)
 +
!Associate Editor
 +
!Date of Last Editor Review (5th Edition)
 +
!Notes (5th Edition)
 +
!Correlated Prior Disease Name (4th Edition)
 +
!Correlated Prior Author (4th Edition)
 +
!Prior Content Status (4th Edition)(Pending or Complete)
 +
!Prior Date of Last Editor Review (4th Edition)
 +
!Prior Notes (4th Edition)
 
|-
 
|-
−
|Immunoglobulin-related (AL) amyloidosis||Disease||Heather E. Williams, PhD, MS, PgD, ErCLG|| || || || ||SP||
+
|[[HAEM5:Cold agglutinin disease|Cold agglutinin disease]]
−
| ||
+
|Disease
 +
|
 +
|
 +
|
 +
|
 +
|
 +
|SG
 +
|
 +
|
 +
|NEW (No Prior)
 +
|NEW (No Prior)
 +
|NEW (No Prior)
 +
|NEW (No Prior)
 +
|NEW (No Prior)
 
|-
 
|-
−
|Monoclonal immunoglobulin deposition disease||Disease||Chen Yang, MD, PhD, University of Michigan|| || || || ||SP||
+
|[[HAEM5:IgM monoclonal gammopathy of undetermined significance|IgM monoclonal gammopathy of undetermined significance]]||Disease|| || || || || ||SG|| ||
−
| ||
+
|NEW (No Prior)
 +
|NEW (No Prior)
 +
|NEW (No Prior)
 +
|NEW (No Prior)
 +
|NEW (No Prior)
 
|-
 
|-
−
|Mu heavy chain disease||Disease|| || || || || ||SP||
+
|[[HAEM5:Non-IgM monoclonal gammopathy of undetermined significance|Non-IgM monoclonal gammopathy of undetermined significance]]||Disease|| || || || || ||SG|| ||
−
| ||
+
|NEW (No Prior)
 +
|NEW (No Prior)
 +
|NEW (No Prior)
 +
|NEW (No Prior)
 +
|NEW (No Prior)
 
|-
 
|-
−
|Gamma heavy chain disease||Disease||Manisha Brahmbhatt-Sutariya  Asst. Professor, Dept. of Pathology and Human Anatomy  Technical Supervisor, Clinical Genetics Laboratory  Loma Linda University, Medical Center, CA|| || || || ||SP||
+
|[[HAEM5:Monoclonal gammopathy of renal significance|Monoclonal gammopathy of renal significance]]||Disease|| || || || || ||SG
 
| ||
 
| ||
 +
|NEW (No Prior)
 +
|NEW (No Prior)
 +
|NEW (No Prior)
 +
|NEW (No Prior)
 +
|NEW (No Prior)
 
|-
 
|-
−
|Alpha heavy chain disease||Disease|| || || || || ||SP||
+
|[[HAEM5:Immunoglobulin-related (AL) amyloidosis|Immunoglobulin-related (AL) amyloidosis]]||Disease||PENDING
 +
| || || || ||SG
 
| ||
 
| ||
 +
|Primary Amyloidosis
 +
|Heather E. Williams, PhD, MS, PgD, ErCLG
 +
|?PENDING<br />
 +
|
 +
|
 
|-
 
|-
−
|Plasmacytoma||Disease|| || || || || ||SP||
+
|[[HAEM5:Monoclonal immunoglobulin deposition disease|Monoclonal immunoglobulin deposition disease]]||Disease||PENDING
 +
| || || || ||SG
 
| ||
 
| ||
 +
|Light Chain and Heavy Chain Deposition Disease
 +
|Chen Yang, MD, PhD, University of Michigan
 +
|Complete
 +
|10/15/2022
 +
|
 
|-
 
|-
−
|Plasma cell myeloma / multiple myeloma||Disease||*Huan Mo, MD, MS *Zhenya Tang, MD, PhD  The University Of Texas MD Anderson Cancer Center, Department of Hematopathology, Houston, Texas|| || || || ||SP||
+
|[[HAEM5:Mu heavy chain disease|Mu heavy chain disease]]||Disease|| || || || || ||SG
 
| ||
 
| ||
 +
|NEW (No Prior)
 +
|NEW (No Prior)
 +
|NEW (No Prior)
 +
|NEW (No Prior)
 +
|NEW (No Prior)
 
|-
 
|-
−
|Plasma cell neoplasms with associated paraneoplastic syndrome||Disease||Sohini Anand, MBBS  Tharanga Niroshini Senaratne, PhD|| || || || ||SP||
+
|[[HAEM5:Gamma heavy chain disease|Gamma heavy chain disease]]||Disease||PENDING
 +
| || || || ||SG
 
| ||
 
| ||
 +
|Gamma Heavy Chain Disease
 +
|Manisha Brahmbhatt-Sutariya  Asst. Professor, Dept. of Pathology and Human Anatomy  Technical Supervisor, Clinical Genetics Laboratory  Loma Linda University, Medical Center, CA
 +
|Complete
 +
|5/26/2021
 +
|
 
|-
 
|-
−
|Kikuchi-Fujimoto disease||Disease|| || || || || ||SP||
+
|[[HAEM5:Alpha heavy chain disease|Alpha heavy chain disease]]||Disease|| || || || || ||SG
 
| ||
 
| ||
 +
|NEW (No Prior)
 +
|NEW (No Prior)
 +
|NEW (No Prior)
 +
|NEW (No Prior)
 +
|NEW (No Prior)
 
|-
 
|-
−
|Autoimmune lymphoproliferative syndrome||Disease|| || || || || ||SP||
+
|[[HAEM5:Plasmacytoma|Plasmacytoma]]||Disease||PENDING
−
| ||
+
| || || ||
 +
|SG
 +
| ||author needs to include Solitary plasmacytoma of bone, Extraosseous plasmacytoma (extramedullary) (v4 page did not have content on ccga)
 +
|NEW (No Prior) - no content on version 4 page "Plasmacytoma' originally assigned to Zhenya Tang
 +
|NEW (No Prior)
 +
|NEW (No Prior)
 +
|NEW (No Prior)
 +
|NEW (No Prior)
 
|-
 
|-
−
|Indolent T-lymphoblastic proliferation||Disease|| || || || || ||SP||
+
!Disease (5th Edition)
−
| ||
+
!Page Type
 +
!<span style="color:#0070C0">Author (5th Edition) (Note: please indicate trainees in parentheses)
 +
!Date Assigned to Author (5th Edition)
 +
!Target Completion Date (5th Edition)
 +
!Content Status (5th Edition)(Pending or Complete)
 +
!Date Completed by Author (5th Edition)
 +
!Associate Editor
 +
!Date of Last Editor Review (5th Edition)
 +
!Notes (5th Edition)
 +
!Correlated Prior Disease Name (4th Edition)
 +
!Correlated Prior Author (4th Edition)
 +
!Prior Content Status (4th Edition)(Pending or Complete)
 +
!Prior Date of Last Editor Review (4th Edition)
 +
!Prior Notes (4th Edition)
 
|-
 
|-
−
|T-prolymphocytic leukaemia||Disease|| || || || || ||SP||
+
|[[HAEM5:Plasma cell myeloma / multiple myeloma|Plasma cell myeloma / multiple myeloma]]||Disease||PENDING
−
| ||
+
| || || || ||SG
 +
| ||Note: author needs to include Plasma_Cell_Myeloma_Variants content in this page
 +
|(1) Plasma Cell Myeloma + (2) Plasma Cell Myeloma Variants
 +
|(1) Huan Mo, MD, MS and Zhenya Tang, MD, PhD  The University Of Texas MD Anderson Cancer Center, Department of Hematopathology, Houston, Texas + (2) Fariborz Rashid-Kolvear, PhD, FACMG, FCCMG
 +
|Pending
 +
|
 +
|
 
|-
 
|-
−
|T-large granular lymphocytic leukaemia||Disease||*Michelle Don, MD, MS|| || || || ||SP||
+
|[[HAEM5:Plasma cell neoplasms with associated paraneoplastic syndrome|Plasma cell neoplasms with associated paraneoplastic syndrome]]||Disease||PENDING
−
| ||
+
| || || ||
 +
|SG
 +
| ||Note: author needs to include POEMS, TEMPI, and look for AESOP content
 +
|(1) POEMS Syndrome + (2) TEMPI Syndrome
 +
|(1 and 2) Sohini Anand, MBBS  Tharanga Niroshini Senaratne, PhD
 +
|?PENDING
 +
|
 +
|
 
|-
 
|-
−
|NK-large granular lymphocytic leukaemia||Disease||Michelle Don, MD|| || || || ||SP||
+
|Disease (5th Edition)
−
| ||
+
|Page Type
 +
|Author (5th Edition) (Note: please indicate trainees in parenthesis)
 +
|Date Assigned to Author (5th Edition)
 +
|Target Completion Date (5th Edition)
 +
|Content Status (5th Edition) (Pending or Complete)
 +
|Date Completed by Author (5th Edition)
 +
|Associate Editor
 +
|Date of Last Editor Review (5th Edition)
 +
|Notes (5th Edition)
 +
|Correlated Prior Disease Name (4th Edition)
 +
|Correlated Prior Author (4th Edition)
 +
|Prior Content Status (4th Edition) (Pending or Complete)
 +
|Prior Date of Last Editor Review (4th Edition)
 +
|Prior Notes (4th Edition)
 
|-
 
|-
−
|Adult T-cell leukaemia/lymphoma||Disease||Prasad R. Kopparapu, PhD and Ferrin C. Wheeler, PhD, FACMG  Vanderbilt University Medical Center|| || || || ||SP||
+
|
−
| ||
+
====CHAPTER 5 (T-CELL AND NK-CELL LYMPHOID PROLIFERATIONS AND LYMPHOMAS)====
 +
|
 +
----<br />
 +
|
 +
----<br />
 +
|
 +
----<br />
 +
|
 +
----<br />
 +
|
 +
----<br />
 +
|
 +
----<br />
 +
|
 +
----<br />
 +
|
 +
----<br />
 +
|
 +
----<br />
 +
|
 +
----<br />
 +
|
 +
----<br />
 +
|
 +
----<br />
 +
|
 +
----<br />
 +
|
 +
----<br />
 
|-
 
|-
−
|Sezary syndrome||Disease||Madison E. Hannay, DO, Medical University of South Carolina  Tingting Barrett, MD, Medical University of South Carolina  Daynna J. Wolff, PhD, Medical University of South Carolina|| || || || ||SP||
+
|[[HAEM5:Kikuchi-Fujimoto disease|Kikuchi-Fujimoto disease]]||Disease|| || || || || ||Sumi Kitahara (SK)
 
| ||
 
| ||
 +
|NEW (No Prior)
 +
|NEW (No Prior)
 +
|NEW (No Prior)
 +
|NEW (No Prior)
 +
|NEW (No Prior)
 
|-
 
|-
−
|Aggressive NK-cell leukaemia||Disease||Shanelle De Lancy, MD, Shashirekha Shetty, PhD|| || || || ||SP||
+
|[[HAEM5:Autoimmune lymphoproliferative syndrome|Autoimmune lymphoproliferative syndrome]]||Disease||Aviv Oren, MD (trainee), Karin Miller, MD
−
| ||
+
|3/25/2024
 +
| || || ||SK|| ||
 +
|NEW (No Prior)
 +
|NEW (No Prior)
 +
|NEW (No Prior)
 +
|NEW (No Prior)
 +
|NEW (No Prior)
 
|-
 
|-
−
|Primary cutaneous CD4-positive small or medium T-cell lymphoproliferative disorder||Disease|| || || || || ||SP||
+
|[[HAEM5:Indolent T-lymphoblastic proliferation|Indolent T-lymphoblastic proliferation]]||Disease|| || || || || ||SK|| ||
−
| ||
+
|NEW (No Prior)
 +
|NEW (No Prior)
 +
|NEW (No Prior)
 +
|NEW (No Prior)
 +
|NEW (No Prior)
 
|-
 
|-
−
|Primary cutaneous acral CD8-positive T-cell lymphoproliferative disorder||Disease|| || || || || ||SP||
+
|[[HAEM5:T-lymphoblastic leukaemia / lymphoma, NOS|T-lymphoblastic leukaemia / lymphoma, NOS]]||Disease|| || || || || ||SK|| ||
−
| ||
+
|NEW (No Prior)
 +
|NEW (No Prior)
 +
|NEW (No Prior)
 +
|NEW (No Prior)
 +
|NEW (No Prior)
 
|-
 
|-
−
|Mycosis fungoides||Disease||Jane Scribner, MD and Daynna J. Wolff, PhD|| || || || ||SP||
+
|[[HAEM5:Early T-precursor lymphoblastic leukaemia / lymphoma|Early T-precursor lymphoblastic leukaemia / lymphoma]]
−
| ||
+
|Disease
 +
|Fei Yang, MD
 +
|
 +
|
 +
|Pending
 +
|
 +
|SK
 +
|
 +
|
 +
|Early T-Cell Precursor Lymphoblastic Leukemia
 +
|Fei Yang, MD, FACMG, Kaiser Permanente Northwest
 +
|Pending
 +
|
 +
|
 
|-
 
|-
−
|Primary cutaneous CD30-positive T-cell lymphoproliferative disorder: Lymphomatoid papulosis||Disease|| || || || || ||SP||
+
|[[HAEM5:T-prolymphocytic leukaemia|T-prolymphocytic leukaemia]]
−
| ||
+
|Disease
 +
|Parastou Tizro, MD (trainee); Celeste Eno, PhD
 +
|3/17/2024
 +
|
 +
|Complete
 +
|6/24/2024
 +
|SK
 +
|7/1/2024
 +
|
 +
|NEW (No Prior)
 +
|NEW (No Prior)
 +
|NEW (No Prior)
 +
|NEW (No Prior)
 +
|NEW (No Prior)
 
|-
 
|-
−
|Primary cutaneous CD30-positive T-cell lymphoproliferative disorder: Primary cutaneous anaplastic large cell lymphoma||Disease||Theresa Spivey, MD, Shashirekha Shetty, PhD|| || || || ||SP||
+
!Disease (5th Edition)
−
| ||
+
!Page Type
 +
!<span style="color:#0070C0">Author (5th Edition) (Note: please indicate trainees in parentheses)
 +
!Date Assigned to Author (5th Edition)
 +
!Target Completion Date (5th Edition)
 +
!Content Status (5th Edition)(Pending or Complete)
 +
!Date Completed by Author (5th Edition)
 +
!Associate Editor
 +
!Date of Last Editor Review (5th Edition)
 +
!Notes (5th Edition)
 +
!Correlated Prior Disease Name (4th Edition)
 +
!Correlated Prior Author (4th Edition)
 +
!Prior Content Status (4th Edition)(Pending or Complete)
 +
!Prior Date of Last Editor Review (4th Edition)
 +
!Prior Notes (4th Edition)
 
|-
 
|-
−
|Subcutaneous panniculitis-like T-cell lymphoma||Disease|| || || || || ||SP||
+
|[[HAEM5:T-large granular lymphocytic leukaemia|T-large granular lymphocytic leukaemia]]||Disease||Nicolas LaScala (trainee); Michelle Don, MD, MS
−
| ||
+
|3/17/2024 (trainee name added on 9/9/24 by JH)
 +
|6/30/24
 +
|Pending
 +
| ||SK|| ||
 +
|T-cell Large Granular Lymphocytic Leukemia
 +
|Michelle Don, MD, MS
 +
|Pending
 +
|
 +
|
 
|-
 
|-
−
|Primary cutaneous gamma/delta T-cell lymphoma||Disease|| || || || || ||SP||
+
|[[HAEM5:NK-large granular lymphocytic leukaemia|NK-large granular lymphocytic leukaemia]]||Disease||Hailee St. Louis (trainee);
−
| ||
+
Michelle Don, MD, MS
 +
|3/17/2024
 +
|6/30/24
 +
|Pending
 +
| ||SK|| ||
 +
|Chronic Lymphoproliferative Disorder of NK Cells
 +
|Michelle Don, MD
 +
|Pending
 +
|
 +
|
 
|-
 
|-
−
|Primary cutaneous CD8-positive aggressive epidermotropic cytotoxic T-cell lymphoma||Disease|| || || || || ||SP||
+
|[[HAEM5:Adult T-cell leukaemia/lymphoma|Adult T-cell leukaemia/lymphoma]]||Disease||
−
| ||
+
| || || || ||SK|| ||
 +
|Adult T-cell Leukemia/Lymphoma
 +
|Prasad R. Kopparapu, PhD and Ferrin C. Wheeler, PhD, FACMG  Vanderbilt University Medical Center
 +
|?Pending
 +
|
 +
|
 
|-
 
|-
−
|Primary cutaneous peripheral T-cell lymphoma, NOS||Disease|| || || || || ||SP||
+
|[[HAEM5:Sezary syndrome|Sezary syndrome]]||Disease||Daynna J. Wolff, PhD
−
| ||
+
|3/22/2024
 +
| || || ||SK|| ||
 +
|Sézary Syndrome
 +
|Madison E. Hannay, DO, Medical University of South Carolina  Tingting Barrett, MD, Medical University of South Carolina  Daynna J. Wolff, PhD, Medical University of South Carolina
 +
|Pending
 +
|
 +
|
 
|-
 
|-
−
|Indolent T-cell lymphoma of the gastrointestinal tract||Disease||Derick Okwan-Duodu MD, PhD; Sumire Kitahara, MD|| || || || ||SP||
+
|[[HAEM5:Aggressive NK-cell leukaemia|Aggressive NK-cell leukaemia]]||Disease||Rabail Aslam, MD (fellow); Shashirekha Shetty, PhD
−
| ||
+
|7/1/2024||8/31/2024
 +
|Pending
 +
| ||SK|| ||
 +
|Aggressive NK-cell Leukemia
 +
|Shanelle De Lancy, MD, Shashirekha Shetty, PhD
 +
|?Pending
 +
|
 +
|
 
|-
 
|-
−
|Indolent NK-cell lymphoproliferative disorder of the gastrointestinal tract||Disease|| || || || || ||SP||
+
|[[HAEM5:Primary cutaneous CD4-positive small or medium T-cell lymphoproliferative disorder|Primary cutaneous CD4-positive small or medium T-cell lymphoproliferative disorder]]||Disease||Amanda Xu, MD/MSc, Teodora Popa (resident)
−
| ||
+
|3/19/2024
 +
| ||Pending
 +
| ||SK|| ||
 +
|NEW (No Prior)
 +
|NEW (No Prior)
 +
|NEW (No Prior)
 +
|NEW (No Prior)
 +
|NEW (No Prior)
 
|-
 
|-
−
|Enteropathy-associated T-cell lymphoma||Disease||*Derick Okwan-Duodu, MD, PhD *Sumire Kitahara, MD|| || || || ||SP||
+
|[[HAEM5:Primary cutaneous acral CD8-positive T-cell lymphoproliferative disorder|Primary cutaneous acral CD8-positive T-cell lymphoproliferative disorder]]||Disease||Ahmed Eladely (trainee),
−
| ||
+
 
 +
Andrew Siref, MD
 +
|4/12/2024
 +
| ||Pending
 +
| ||SK|| ||
 +
|NEW (No Prior)
 +
|NEW (No Prior)
 +
|NEW (No Prior)
 +
|NEW (No Prior)
 +
|NEW (No Prior)
 
|-
 
|-
−
|Monomorphic epitheliotropic intestinal T-cell lymphoma||Disease||Derick Okwan-Duodu MD, PhD; Sumire Kitahara, MD|| || || || ||SP||
+
|[[HAEM5:Mycosis fungoides|Mycosis fungoides]]||Disease||Daynna J. Wolff, PhD
−
| ||
+
|3/22/2024
 +
| || || ||SK|| ||
 +
|Mycosis Fungoides
 +
|Jane Scribner, MD and Daynna J. Wolff, PhD
 +
|Pending
 +
|
 +
|
 
|-
 
|-
−
|Intestinal T-cell lymphoma, NOS||Disease||Derick Okwan MD, PhD (Stanford Medicine, CA)   Sumire Kitahara MD (Cedars-Sinai, CA)|| || || || ||SP||
+
|[[HAEM5:Primary cutaneous CD30-positive T-cell lymphoproliferative disorder: Lymphomatoid papulosis|Primary cutaneous CD30-positive T-cell lymphoproliferative disorder: Lymphomatoid papulosis]]||Disease||Rabail Aslam, MD (fellow); Shashirekha Shetty, PhD
−
| ||
+
|7/1/2024
 +
|8/31/224
 +
|Pending
 +
| ||SK|| ||
 +
|NEW (No Prior)
 +
|NEW (No Prior)
 +
|NEW (No Prior)
 +
|NEW (No Prior)
 +
|NEW (No Prior)
 
|-
 
|-
−
|Hepatosplenic T-cell lymphoma||Disease||*Michelle Don, MD, MS|| || || || ||SP||
+
|[[HAEM5:Primary cutaneous CD30-positive T-cell lymphoproliferative disorder: Primary cutaneous anaplastic large cell lymphoma|Primary cutaneous CD30-positive T-cell lymphoproliferative disorder: Primary cutaneous anaplastic large cell lymphoma]]||Disease||Rabail Aslam, MD (fellow); Shashirekha Shetty, PhD
−
| ||
+
|7/1/2024||8/31/2024
 +
|Pending
 +
| ||SK|| ||
 +
|Primary Cutaneous Anaplastic Large Cell Lymphoma
 +
|Theresa Spivey, MD, Shashirekha Shetty, PhD
 +
|Pending
 +
|
 +
|
 
|-
 
|-
−
|ALK-positive anaplastic large cell lymphoma||Disease|| || || || || ||SP||
+
!Disease (5th Edition)
−
| ||
+
!Page Type
 +
!<span style="color:#0070C0">Author (5th Edition) (Note: please indicate trainees in parentheses)
 +
!Date Assigned to Author (5th Edition)
 +
!Target Completion Date (5th Edition)
 +
!Content Status (5th Edition)(Pending or Complete)
 +
!Date Completed by Author (5th Edition)
 +
!Associate Editor
 +
!Date of Last Editor Review (5th Edition)
 +
!Notes (5th Edition)
 +
!Correlated Prior Disease Name (4th Edition)
 +
!Correlated Prior Author (4th Edition)
 +
!Prior Content Status (4th Edition)(Pending or Complete)
 +
!Prior Date of Last Editor Review (4th Edition)
 +
!Prior Notes (4th Edition)
 
|-
 
|-
−
|ALK-negative anaplastic large cell lymphoma||Disease||Miguel Gonzalez Mancera, MD  Sumire Kitahara, MD  Cedars-Sinai, Los Angeles, CA|| || || || ||SP||
+
|[[HAEM5:Subcutaneous panniculitis-like T-cell lymphoma|Subcutaneous panniculitis-like T-cell lymphoma]]||Disease||Raniah Alamri (Hemepath trainee)
−
| ||
+
|3/19/2024
 +
| ||Pending
 +
| ||SK|| ||
 +
|NEW (No Prior)
 +
|NEW (No Prior)
 +
|NEW (No Prior)
 +
|NEW (No Prior)
 +
|NEW (No Prior)
 
|-
 
|-
−
|Breast implant-associated anaplastic large cell lymphoma||Disease||Derick Okwan-Duodu, MD, PhD; Sumire Kitahara, MD Cedars-Sinai Medical Center|| || || || ||SP||
+
|[[HAEM5:Primary cutaneous gamma/delta T-cell lymphoma|Primary cutaneous gamma/delta T-cell lymphoma]]||Disease||Mahzad Azimpouran (trainee); Sumire Kitahara, MD
−
| ||
+
|6/30/2024
 +
| ||Pending
 +
| ||SK|| ||
 +
|NEW (No Prior)
 +
|NEW (No Prior)
 +
|NEW (No Prior)
 +
|NEW (No Prior)
 +
|NEW (No Prior)
 
|-
 
|-
−
|Nodal TFH cell lymphoma, angioimmunoblastic-type||Disease||* Sara Akhavanfard, M.D., Ph.D. * Ruthann Pfau, Ph.D., FACMG|| || || || ||SP||
+
|[[HAEM5:Primary cutaneous CD8-positive aggressive epidermotropic cytotoxic T-cell lymphoma|Primary cutaneous CD8-positive aggressive epidermotropic cytotoxic T-cell lymphoma]]||Disease||Ahmed Eladely (trainee),
−
| ||
+
 
 +
Andrew Siref, MD
 +
|4/12/2024|| ||Pending
 +
| ||SK|| ||
 +
|NEW (No Prior)
 +
|NEW (No Prior)
 +
|NEW (No Prior)
 +
|NEW (No Prior)
 +
|NEW (No Prior)
 
|-
 
|-
−
|Nodal TFH cell lymphoma, follicular-type||Disease|| || || || || ||SP||
+
|[[HAEM5:Primary cutaneous peripheral T-cell lymphoma, NOS|Primary cutaneous peripheral T-cell lymphoma, NOS]]||Disease|| || || || || ||SK|| ||
−
| ||
+
|NEW (No Prior)
 +
|NEW (No Prior)
 +
|NEW (No Prior)
 +
|NEW (No Prior)
 +
|NEW (No Prior)
 
|-
 
|-
−
|Nodal TFH cell lymphoma, NOS||Disease||Hans Magne Hamnvåg, MD  Kamran Mirza, MD, PhD|| || || || ||SP||
+
|[[HAEM5:Indolent T-cell lymphoma of the gastrointestinal tract|Indolent T-cell lymphoma of the gastrointestinal tract]]||Disease||
−
| ||
+
| || || || ||SK|| ||
 +
|Indolent T-cell Lymphoproliferative Disorder of the Gastrointestinal Tract
 +
|Derick Okwan-Duodu MD, PhD; Sumire Kitahara, MD
 +
|Pending
 +
|
 +
|
 
|-
 
|-
−
|Peripheral T-cell lymphoma, NOS||Disease|| || || || || ||SP||
+
|[[HAEM5:Indolent NK-cell lymphoproliferative disorder of the gastrointestinal tract|Indolent NK-cell lymphoproliferative disorder of the gastrointestinal tract]]||Disease|| || || || || ||SK|| ||
−
| ||
+
|NEW (No Prior)
 +
|NEW (No Prior)
 +
|NEW (No Prior)
 +
|NEW (No Prior)
 +
|NEW (No Prior)
 
|-
 
|-
−
|EBV-positive nodal T- and NK-cell lymphoma||Disease|| || || || || ||SP||
+
|[[HAEM5:Enteropathy-associated T-cell lymphoma|Enteropathy-associated T-cell lymphoma]]||Disease||Fnu Monika, MBBS (trainee),
−
| ||
+
Andrew Siref, MD
 +
|3/20/2024
 +
| ||Pending|| ||SK|| ||
 +
|Enteropathy-Associated T-cell Lymphoma
 +
|*Derick Okwan-Duodu, MD, PhD *Sumire Kitahara, MD
 +
|Complete
 +
|1/21/2021
 +
|
 
|-
 
|-
−
|Extranodal NK/T-cell lymphoma||Disease|| || || || || ||SP||
+
|[[HAEM5:Monomorphic epitheliotropic intestinal T-cell lymphoma|Monomorphic epitheliotropic intestinal T-cell lymphoma]]||Disease||Fnu Monika, MBBS (trainee),
−
| ||
+
Andrew Siref, MD
 +
|3/20/2024
 +
| ||Pending|| ||SK|| ||
 +
|Monomorphic Epitheliotropic Intestinal T-cell Lymphoma
 +
|Derick Okwan-Duodu MD, PhD; Sumire Kitahara, MD
 +
|Pending
 +
|
 +
|
 
|-
 
|-
−
|Severe mosquito bite allergy||Disease|| || || || || ||SP||
+
|[[HAEM5:Intestinal T-cell lymphoma, NOS|Intestinal T-cell lymphoma, NOS]]||Disease||
−
| ||
+
| || || || ||SK|| ||
 +
|Intestinal T-cell Lymphoma, Not Otherwise Specified (NOS)
 +
|Derick Okwan MD, PhD (Stanford Medicine, CA)  Sumire Kitahara MD (Cedars-Sinai, CA)
 +
|Complete
 +
|9/26/2022
 +
|
 
|-
 
|-
−
|Hydroa vacciniforme lymphoproliferative disorder||Disease|| || || || || ||SP||
+
|[[HAEM5:Hepatosplenic T-cell lymphoma|Hepatosplenic T-cell lymphoma]]||Disease||Forough Sargolzaeiaval (trainee);
−
| ||
+
Michelle Don, MD, MS
 +
|3/19/2024
 +
|6/30/24
 +
|Complete
 +
|5/13/24||SK||10/18/24||
 +
|Hepatosplenic T-cell Lymphoma
 +
|Michelle Don, MD, MS
 +
|Complete
 +
|1/21/2021
 +
|
 
|-
 
|-
−
|Systemic chronic active EBV disease||Disease|| || || || || ||SP||
+
!Disease (5th Edition)
−
| ||
+
!Page Type
 +
!<span style="color:#0070C0">Author (5th Edition) (Note: please indicate trainees in parentheses)
 +
!Date Assigned to Author (5th Edition)
 +
!Target Completion Date (5th Edition)
 +
!Content Status (5th Edition)(Pending or Complete)
 +
!Date Completed by Author (5th Edition)
 +
!Associate Editor
 +
!Date of Last Editor Review (5th Edition)
 +
!Notes (5th Edition)
 +
!Correlated Prior Disease Name (4th Edition)
 +
!Correlated Prior Author (4th Edition)
 +
!Prior Content Status (4th Edition)(Pending or Complete)
 +
!Prior Date of Last Editor Review (4th Edition)
 +
!Prior Notes (4th Edition)
 
|-
 
|-
−
|Systemic EBV-positive T-cell lymphoma of childhood||Disease||*Lisa A. Lansdon, PhD & Linda D. Cooley, MD, MBA|| || || || ||SP||
+
|[[HAEM5:ALK-positive anaplastic large cell lymphoma|ALK-positive anaplastic large cell lymphoma]]||Disease||Miguel Gonzalez Mancera, MD (trainee)
−
| ||
+
 
 +
Sumire Kitahara, MD
 +
|6/6/24|| ||Pending
 +
| ||SK|| ||
 +
|Anaplastic Large Cell Lymphoma, ALK-Positive
 +
|Miguel Gonzalez Mancera, MD
 +
 
 +
Sumire Kitahara, MD
 +
 
 +
Cedars-Sinai, Los Angeles, CA
 +
|Complete
 +
|09/23/2022
 +
|
 
|-
 
|-
−
|Follicular dendritic cell sarcoma||Disease||Anna Heimes Dillon, MD and Shivani Golem, PhD, FACMG|| || || || ||SP||
+
|[[HAEM5:ALK-negative anaplastic large cell lymphoma|ALK-negative anaplastic large cell lymphoma]]||Disease||Miguel Gonzalez Mancera, MD (trainee)
−
| ||
+
Sumire Kitahara, MD
 +
|6/6/24|| ||Pending
 +
| ||SK|| ||
 +
|Anaplastic Large Cell Lymphoma, ALK-Negative
 +
|Miguel Gonzalez Mancera, MD  Sumire Kitahara, MD  Cedars-Sinai, Los Angeles, CA
 +
|Complete
 +
|09/23/2022
 +
|
 
|-
 
|-
−
|EBV-positive inflammatory follicular dendritic cell sarcoma||Disease|| || || || || ||SP||
+
|[[HAEM5:Breast implant-associated anaplastic large cell lymphoma|Breast implant-associated anaplastic large cell lymphoma]]||Disease||Lynne Abruzzo, MD, PhD
−
| ||
+
|4/1/2024
 +
| ||Pending|| ||SK|| ||
 +
|Breast Implant-Associated Anaplastic Large Cell Lymphoma
 +
|Derick Okwan-Duodu, MD, PhD; Sumire Kitahara, MD  Cedars-Sinai Medical Center
 +
|Pending
 +
|
 +
|
 
|-
 
|-
−
|Fibroblastic reticular cell tumour||Disease|| || || || || ||SP||
+
|[[HAEM5:Nodal TFH cell lymphoma, angioimmunoblastic-type|Nodal TFH cell lymphoma, angioimmunoblastic-type]]||Disease||Rachel Burnside, PhD||7/28/2023
−
| ||
+
| ||Pending|| ||SK|| ||prior authors not available
 +
|Angioimmunoblastic T-cell Lymphoma
 +
|Sara Akhavanfard, M.D., Ph.D. and Ruthann Pfau, Ph.D., FACMG
 +
|Pending
 +
|
 +
|
 
|-
 
|-
−
|Intranodal palisaded myofibroblastoma||Disease|| || || || || ||SP||
+
|[[HAEM5:Nodal TFH cell lymphoma, follicular-type|Nodal TFH cell lymphoma, follicular-type]]||Disease||Rachel Burnside, PhD||7/28/2023
−
| ||
+
| ||Pending|| ||SK|| ||
 +
|NEW (No Prior)
 +
|NEW (No Prior)
 +
|NEW (No Prior)
 +
|NEW (No Prior)
 +
|NEW (No Prior)
 
|-
 
|-
−
|Littoral cell angioma||Disease|| || || || || ||SP||
+
|[[HAEM5:Nodal TFH cell lymphoma, NOS|Nodal TFH cell lymphoma, NOS]]||Disease||
−
| ||
+
| || || || ||SK|| ||
 +
|Nodal Peripheral T-cell Lymphoma with T Follicular Helper Phenotype
 +
|Hans Magne Hamnvåg, MD  Kamran Mirza, MD, PhD
 +
|Pending
 +
|
 +
|
 
|-
 
|-
−
|Splenic hamartoma||Disease|| || || || || ||SP||
+
|[[HAEM5:Peripheral T-cell lymphoma, NOS|Peripheral T-cell lymphoma, NOS]]||Disease||Bo Hong, MD
−
| ||
+
|6/25/2023
 +
| || || ||SK|| ||
 +
|NEW (No Prior)
 +
|NEW (No Prior)
 +
|NEW (No Prior)
 +
|NEW (No Prior)
 +
|NEW (No Prior)
 
|-
 
|-
−
|Sclerosing angiomatoid nodular transformation (SANT) of spleen||Disease|| || || || || ||SP||
+
|[[HAEM5:EBV-positive nodal T- and NK-cell lymphoma|EBV-positive nodal T- and NK-cell lymphoma]]||Disease||Fnu Monika, MBBS (trainee), Andrew Siref, MD||3/22/2024|| ||Pending|| ||SK|| ||
−
| ||
+
|NEW (No Prior)
 +
|NEW (No Prior)
 +
|NEW (No Prior)
 +
|NEW (No Prior)
 +
|NEW (No Prior)
 
|-
 
|-
−
|B-lymphoblastic leukaemia/lymphoma||Disease|| || || || || ||YA||
+
|[[HAEM5:Extranodal NK/T-cell lymphoma|Extranodal NK/T-cell lymphoma]]||Disease||Amanda Xu, MD/MSc, Teodora Popa (resident)
−
| ||
+
|3/19/2024
 +
| ||Pending
 +
| ||SK|| ||
 +
|NEW (No Prior)
 +
|NEW (No Prior)
 +
|NEW (No Prior)
 +
|NEW (No Prior)
 +
|NEW (No Prior)
 
|-
 
|-
−
|B-lymphoblastic leukaemia/lymphoma with high hyperdiploidy||Disease||Afia Hasnain, MBBS, PhD; Yassmine Akkari, PhD, FACMG|| || || || ||YA||
+
|[[HAEM5:Severe mosquito bite allergy|Severe mosquito bite allergy]]||Disease|| || || || || ||SK|| ||
−
| ||
+
|NEW (No Prior)
 +
|NEW (No Prior)
 +
|NEW (No Prior)
 +
|NEW (No Prior)
 +
|NEW (No Prior)
 
|-
 
|-
−
|B-lymphoblastic leukaemia/lymphoma with hypodiploidy||Disease||Ashwini Yenamandra PhD FACMG  Lisa Smith PhD FACMG  Yassmine Akkari PhD FACMG|| || || || ||YA||
+
!Disease (5th Edition)
−
| ||
+
!Page Type
 +
!<span style="color:#0070C0">Author (5th Edition) (Note: please indicate trainees in parentheses)
 +
!Date Assigned to Author (5th Edition)
 +
!Target Completion Date (5th Edition)
 +
!Content Status (5th Edition)(Pending or Complete)
 +
!Date Completed by Author (5th Edition)
 +
!Associate Editor
 +
!Date of Last Editor Review (5th Edition)
 +
!Notes (5th Edition)
 +
!Correlated Prior Disease Name (4th Edition)
 +
!Correlated Prior Author (4th Edition)
 +
!Prior Content Status (4th Edition)(Pending or Complete)
 +
!Prior Date of Last Editor Review (4th Edition)
 +
!Prior Notes (4th Edition)
 
|-
 
|-
−
|B-lymphoblastic leukaemia/lymphoma with iAMP21||Disease||Holli M. Drendel, PhD, FACMGG, Carolinas Pathology Group, Charlotte|| || || || ||YA||
+
|[[HAEM5:Hydroa vacciniforme lymphoproliferative disorder|Hydroa vacciniforme lymphoproliferative disorder]]||Disease|| || || || || ||SK|| ||
−
| ||
+
|NEW (No Prior)
 +
|NEW (No Prior)
 +
|NEW (No Prior)
 +
|NEW (No Prior)
 +
|NEW (No Prior)
 
|-
 
|-
−
|B-lymphoblastic leukaemia/lymphoma with BCR::ABL1 fusion||Disease||Afia Hasnain, MBBS, PhD; Yassmine Akkari, PhD, FACMG|| || || || ||YA||
+
|[[HAEM5:Systemic chronic active EBV disease|Systemic chronic active EBV disease]]||Disease||Karin Miller, MD
−
| ||
+
|3/25/2024
 +
| || || ||SK|| ||
 +
|NEW (No Prior)
 +
|NEW (No Prior)
 +
|NEW (No Prior)
 +
|NEW (No Prior)
 +
|NEW (No Prior)
 
|-
 
|-
−
|B-lymphoblastic leukaemia/lymphoma with BCR::ABL1-like features||Disease||Mark G. Evans, MD, University of California, Irvine  Fabiola Quintero-Rivera, MD, University of California, Irvine|| || || || ||YA||
+
|[[HAEM5:Systemic EBV-positive T-cell lymphoma of childhood|Systemic EBV-positive T-cell lymphoma of childhood]]||Disease||Karin Miller, MD
−
| ||
+
|3/25/2024
 +
| || || ||SK|| ||prior authors not available
 +
|Systemic EBV-Positive T-cell Lymphoma of Childhood
 +
|Lisa A. Lansdon, PhD and Linda D. Cooley, MD, MBA
 +
|Complete
 +
|11/21/2021
 +
|
 
|-
 
|-
−
|B lymphoblastic leukaemia/lymphoma with KMT2A rearrangement||Disease||Yassmine Akkari  Nicolas Millan|| || || || ||YA||
+
|
−
| ||
+
====CHAPTER 6 (STROMA-DERIVED NEOPLASMS OF LYMPHOID TISSUES)====
 +
|
 +
----<br />
 +
|
 +
----<br />
 +
|
 +
----<br />
 +
|
 +
----<br />
 +
|
 +
----<br />
 +
|
 +
----<br />
 +
|
 +
----<br />
 +
|
 +
----<br />
 +
|
 +
----<br />
 +
|
 +
----<br />
 +
|
 +
----<br />
 +
|
 +
----<br />
 +
|
 +
----<br />
 +
|
 +
----<br />
 
|-
 
|-
−
|B lymphoblastic leukaemia/lymphoma with ETV6::RUNX1 fusion||Disease||Marilena Melas, PhD; Yassmine Akkari, PhD, FACMG  Cancer Category/Type    B-Lymphoblastic Leukemia/Lymphoma|| || || || ||YA||
+
|[[HAEM5:Follicular dendritic cell sarcoma|Follicular dendritic cell sarcoma]]
−
| ||
+
|Disease
 +
|PENDING
 +
|
 +
|
 +
|
 +
|
 +
|GC
 +
|
 +
|
 +
|Follicular Dendritic Cell Sarcoma
 +
|Anna Heimes Dillon, MD and Shivani Golem, PhD, FACMG
 +
|?Pending
 +
|
 +
|
 
|-
 
|-
−
|B-lymphoblastic leukaemia/lymphoma with ETV6::RUNX1-like features||Disease|| || || || || ||YA||
+
|[[HAEM5:EBV-positive inflammatory follicular dendritic cell sarcoma|EBV-positive inflammatory follicular dendritic cell sarcoma]]
−
| ||
+
|Disease
 +
|
 +
|
 +
|
 +
|
 +
|
 +
|GC
 +
|
 +
|
 +
|NEW (No Prior)
 +
|NEW (No Prior)
 +
|NEW (No Prior)
 +
|NEW (No Prior)
 +
|NEW (No Prior)
 
|-
 
|-
−
|B lymphoblastic leukaemia/lymphoma with TCF3::PBX1 fusion||Disease||Binu Porath, PhD. Vanderbilt University Medical Center, Nashville, TN  Linda D. Cooley, MD, MBA. Children's Mercy Kansas City, Kansas City, MO|| || || || ||YA||
+
|[[HAEM5:Fibroblastic reticular cell tumour|Fibroblastic reticular cell tumour]]
−
| ||
+
|Disease
 +
|
 +
|
 +
|
 +
|
 +
|
 +
|GC
 +
|
 +
|
 +
|NEW (No Prior)
 +
|NEW (No Prior)
 +
|NEW (No Prior)
 +
|NEW (No Prior)
 +
|NEW (No Prior)
 
|-
 
|-
−
|B lymphoblastic leukaemia/lymphoma with IGH::IL3 fusion||Disease||Binu Porath, PhD. Vanderbilt University Medical Center, Nashville, TN  Linda D. Cooley, MD, MBA. Children's Mercy Kansas City, Kansas City, MO|| || || || ||YA||
+
|[[HAEM5:Intranodal palisaded myofibroblastoma|Intranodal palisaded myofibroblastoma]]
−
| ||
+
|Disease
 +
|
 +
|
 +
|
 +
|
 +
|
 +
|GC
 +
|
 +
|
 +
|NEW (No Prior)
 +
|NEW (No Prior)
 +
|NEW (No Prior)
 +
|NEW (No Prior)
 +
|NEW (No Prior)
 
|-
 
|-
−
|B lymphoblastic leukaemia/lymphoma with TCF3::HLF fusion||Disease|| || || || || ||YA||
+
!Disease (5th Edition)
−
| ||
+
!Page Type
 +
!<span style="color:#0070C0">Author (5th Edition) (Note: please indicate trainees in parentheses)
 +
!Date Assigned to Author (5th Edition)
 +
!Target Completion Date (5th Edition)
 +
!Content Status (5th Edition)(Pending or Complete)
 +
!Date Completed by Author (5th Edition)
 +
!Associate Editor
 +
!Date of Last Editor Review (5th Edition)
 +
!Notes (5th Edition)
 +
!Correlated Prior Disease Name (4th Edition)
 +
!Correlated Prior Author (4th Edition)
 +
!Prior Content Status (4th Edition)(Pending or Complete)
 +
!Prior Date of Last Editor Review (4th Edition)
 +
!Prior Notes (4th Edition)
 
|-
 
|-
−
|B-lymphoblastic leukaemia/lymphoma with other defined genetic alterations||Disease|| || || || || ||YA||
+
|[[HAEM5:Littoral cell angioma|Littoral cell angioma]]
−
| ||
+
|Disease
 +
|
 +
|
 +
|
 +
|
 +
|
 +
|GC
 +
|
 +
|
 +
|NEW (No Prior)
 +
|NEW (No Prior)
 +
|NEW (No Prior)
 +
|NEW (No Prior)
 +
|NEW (No Prior)
 
|-
 
|-
−
|B-lymphoblastic leukaemia/lymphoma, NOS||Disease|| || || || || ||YA||
+
|[[HAEM5:Splenic hamartoma|Splenic hamartoma]]
−
| ||
+
|Disease
 +
|
 +
|
 +
|
 +
|
 +
|
 +
|GC
 +
|
 +
|
 +
|NEW (No Prior)
 +
|NEW (No Prior)
 +
|NEW (No Prior)
 +
|NEW (No Prior)
 +
|NEW (No Prior)
 
|-
 
|-
−
|T-lymphoblastic leukaemia / lymphoma, NOS||Disease|| || || || || ||YA||
+
|[[HAEM5:Sclerosing angiomatoid nodular transformation (SANT) of spleen|Sclerosing angiomatoid nodular transformation (SANT) of spleen]]
−
| ||
+
|Disease
 +
|
 +
|
 +
|
 +
|
 +
|
 +
|GC
 +
|
 +
|
 +
|NEW (No Prior)
 +
|NEW (No Prior)
 +
|NEW (No Prior)
 +
|NEW (No Prior)
 +
|NEW (No Prior)
 
|-
 
|-
−
|Early T-precursor lymphoblastic leukaemia / lymphoma||Disease||Fei Yang, MD, FACMG, Kaiser Permanente Northwest|| || || || ||YA||
+
|
−
| ||
+
====CHAPTER 7 (GENETIC TUMOUR SYNDROMES)====
 +
|
 +
----<br />
 +
|
 +
----<br />
 +
|
 +
----<br />
 +
|
 +
----<br />
 +
|
 +
----<br />
 +
|
 +
----<br />
 +
|
 +
----<br />
 +
|
 +
----<br />
 +
|
 +
----<br />
 +
|
 +
----<br />
 +
|
 +
----<br />
 +
|
 +
----<br />
 +
|
 +
----<br />
 +
|
 +
----<br />
 
|-
 
|-
−
|Fanconi anaemia||Disease|| || || || || ||NA||
+
|[[HAEM5:Fanconi anaemia|Fanconi anaemia]]||Disease||[[GTS5:Volunteer Assignments and Opportunities|See GTS5 volunteer sheet for authorship status]]
−
| ||
+
|N/A||N/A
 +
|N/A
 +
|N/A
 +
|N/A
 +
|N/A
 +
|N/A
 +
|NEW (No Prior)
 +
|NEW (No Prior)
 +
|NEW (No Prior)
 +
|NEW (No Prior)
 +
|NEW (No Prior)
 
|-
 
|-
−
|Bloom syndrome||Disease|| || || || || ||NA||
+
|[[HAEM5:Bloom syndrome|Bloom syndrome]]||Disease||[[GTS5:Volunteer Assignments and Opportunities|See GTS5 volunteer sheet for authorship status]]
−
| ||
+
|N/A
 +
|N/A
 +
|N/A
 +
|N/A
 +
|N/A
 +
|N/A
 +
|N/A
 +
|NEW (No Prior)
 +
|NEW (No Prior)
 +
|NEW (No Prior)
 +
|NEW (No Prior)
 +
|NEW (No Prior)
 
|-
 
|-
−
|Ataxia-telangiectasia syndrome||Disease|| || || || || ||NA||
+
|[[HAEM5:Ataxia-telangiectasia syndrome|Ataxia-telangiectasia syndrome]]||Disease||[[GTS5:Volunteer Assignments and Opportunities|See GTS5 volunteer sheet for authorship status]]||N/A||N/A||N/A||N/A||N/A||N/A||N/A
−
| ||
+
|NEW (No Prior)
 +
|NEW (No Prior)
 +
|NEW (No Prior)
 +
|NEW (No Prior)
 +
|NEW (No Prior)
 
|-
 
|-
−
|RASopathies||Disease|| || || || || ||NA||
+
|[[HAEM5:RASopathies|RASopathies]]||Disease|| || || || || ||NA|| ||
−
| ||
+
|NEW (No Prior)
 +
|NEW (No Prior)
 +
|NEW (No Prior)
 +
|NEW (No Prior)
 +
|NEW (No Prior)
 
|}
 
|}

Latest revision as of 10:54, 19 November 2024

Welcome!

A new version of the Heme/Lymphoid book (5th edition) is in beta form on the WHO website with publication of a final form anticipated in 2024; we're aligning the related CCGA content to the new structure.

  • For assignments, please see the "Author" column below (highlighted blue).
  • If empty (no name is present), please volunteer to create content for that disease!
  • If "PENDING" is present, the original author of that disease page is currently being contacted about revising the content.
  • To volunteer, please [Contact us] with your page of interest.
  • Note - "NEW (No Prior)" in the 4th edition columns means either the disease is a new entity in the 5th edition or the disease was present in the 4th edition without content previously added.


WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues (5th Edition) Content
Disease (5th Edition) Page Type Author (5th Edition) (Note: please indicate trainees in parentheses) Date Assigned to Author (5th Edition) Target Completion Date (5th Edition) Content Status (5th Edition)(Pending or Complete) Date Completed by Author (5th Edition) Associate Editor Date of Last Editor Review (5th Edition) Notes (5th Edition) Correlated Prior Disease Name (4th Edition) Correlated Prior Author (4th Edition) Prior Content Status (4th Edition)(Pending or Complete) Prior Date of Last Editor Review (4th Edition) Prior Notes (4th Edition)

CHAPTER 2 (MYELOID PROLIFERATIONS AND NEOPLASMS)














Clonal haematopoiesis Disease Meenakshi Mehrotra 4/8/24 Pending Fabiola Quintero-Rivera (FQR) NEW (No Prior) NEW (No Prior) NEW (No Prior) NEW (No Prior) NEW (No Prior)
Clonal cytopenias of undetermined significance Disease FQR NEW (No Prior) NEW (No Prior) NEW (No Prior) NEW (No Prior) NEW (No Prior)
Chronic myeloid leukaemia Disease PENDING FQR Chronic Myeloid Leukemia (CML), BCR-ABL1 Positive Jack Reid, MD (University of California, Irvine) Mark Evans, MD (University of California, Irvine) Fabiola Quintero-Rivera, MD (University of California, Irvine) Complete Date page was created
Chronic neutrophilic leukaemia Disease PENDING FQR Chronic Neutrophilic Leukemia (CNL) Anamaria Munteanu, MD, Ph.D**, Harbor-UCLA Medical Center, Joseph J. Merlo Jr, MD. Ph.D**, Ashion Analytics, Fabiola Quintero-Rivera, University of California Irvine **contributed equally Complete Date page was created
Chronic eosinophilic leukaemia Disease PENDING FQR Chronic Eosinophilic Leukemia, Not Otherwise Specified Chelsea D. Kramish; Daynna J.Wolff complete/pending faculty review
Polycythaemia vera Disease PENDING FQR Polycythemia Vera (PV) Gokce A. Toruner, MD, PhD UT MD Anderson Cancer Center Complete
Essential thrombocythaemia Disease PENDING FQR Essential Thrombocythemia (ET) Rebecca Smith, PhD, Director, Genetics Associates, Nashville, TN Complete
Primary myelofibrosis Disease PENDING FQR Primary Myelofibrosis (PMF) T. Niroshi Senaratne, UCLA Complete 8/4/2020 before submission
Juvenile myelomonocytic leukaemia Disease PENDING FQR Juvenile Myelomonocytic Leukemia (JMML) Sarah Rapisardo, PhD, FACMG | Assistant Professor, Pathology

Associate Director | Division of Molecular Pathology, Genetics and Genomics

Duke University Health System Clinical Laboratories

PENDING importing content and reference formatting FQR has emailed SR several times, last 4/20/22
Disease (5th Edition) Page Type Author (5th Edition) (Note: please indicate trainees in parentheses) Date Assigned to Author (5th Edition) Target Completion Date (5th Edition) Content Status (5th Edition)(Pending or Complete) Date Completed by Author (5th Edition) Associate Editor Date of Last Editor Review (5th Edition) Notes (5th Edition) Correlated Prior Disease Name (4th Edition) Correlated Prior Author (4th Edition) Prior Content Status (4th Edition)(Pending or Complete) Prior Date of Last Editor Review (4th Edition) Prior Notes (4th Edition)
Myeloproliferative neoplasm, NOS Disease PENDING FQR Myeloproliferative Neoplasm (MPN), Unclassifiable Thomas Lee, MD, PhD, University of California, Los Angeles Complete
Cutaneous mastocytosis Disease PENDING FQR Cutaneous Mastocytosis S. Shawn Liu, MD, PhD and Thuy Phung, MD, PhD Complete
Systemic mastocytosis Disease PENDING FQR Systemic Mastocytosis Abdullah Osme, MD, University Hospitals Cleveland Medical Center, Case Western Reserve University Shashi Shetty, Ph.D. FACMG, FCCMG, University Hospitals Cleveland Medical Center, Case Western Reserve University Complete
Mast cell sarcoma Disease PENDING FQR Mast Cell Sarcoma Jordan Lowery, MD and Thuy Phung, MD, PhD Department of Pathology, University of South Alabama, Mobile, AL Complete
Myelodysplastic neoplasm with low blasts and 5q deletion Disease PENDING FQR Myelodysplastic Syndrome (MDS) with Isolated del(5q) Xiaolin Hu, Ph.D; Teresa Smolarek, Ph.D, FACMG Complete
Myelodysplastic neoplasm with low blasts and SF3B1 mutation Disease PENDING FQR NEW (No Prior) NEW (No Prior) NEW (No Prior) NEW (No Prior) NEW (No Prior)
Myelodysplastic neoplasm with biallelic TP53 inactivation Disease Eric McGinnis (assigned to new 5th edition page - FQR is this reviewed?) FQR NEW (No Prior) NEW (No Prior) NEW (No Prior) NEW (No Prior) NEW (No Prior)
Myelodysplastic neoplasm with low blasts Disease FQR NEW (No Prior) NEW (No Prior) NEW (No Prior) NEW (No Prior) NEW (No Prior)
Myelodysplastic neoplasm, hypoplastic Disease FQR NEW (No Prior) NEW (No Prior) NEW (No Prior) NEW (No Prior) NEW (No Prior)
Myelodysplastic neoplasm with increased blasts Disease PENDING FQR Myelodysplastic Syndrome (MDS) with Excess Blasts Xiaoli Du, Ph.D; Teresa A. Smolarek, Ph.D, FACMG Division of Human Genetics, Cincinnati Children's Hospital Medical Center Complete
Disease (5th Edition) Page Type Author (5th Edition) (Note: please indicate trainees in parentheses) Date Assigned to Author (5th Edition) Target Completion Date (5th Edition) Content Status (5th Edition)(Pending or Complete) Date Completed by Author (5th Edition) Associate Editor Date of Last Editor Review (5th Edition) Notes (5th Edition) Correlated Prior Disease Name (4th Edition) Correlated Prior Author (4th Edition) Prior Content Status (4th Edition)(Pending or Complete) Prior Date of Last Editor Review (4th Edition) Prior Notes (4th Edition)
Childhood myelodysplastic neoplasm with low blasts Disease PENDING FQR Refractory Cytopenia of Childhood Xiaoli Du, Ph.D; Teresa A. Smolarek, Ph.D, FACMG Division of Human Genetics, Cincinnati Children's Hospital Medical Center Complete
Childhood myelodysplastic neoplasm with increased blasts Disease PENDING FQR Refractory Cytopenia of Childhood Xiaoli Du, Ph.D; Teresa A. Smolarek, Ph.D, FACMG Division of Human Genetics, Cincinnati Children's Hospital Medical Center Complete
Chronic myelomonocytic leukaemia Disease PENDING FQR Chronic Myelomonocytic Leukemia (CMML) Linsheng Zhang, MD, PhD Complete
Myelodysplastic/myeloproliferative neoplasm with neutrophilia Disease PENDING FQR Atypical Chronic Myeloid Leukemia (aCML), BCR-ABL1 Negative Linsheng Zhang, MD, PhD Complete
Myelodysplastic/myeloproliferative neoplasm with SF3B1 mutation and thrombocytosis Disease PENDING FQR Myelodysplastic/Myeloproliferative Neoplasms with Ring Sideroblasts and Thrombocytosis (MDS/MPN-RS-T) Anamaria Munteanu, MD, Ph.D, Harbor-UCLA Medical Center, Fabiola Quintero-Rivera, University of California Irvine Complete Date page was created
Myelodysplastic/myeloproliferative neoplasm, NOS Disease PENDING FQR Myelodysplastic/Myeloproliferative Neoplasms (MDS/MPN), Unclassifiable Ruth MacKinnon PhD Victorian Cancer Cytogenetics Service Melbourne, Australia Complete
Acute promyelocytic leukaemia with PML::RARA fusion Disease (Rabail Aslam, MD)

Shashi Shetty, Ph.D.

7/1/24 Jennelle Hodge (JH)/ Malini Sathanoori (MS) Acute Promyelocytic Leukemia (APL) with PML-RARA Yiming Zhong, Ph.D., Megan Piazza, Ph.D., and Shashi Shetty, Ph.D. Complete 03/01/2021-MS (re-review)
Acute myeloid leukaemia with RUNX1::RUNX1T1 fusion Disease Mayuri Shende (trainee) and Scott Turner (mentor)
 9/22/24 Pending JH_MS Acute Myeloid Leukemia (AML) with t(8;21)(q22;q22.1); RUNX1-RUNX1T1 Christine Bryke, MD
Beth Israel Deaconess Medical Center, Boston, MA 		Complete 04/26/2021-MS (re-review)
Acute myeloid leukaemia with CBFB::MYH11 fusion Disease Mayuri Shende (trainee) and Scott Turner (mentor)
 9/22/24 Pending JH_MS Acute Myeloid Leukemia (AML) with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11 Christine Bryke, MD
Beth Israel Deaconess Medical Center, Boston, MA 		Complete 03/01/2021-MS (re-review)
Acute myeloid leukaemia with DEK::NUP214 fusion Disease PENDING JH_MS Acute Myeloid Leukemia (AML) with t(6;9)(p23;q34.1); DEK-NUP214 Jennelle C. Hodge, PhD, FACMG Complete 02/24/2021-MS (re-review)
Disease (5th Edition) Page Type Author (5th Edition) (Note: please indicate trainees in parentheses) Date Assigned to Author (5th Edition) Target Completion Date (5th Edition) Content Status (5th Edition)(Pending or Complete) Date Completed by Author (5th Edition) Associate Editor Date of Last Editor Review (5th Edition) Notes (5th Edition) Correlated Prior Disease Name (4th Edition) Correlated Prior Author (4th Edition) Prior Content Status (4th Edition)(Pending or Complete) Prior Date of Last Editor Review (4th Edition) Prior Notes (4th Edition)
Acute myeloid leukaemia with RBM15::MRTFA fusion Disease PENDING JH_MS Acute Myeloid Leukemia (AML) Megakaryoblastic with t(1;22)(p13.3;q13.1);RBM15-MKL1 Jennelle C. Hodge, PhD, FACMG Complete
Acute myeloid leukaemia with BCR::ABL1 fusion Disease JH_MS Acute Myeloid Leukemia (AML) with BCR-ABL1 Kay Weng Choy MBBS, Monash Medical Centre Complete
Acute myeloid leukaemia with KMT2A rearrangement Disease (Rabail Aslam, MD)

Shashi Shetty, Ph.D.

7/1/24 JH_MS Acute Myeloid Leukemia (AML) with t(9;11)(p21.3;q23.3); KMT2A-MLLT3 Megan Piazza, Ph.D., Yiming Zhong, Ph.D., Shashi Shetty, Ph.D. Complete 03/01/2021-MS (re-review)
Acute myeloid leukaemia with MECOM rearrangement Disease PENDING JH_MS Acute Myeloid Leukemia (AML) with inv(3)(q21.3q26.2) or t(3;3)(q21.3;q26.2);GATA2, MECOM Gordana Raca MD PhD, University of Southern California, Los Angeles Complete Need permission for figure? Update WHO?
Acute myeloid leukaemia with NUP98 rearrangement Disease Eric McGinnis, MD, Fatma Al-Bulushi (trannee) 12/20/23 JH_MS NEW (No Prior) NEW (No Prior) NEW (No Prior) NEW (No Prior) NEW (No Prior)
Acute myeloid leukaemia with NPM1 mutation Disease PENDING JH_MS Acute Myeloid Leukemia (AML) with Mutated NPM1 Xinjie Xu, PhD, FACMG Complete Add WHO reference
Acute myeloid leukaemia with CEBPA mutation Disease JH_MS Acute Myeloid Leukemia (AML) with Biallelic Mutations of CEBPA Paul Defazio, MSc, Monash Health Complete
Acute myeloid leukaemia, myelodysplasia-related Disease PENDING JH_MS Acute Myeloid Leukemia (AML) with Myelodysplasia-Related Changes Fei Yang, MD, FACMG
Oregon Health & Science University 		Complete
Acute myeloid leukaemia with other defined genetic alterations Disease JH_MS NEW (No Prior) NEW (No Prior) NEW (No Prior) NEW (No Prior) NEW (No Prior)
Acute myeloid leukaemia with minimal differentiation Disease JH_MS Acute Myeloid Leukemia (AML) with Minimal Differentiation Celeste Eno, PhD, Cedars Sinai Medical Center, Los Angeles, Fabiola Quintero-Rivera, MD, FACMG, University of California Irvine Complete
Disease (5th Edition) Page Type Author (5th Edition) (Note: please indicate trainees in parentheses) Date Assigned to Author (5th Edition) Target Completion Date (5th Edition) Content Status (5th Edition)(Pending or Complete) Date Completed by Author (5th Edition) Associate Editor Date of Last Editor Review (5th Edition) Notes (5th Edition) Correlated Prior Disease Name (4th Edition) Correlated Prior Author (4th Edition) Prior Content Status (4th Edition)(Pending or Complete) Prior Date of Last Editor Review (4th Edition) Prior Notes (4th Edition)
Acute myeloid leukaemia without maturation Disease PENDING JH_MS Acute Myeloid Leukemia (AML) without Maturation Jennelle C. Hodge, PhD, FACMG Complete
Acute myeloid leukaemia with maturation Disease PENDING JH_MS Acute Myeloid Leukemia (AML) with Maturation Jennelle C. Hodge, PhD, FACMG Complete
Acute basophilic leukaemia Disease Ashwini Yenamandra PhD FACMG 5/1/24 JH_MS Acute Basophilic Leukemia Ashwini Yenamandra PhD FACMG Complete
Acute myelomonocytic leukaemia Disease PENDING JH_MS Acute Myelomonocytic Leukemia Fei Yang, MD, FACMG
Oregon Health & Science University 		Complete
Acute monocytic leukaemia Disease PENDING JH_MS Acute Monoblastic and Monocytic Leukemia Fei Yang, MD, FACMG
Oregon Health & Science University 		Complete
Acute erythroid leukaemia Disease Ashwini Yenamandra PhD FACMG 5/1/24 JH_MS Pure Erythroid Leukemia Ashwini Yenamandra PhD FACMG Complete
Acute megakaryoblastic leukaemia Disease PENDING JH_MS Acute Megakaryoblastic Leukemia (AMKL) Fei Yang, MD, FACMG
Oregon Health & Science University 		Complete
Myeloid sarcoma Disease Yalda Naeini 6/11/24 JH_MS Myeloid Sarcoma Yalda Naeini, MD, School of Medicine at University of California Los Angeles Fabiola Quintero-Rivera, MD, FACMG, School of Medicine at University of California Irvine Complete
RESOLVE 4th edition AML-Related NON-WHO entities content Acute Myeloid Leukemia (AML) with Mutated FLT3 + Acute Myeloid Leukemia (AML) with NUP214-ABL1 + Acute Myeloid Leukemia (AML) with t(4;12)(q12;p13); CHIC2-ETV6 ISSUE- FIX


Resolve Non-WHO entities

Myeloid neoplasm post cytotoxic therapy Disease (Rabail Aslam, MD)

Shashi Shetty, Ph.D.

7/1/24 JH_MS Therapy-Related Myeloid Neoplasms Shawn A. Silver, DO, Shashi Shetty, Ph.D. Complete Check reference format
Disease (5th Edition) Page Type Author (5th Edition) (Note: please indicate trainees in parentheses) Date Assigned to Author (5th Edition) Target Completion Date (5th Edition) Content Status (5th Edition)(Pending or Complete) Date Completed by Author (5th Edition) Associate Editor Date of Last Editor Review (5th Edition) Notes (5th Edition) Correlated Prior Disease Name (4th Edition) Correlated Prior Author (4th Edition) Prior Content Status (4th Edition)(Pending or Complete) Prior Date of Last Editor Review (4th Edition) Prior Notes (4th Edition)
Myeloid neoplasms associated with germline predisposition Disease PENDING JH_MS Multiple pages including overview page (Myeloid Neoplasms with Germline Predisposition - Compendium of Cancer Genome Aberrations (ccga.io)) and 6 disease pages ( HAEM4:Acute Myeloid Leukaemia with Germline CEBPA Mutation, HAEM4:Myeloid Neoplasms with Germline DDX41 Mutation, HAEM4:Myeloid Neoplasms with Germline ETV6 Mutation, HAEM4:Myeloid Neoplasms with Germline GATA2 Mutation, HAEM4:Myeloid Neoplasms with Germline RUNX1 Mutation, HAEM4:Myeloid Neoplasms with Germline ANKRD26 Mutation) See links from instructions on the 5th edition page Complete Most were re-reviewed by MS on 03/02/2021 For page Acute Myeloid Leukaemia with Germline CEBPA Mutation - Note by MS of "Review completed, awaiting some clarification from JH - 07/04/2022"
Myeloid proliferations associated with Down syndrome Disease PENDING JH_MS MERGE 3 PAGES --> Transient Abnormal Myelopoiesis (TAM) Associated with Down Syndrome + Transient Abnormal Myelopoiesis (TAM) Associated with Down Syndrome + Myeloid Leukemia Associated with Down Syndrome Linda D Cooley, MD, MBA, Children's Mercy Hospital, Kansas City, MO Complete (all three pages)
Myeloid/lymphoid neoplasm with PDGFRA rearrangement Disease PENDING FQR Myeloid/Lymphoid Neoplasms with PDGFRA Rearrangement Jay Alden, DO Complete
Myeloid/lymphoid neoplasm with PDGFRB rearrangement Disease PENDING FQR Myeloid/Lymphoid Neoplasms with PDGFRB Rearrangement Christopher Sullivan, MD, MPH and Daynna J. Wolff, PhD Complete
Myeloid/lymphoid neoplasm with FGFR1 rearrangement Disease PENDING FQR Myeloid/Lymphoid Neoplasms with FGFR1 Rearrangement Yanna Ding, MD PhD Complete
Myeloid/lymphoid neoplasm with JAK2 rearrangement Disease ISSUE- FIX


Resolve Non-WHO entities

FQR Myeloid/Lymphoid Neoplasms with PCM1-JAK2 + consider a non-WHO page Myeloid/Lymphoid Neoplasms with ETV6-JAK2 (Myeloid/Lymphoid Neoplasms with ETV6-JAK2 - Compendium of Cancer Genome Aberrations (ccga.io)) + another non-WHO page Myeloid/Lymphoid Neoplasms with BCR-JAK2 (Myeloid/Lymphoid Neoplasms with BCR-JAK2 - Compendium of Cancer Genome Aberrations (ccga.io) ) - both non-WHO pages are authored by trainee Lauren Crowson-Hindman and Daynna Wolff Jessica Snider, M.D. and Daynna J. Wolff, PhD + non-WHO pages by trainee Lauren Crowson-Hindman and Daynna Wolff Complete
Myeloid/lymphoid neoplasm with FLT3 rearrangement Disease FQR NEW (No Prior) NEW (No Prior) NEW (No Prior) NEW (No Prior) NEW (No Prior)
Myeloid/lymphoid neoplasm with ETV6::ABL1 fusion Disease Mayuri Shende (trainee) and Scott Turner (mentor)
 9/22/24 Pending FQR NEW (No Prior) NEW (No Prior) NEW (No Prior) NEW (No Prior) NEW (No Prior)
Myeloid/lymphoid neoplasms with other tyrosine kinase fusion genes Disease FQR NEW (No Prior) NEW (No Prior) NEW (No Prior) NEW (No Prior) NEW (No Prior)
Mixed-phenotype acute leukaemia with BCR::ABL1 fusion Disease Tracy Tucker, PhD, FCCMG 4/6/24 Pending JH_MS Mixed Phenotype Acute Leukemia (MPAL) with t(9;22)(q34.1;q11.2); BCR-ABL1 Tracy Tucker, PhD, FCCMG Complete
Disease (5th Edition) Page Type Author (5th Edition) (Note: please indicate trainees in parentheses) Date Assigned to Author (5th Edition) Target Completion Date (5th Edition) Content Status (5th Edition)(Pending or Complete) Date Completed by Author (5th Edition) Associate Editor Date of Last Editor Review (5th Edition) Notes (5th Edition) Correlated Prior Disease Name (4th Edition) Correlated Prior Author (4th Edition) Prior Content Status (4th Edition)(Pending or Complete) Prior Date of Last Editor Review (4th Edition) Prior Notes (4th Edition)
Mixed-phenotype acute leukaemia with KMT2A rearrangement Disease Tracy Tucker, PhD, FCCMG 4/6/24 Pending JH_MS Mixed Phenotype Acute Leukemia (MPAL) with t(v;11q23.3); KMT2A Rearranged Tracy Tucker, PhD, FCCMG Complete
Acute leukaemia of ambiguous lineage with other defined genetic alterations Disease JH_MS NEW (No Prior) NEW (No Prior) NEW (No Prior) NEW (No Prior) NEW (No Prior)
Mixed-phenotype acute leukaemia, B/myeloid Disease (Rabail Aslam, MD)

Shashi Shetty, Ph.D.

7/1/24 JH_MS Mixed Phenotype Acute Leukemia (MPAL), B/Myeloid, Not Otherwise Specified Priyatharsini Nirmalanantham, MD and Shashi Shetty, PhD Complete
Mixed-phenotype acute leukaemia, T/myeloid Disease PENDING JH_MS Mixed Phenotype Acute Leukemia (MPAL), T/Myeloid, Not Otherwise Specified Narsis Attar, MD, PhD, Fabiola Quintero-Rivera, MD University of California, Irvine Complete
Mixed-phenotype acute leukaemia, rare types Disease Daynna Wolff, PhD 5/9/24 JH_MS Mixed-Phenotype Acute Leukemia, Not Otherwise Specified (NOS), Rare Types Elicia Goodale, MD, Medical University of South Carolina Daynna Wolff, PhD, Medical University of South Carolina PENDING
Acute leukaemia of ambiguous lineage, NOS Disease JH_MS NEW (No Prior) NEW (No Prior) NEW (No Prior) NEW (No Prior) NEW (No Prior)
Acute undifferentiated leukaemia Disease (Rabail Aslam, MD)

Shashi Shetty, Ph.D.

7/1/24 JH_MS Acute Undifferentiated Leukemia Amelia Nakanishi, MD and Shashi Shetty, PhD Complete Check reference format

CHAPTER 3 (HISTIOCYTIC/DENRITIC CELL NEOPLASMS)














Mature plasmacytoid dendritic cell proliferation associated with myeloid neoplasm Disease Greg Corboy (GC) NEW (No Prior) NEW (No Prior) NEW (No Prior) NEW (No Prior) NEW (No Prior)
Blastic plasmacytoid dendritic cell neoplasm Disease PENDING GC Blastic Plasmacytoid Dendritic Cell Neoplasm Hao Liu, MD and Daynna J. Wolff, PhD Complete Previously within myeloid section under JH/MS editors
Disease (5th Edition) Page Type Author (5th Edition) (Note: please indicate trainees in parentheses) Date Assigned to Author (5th Edition) Target Completion Date (5th Edition) Content Status (5th Edition)(Pending or Complete) Date Completed by Author (5th Edition) Associate Editor Date of Last Editor Review (5th Edition) Notes (5th Edition) Correlated Prior Disease Name (4th Edition) Correlated Prior Author (4th Edition) Prior Content Status (4th Edition)(Pending or Complete) Prior Date of Last Editor Review (4th Edition) Prior Notes (4th Edition)
Langerhans cell histiocytosis Disease PENDING GC Langerhans Cell Histiocytosis Dr Malaika Perchard BSci(MedSci), MBBS, FRACP, FRCPA, (Paediatric Haematologist) Pathology Queensland Complete 5/19/2022
 Date completed by author: 04/28/2022
Langerhans cell sarcoma Disease PENDING GC Langerhans Cell Sarcoma Dr Malaika Perchard BSci(MedSci), MBBS, FRACP, FRCPA, (Paediatric Haematologist) Pathology Queensland Complete 5/19/2022
 Date completed by author: 04/28/2022
Indeterminate dendritic cell tumour Disease GC NEW (No Prior) NEW (No Prior) NEW (No Prior) NEW (No Prior) NEW (No Prior)
Interdigitating dendritic cell sarcoma Disease GC NEW (No Prior) NEW (No Prior) NEW (No Prior) NEW (No Prior) NEW (No Prior)
Juvenile xanthogranuloma Disease Mayuri Shende (trainee) and Scott Turner (mentor)
 9/22/24 Pending GC NEW (No Prior) NEW (No Prior) NEW (No Prior) NEW (No Prior) NEW (No Prior)
Erdheim-Chester disease Disease Mayuri Shende (trainee) and Scott Turner (mentor)
 9/22/24 Pending GC NEW (No Prior) NEW (No Prior) NEW (No Prior) NEW (No Prior) NEW (No Prior)
Rosai-Dorfman Disease Disease Mayuri Shende (trainee) and Scott Turner (mentor)
 9/22/24 Pending GC NEW (No Prior) NEW (No Prior) NEW (No Prior) NEW (No Prior) NEW (No Prior)
ALK-positive histiocytosis Disease GC NEW (No Prior) NEW (No Prior) NEW (No Prior) NEW (No Prior) NEW (No Prior)
Histiocytic sarcoma Disease PENDING GC Histiocytic Sarcoma Marie-France Gagnon, MD, Mayo Clinic, Xinjie Xu, PhD FACMG, Mayo Clinic Complete 10/01/2021 Date completed by author: 10/01/2021
Disease (5th Edition) Page Type Author (5th Edition) (Note: please indicate trainees in parentheses) Date Assigned to Author (5th Edition) Target Completion Date (5th Edition) Content Status (5th Edition)(Pending or Complete) Date Completed by Author (5th Edition) Associate Editor Date of Last Editor Review (5th Edition) Notes (5th Edition) Correlated Prior Disease Name (4th Edition) Correlated Prior Author (4th Edition) Prior Content Status (4th Edition)(Pending or Complete) Prior Date of Last Editor Review (4th Edition) Prior Notes (4th Edition)

CHAPTER 4 (B-CELL LYMPHOID PROLIFERATIONS AND LYMPHOMAS)














Reactive B-cell rich lymphoid proliferations that can mimic lymphoma Disease GC NEW (No Prior) NEW (No Prior) NEW (No Prior) NEW (No Prior) NEW (No Prior)
IgG4-related disease Disease GC NEW (No Prior) NEW (No Prior) NEW (No Prior) NEW (No Prior) NEW (No Prior)
Unicentric Castleman disease Disease GC NEW (No Prior) NEW (No Prior) NEW (No Prior) NEW (No Prior) NEW (No Prior)
Idiopathic multicentric Castleman disease Disease GC NEW (No Prior) NEW (No Prior) NEW (No Prior) NEW (No Prior) NEW (No Prior)
KSHV/HHV8-associated multicentric Castleman disease Disease PENDING GC Multicentric Castleman Disease Sudha Arumugam, MD Complete 01/24/2022 Date completed by author: 01/24/2022
B-lymphoblastic leukaemia/lymphoma Disease PENDING Holli Drendel (HD) B-Lymphoblastic Leukemia/Lymphoma, Not Otherwise Specified Holli Drendel PENDING
B-lymphoblastic leukaemia/lymphoma with high hyperdiploidy Disease PENDING HD B-Lymphoblastic Leukemia/Lymphoma with Hyperdiploidy Afia Hasnain, MBBS, PhD; Yassmine Akkari, PhD, FACMG PENDING
B-lymphoblastic leukaemia/lymphoma with hypodiploidy Disease PENDING HD B-Lymphoblastic Leukemia/Lymphoma with Hypodiploidy Ashwini Yenamandra PhD FACMG Lisa Smith PhD FACMG Yassmine Akkari PhD FACMG Complete
B-lymphoblastic leukaemia/lymphoma with iAMP21 Disease Holli Drendel ?Complete? Looks like tables need more editing. HD B-Lymphoblastic Leukemia/Lymphoma with iAMP21 [but was completed as a 5th edition page by Holli] Holli M. Drendel, PhD, FACMGG, Carolinas Pathology Group, Charlotte ?Complete
Disease (5th Edition) Page Type Author (5th Edition) (Note: please indicate trainees in parentheses) Date Assigned to Author (5th Edition) Target Completion Date (5th Edition) Content Status (5th Edition)(Pending or Complete) Date Completed by Author (5th Edition) Associate Editor Date of Last Editor Review (5th Edition) Notes (5th Edition) Correlated Prior Disease Name (4th Edition) Correlated Prior Author (4th Edition) Prior Content Status (4th Edition)(Pending or Complete) Prior Date of Last Editor Review (4th Edition) Prior Notes (4th Edition)
B-lymphoblastic leukaemia/lymphoma with BCR::ABL1 fusion Disease PENDING HD B-Lymphoblastic Leukemia/Lymphoma with t(9;22)(q34.1;q11.2); BCR-ABL1 Afia Hasnain, MBBS, PhD; Yassmine Akkari, PhD, FACMG PENDING
B-lymphoblastic leukaemia/lymphoma with BCR::ABL1-like features Disease PENDING HD B-Lymphoblastic Leukemia/Lymphoma, BCR-ABL1-Like Mark G. Evans, MD, University of California, Irvine Fabiola Quintero-Rivera, MD, University of California, Irvine Complete
B lymphoblastic leukaemia/lymphoma with KMT2A rearrangement Disease PENDING HD B-Lymphoblastic Leukemia/Lymphoma with t(v;11q23.3); KMT2A-Rearranged Yassmine Akkari Nicolas Millan PENDING
B lymphoblastic leukaemia/lymphoma with ETV6::RUNX1 fusion Disease PENDING HD B lymphoblastic leukaemia/lymphoma with ETV6::RUNX1 fusion Marilena Melas, PhD; Yassmine Akkari, PhD, FACMG Cancer Category/Type B-Lymphoblastic Leukemia/Lymphoma PENDING
B-lymphoblastic leukaemia/lymphoma with ETV6::RUNX1-like features Disease Lei Zhang and Michelle Fan (trainee) 8/8/2024 Pending HD NEW (No Prior) NEW (No Prior) NEW (No Prior) NEW (No Prior) NEW (No Prior)
B lymphoblastic leukaemia/lymphoma with TCF3::PBX1 fusion Disease PENDING HD B-Lymphoblastic Leukemia/Lymphoma with t(1;19)(q23;p13.3); TCF3-PBX1 Binu Porath, PhD. Vanderbilt University Medical Center, Nashville, TN Linda D. Cooley, MD, MBA. Children's Mercy Kansas City, Kansas City, MO PENDING
B lymphoblastic leukaemia/lymphoma with IGH::IL3 fusion Disease PENDING HD B-Lymphoblastic Leukemia/Lymphoma with t(5;14)(q31.1;q32.1); IGH/IL3 Binu Porath, PhD. Vanderbilt University Medical Center, Nashville, TN Linda D. Cooley, MD, MBA. Children's Mercy Kansas City, Kansas City, MO PENDING
B lymphoblastic leukaemia/lymphoma with TCF3::HLF fusion Disease Aiko Otsubo 6/25/2024 Pending HD NEW (No Prior) NEW (No Prior) NEW (No Prior) NEW (No Prior) NEW (No Prior)
B-lymphoblastic leukaemia/lymphoma with other defined genetic alterations Disease Lei Zhang and Michelle Fan (trainee) 8/8/2024 Pending HD NEW (No Prior) NEW (No Prior) NEW (No Prior) NEW (No Prior) NEW (No Prior)
B-lymphoblastic leukaemia/lymphoma, NOS Disease HD NEW (No Prior) NEW (No Prior) NEW (No Prior) NEW (No Prior) NEW (No Prior)
Disease (5th Edition) Page Type Author (5th Edition) (Note: please indicate trainees in parentheses) Date Assigned to Author (5th Edition) Target Completion Date (5th Edition) Content Status (5th Edition)(Pending or Complete) Date Completed by Author (5th Edition) Associate Editor Date of Last Editor Review (5th Edition) Notes (5th Edition) Correlated Prior Disease Name (4th Edition) Correlated Prior Author (4th Edition) Prior Content Status (4th Edition)(Pending or Complete) Prior Date of Last Editor Review (4th Edition) Prior Notes (4th Edition)
RESOLVE 4th edition ALL-Related NON-WHO entities content B-Lymphoblastic Leukemia/Lymphoma with t(4;14)(q35.2;q32); IGH/DUX4 + B-Lymphoblastic Leukemia/Lymphoma with dic(9;12)(p13;p13); PAX5/ETV6 + B-Lymphoblastic Leukemia/Lymphoma with ZNF384 Rearrangements + B-Lymphoblastic Leukemia/Lymphoma with IKZF1 Deletions + B-Lymphoblastic Leukemia/Lymphoma with TCF3 Rearrangements - Excluding t(1;19) and t(12;19) + B-Lymphoblastic Leukemia/Lymphoma with dic(9;20)(p13;q11) ISSUE- FIX


Resolve Non-WHO entities

ISSUE - FIX
Monoclonal B-cell lymphocytosis Disease PENDING; Shashirekha Shetty Shivani Golem (SG) Monoclonal B-cell Lymphocytosis Tsigab Bahta Hagos (trainee) / Shashirekha Shetty PENDING, 4/30/2024 Assigned 12/19/2022 with completion date of 1/19/2023
Chronic lymphocytic leukaemia/small lymphocytic lymphoma Disease Jaime Nagy, PhD, University of Iowa

Renee Eigsti, MD, Pathology Services of Kalamazoo

Honey Reddi, PhD, Belay Diagnostics

Complete SG Already converted to 5th edition Jamie Nagy, PhD, University of Iowa Honey Reddi, PhD
Hairy cell leukaemia Disease Michael Lack, MD, KUMC (trainee)/Shivani Golem 7/16/24 PENDING SG Need new author to update latest content. Prior author cannot update the page. Hairy Cell Leukemia Snehal Patel, MD, PhD Pending WHO 5th e. July 2024
Splenic marginal zone lymphoma Disease SG Need new author to update latest content. Prior author cannot update the page. Splenic Marginal Zone Lymphoma Snehal Patel, MD, PhD Complete
Splenic diffuse red pulp small B-cell lymphoma Disease SG Need new author to update latest content. Prior author cannot update the page. Splenic Diffuse Red Pulp Small B-cell Lymphoma Snehal Patel, MD, PhD Complete
Splenic B-cell lymphoma/leukaemia with prominent nucleoli Disease SG Need new author to update latest content. Prior author cannot update the page. Hairy Cell Leukemia Variant Snehal Patel, MD, PhD Complete
Lymphoplasmacytic lymphoma Disease PENDING SG Email sent to request to update 2024 (1) Lymphoplasmacytic Lymphoma + (2) Waldenstrom Macroglobulinemia (1 and 2) Kapitolina Semenova, MD, Jack Reid, MD, Fabiola Quintero-Rivera, MD Departments of Pathology, Laboratory Medicine, and Pediatrics, Division of Genetic and Genomic Medicine, University of California, Irvine (UCI) Complete 4/12/2023 by FQR
Extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue Disease PENDING SG Email sent to request to update 2024 Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue (MALT Lymphoma) Whayoung Lee, MD (trainee), Fabiola Quintero-Rivera, MD, FACMG*

Department of Pathology and Laboratory Medicine and *Pediatrics, School of Medicine, University of California Irvine (UCI)

Complete 4/12/23 by FQR
Primary cutaneous marginal zone lymphoma Disease SG NEW (No Prior) NEW (No Prior) NEW (No Prior) NEW (No Prior) NEW (No Prior)
Disease (5th Edition) Page Type Author (5th Edition) (Note: please indicate trainees in parentheses) Date Assigned to Author (5th Edition) Target Completion Date (5th Edition) Content Status (5th Edition)(Pending or Complete) Date Completed by Author (5th Edition) Associate Editor Date of Last Editor Review (5th Edition) Notes (5th Edition) Correlated Prior Disease Name (4th Edition) Correlated Prior Author (4th Edition) Prior Content Status (4th Edition)(Pending or Complete) Prior Date of Last Editor Review (4th Edition) Prior Notes (4th Edition)
Nodal marginal zone lymphoma Disease PENDING SG Nodal Marginal Zone Lymphoma Andrew Ly, DO and Shivani Golem, PhD, FACMG Complete 5/28/2021
Paediatric nodal marginal zone lymphoma Disease PENDING SG Need new author to update latest content. Prior authors cannot update the page. Paediatric Nodal Marginal Zone Lymphoma * Kathleen M. Schieffer, PhD * Ruthann Pfau, PhD Complete; Need new author to update latest content. Primary author cannot update the page. 11/11/2020
In situ follicular B-cell neoplasm Disease Rachel D. Burnside, PhD, MBA, FACMGG 7/28/2023 Pending SG In Situ Follicular Neoplasia Rachel D. Burnside, PhD, MBA, FACMGG Pending
Follicular lymphoma Disease Rachel D. Burnside, PhD, MBA, FACMGG 7/28/2023 Pending SG Author also needs to correlate with 4th edition disease "Testicular Follicular Lymphoma", which is no longer a separate entity (1) Follicular Lymphoma + (2) Testicular Follicular Lymphoma (1 and 2) Ruthann Pfau, PhD, FACMG, Nationwide Children's Hospital Rachel D. Burnside, PhD, MBA, FACMG, University of Florida Pending
Paediatric-type follicular lymphoma Disease PENDING SG Need new author to update latest content. Prior authors cannot update the page. Paediatric-Type Follicular Lymphoma *Kathleen M. Schieffer, PhD *Ruthann Pfau, PhD, FACMG Complete; Need new author to update latest content. Primary author cannot update the page. 8/16/2020
Duodenal-type follicular lymphoma Disease Rachel D. Burnside, PhD, MBA, FACMGG 7/28/2023 Pending SG Duodenal-Type Follicular Lymphoma No prior content
Primary cutaneous follicle centre lymphoma Disease PENDING SG Primary Cutaneous Follicle Centre Lymphoma Linlin Gao, MD, PhD and Shivani Golem, PhD, FACMG Complete 09/10/2022
In situ mantle cell neoplasm Disease PENDING SG In Situ Mantle Cell Neoplasia Rina Kansal, MD; Versiti Blood Center of Wisconsin Complete 7/26/2022
Mantle cell lymphoma Disease PENDING SG Mantle Cell Lymphoma Mahsa Khanlari, MD and Zhenya Tang, MD, PhD The University Of Texas MD Anderson Cancer Center, Department of Hematopathology, Houston, Texas Pending Target completion date 8/15/20
Leukaemic non-nodal mantle cell lymphoma Disease SG NEW (No Prior) NEW (No Prior) NEW (No Prior) NEW (No Prior) NEW (No Prior)
Disease (5th Edition) Page Type Author (5th Edition) (Note: please indicate trainees in parentheses) Date Assigned to Author (5th Edition) Target Completion Date (5th Edition) Content Status (5th Edition)(Pending or Complete) Date Completed by Author (5th Edition) Associate Editor Date of Last Editor Review (5th Edition) Notes (5th Edition) Correlated Prior Disease Name (4th Edition) Correlated Prior Author (4th Edition) Prior Content Status (4th Edition)(Pending or Complete) Prior Date of Last Editor Review (4th Edition) Prior Notes (4th Edition)
Transformations of indolent B-cell lymphomas Disease SG Include content on chronic myelomonocytic leukemia in transformation and refractory anaemia with excess blasts in transformation NEW (No Prior) NEW (No Prior) NEW (No Prior) NEW (No Prior) NEW (No Prior)
Diffuse large B-cell lymphoma, NOS Disease PENDING GC Diffuse Large B-cell Lymphoma, Not Otherwise Specified Ashwini Yenamandra, PhD FACMG, Vanderbilt University Medical Center Pending Requested to update 14022022
T-cell/histiocyte-rich large B-cell lymphoma Disease GC NEW (No Prior) NEW (No Prior) NEW (No Prior) NEW (No Prior) NEW (No Prior)
Diffuse large B-cell lymphoma / high grade B-cell lymphoma with MYC and BCL2 rearrangements Disease PENDING GC High-Grade B-cell Lymphoma with MYC and BCL2 and/or BCL6 Rearrangements Kate Berry, MBBS, BBus (Hons), Pathology Queensland Complete 24/02/2022
ALK-positive large B-cell lymphoma Disease PENDING GC ALK-Positive Large B-cell Lymphoma Manando Nakasaki, MD, PhD (University of California, Irvine) Fabiola Quintero-Rivera, MD, FACMG (University of California, Irvine) Pending Nakasaki Manando removed March 2022 due to no progress/contact 1y. Added Nakasaki Manando back n 8/29/22 based on newer email communication (Jennelle's note). 2021 template added. FQR emailed Manando on 4/12/23
Large B-cell lymphoma with IRF4 rearrangement Disease PENDING GC Large B-cell Lymphoma with IRF4 Rearrangement Afia Hasnain, MBBS, PhD Complete 5/26/2021
High grade B-cell lymphoma with 11q aberrations Disease PENDING GC Burkitt-Like Lymphoma with 11q Aberration Lauren Shealy, MD, Medical University of South Carolina Daynna Wolff, PhD, Medical University of South Carolina Comlete 27/01/2022
Lymphomatoid granulomatosis Disease GC NEW (No Prior) NEW (No Prior) NEW (No Prior) NEW (No Prior) NEW (No Prior)
EBV-positive diffuse large B-cell lymphoma Disease Fnu Monika (trainee) + Andrew Siref as mentor 3/22/24 Pending GC NEW (No Prior) NEW (No Prior) NEW (No Prior) NEW (No Prior) NEW (No Prior)
Diffuse large B-cell lymphoma associated with chronic inflammation Disease GC NEW (No Prior) NEW (No Prior) NEW (No Prior) NEW (No Prior) NEW (No Prior)
Disease (5th Edition) Page Type Author (5th Edition) (Note: please indicate trainees in parentheses) Date Assigned to Author (5th Edition) Target Completion Date (5th Edition) Content Status (5th Edition)(Pending or Complete) Date Completed by Author (5th Edition) Associate Editor Date of Last Editor Review (5th Edition) Notes (5th Edition) Correlated Prior Disease Name (4th Edition) Correlated Prior Author (4th Edition) Prior Content Status (4th Edition)(Pending or Complete) Prior Date of Last Editor Review (4th Edition) Prior Notes (4th Edition)
Fibrin-associated large B-cell lymphoma Disease PENDING GC Note: previously a subset DLBCL assoc with chronic inflam Originally called Fibrin-Associated Diffuse Large B-cell Lymphoma; NEW (No Prior) NEW (No Prior) NEW (No Prior) NEW (No Prior) NEW (No Prior)
Fluid overload-associated large B-cell lymphoma Disease GC NEW (No Prior) NEW (No Prior) NEW (No Prior) NEW (No Prior) NEW (No Prior)
Plasmablastic lymphoma Disease PENDING GC Plasmablastic Lymphoma Mark Evans, MD (University of California, Irvine) Fabiola Quintero-Rivera, MD (University of California, Irvine) Complete 28/03/2022
Primary large B-cell lymphoma of immune-privileged sites Disease PENDING GC (1) Diffuse Large B-cell Lymphoma, Not Otherwise Specified + (2) Primary Diffuse Large B-cell Lymphoma of the CNS (1) Ashwini Yenamandra, PhD FACMG, Vanderbilt University Medical Center + (2) Laveniya Satgunaseelan, FRCPA, Department of Neuropathology, Royal Prince Alfred Hospital (1) Pending + (2) Complete (1) Not ready + (2) 03/28/22 For "Diffuse Large B-cell Lymphoma, Not Otherwise Specified" page from Ash, Greg requested to update 14022022
Primary cutaneous diffuse large B-cell lymphoma, leg type Disease GC NEW (No Prior) NEW (No Prior) NEW (No Prior) NEW (No Prior) NEW (No Prior)
Intravascular large B-cell lymphoma Disease PENDING GC Intravascular Large B-cell Lymphoma Kate Berry, MBBS, BBus (Hons), Pathology Queensland, Greg Corboy Complete 9/1/22 Emailed 28/3/2022 for progress update
Primary mediastinal large B-cell lymphoma Disease GC NEW (No Prior) NEW (No Prior) NEW (No Prior) NEW (No Prior) NEW (No Prior)
Mediastinal grey zone lymphoma Disease GC NEW (No Prior) NEW (No Prior) NEW (No Prior) NEW (No Prior) NEW (No Prior)
High-grade B-cell lymphoma, NOS Disease PENDING GC High-Grade B-cell Lymphoma, Not Otherwise Specified (NOS) Aiko Otsubo, PhD, Indiana University, Holli Drendel Complete 16/11/2021
Burkitt lymphoma Disease PENDING GC Burkitt Lymphoma Becky Leung, MBBS (Hons), BSc, Pathology Queensland Complete 28/06/2021
Disease (5th Edition) Page Type Author (5th Edition) (Note: please indicate trainees in parentheses) Date Assigned to Author (5th Edition) Target Completion Date (5th Edition) Content Status (5th Edition)(Pending or Complete) Date Completed by Author (5th Edition) Associate Editor Date of Last Editor Review (5th Edition) Notes (5th Edition) Correlated Prior Disease Name (4th Edition) Correlated Prior Author (4th Edition) Prior Content Status (4th Edition)(Pending or Complete) Prior Date of Last Editor Review (4th Edition) Prior Notes (4th Edition)
Primary effusion lymphoma Disease GC NEW (No Prior) NEW (No Prior) NEW (No Prior) NEW (No Prior) NEW (No Prior)
KSHV/HHV8-positive diffuse large B-cell lymphoma Disease GC NEW (No Prior) NEW (No Prior) NEW (No Prior) NEW (No Prior) NEW (No Prior)
KSHV/HHV8-positive germinotropic lymphoproliferative disorder Disease GC NEW (No Prior) NEW (No Prior) NEW (No Prior) NEW (No Prior) NEW (No Prior)
Hyperplasias arising in immune deficiency/dysregulation Disease FIX ISSUE! (on 5th edition page instructions say "encompassing non-destructive post-transplant lymphoproliferative disorders, among others"). "Non-Destructive Post-Transplant Lymphoproliferative Disorders" was a HAME4 page but no content. What are "among others" from HAEM4 to see if we need to pull prior content into 5th edition page. GC
Polymorphic lymphoproliferative disorders arising in immune deficiency / dysregulation Disease FIX ISSUE! (on 5th edition page instructions say "This page was converted to the new template on 2023-12-07. The original page can be found at HAEM4:Polymorphic Post-Transplant Lymphoproliferative Disorders.

Note: encompassing polymorphic PTLD, other iatrogenic immunodef-assoc lympho disorders, among others)"

GC Polymorphic Post-Transplant Lymphoproliferative Disorders Anna Shestakova, MD, PhD, Fellow, University of Utah/ARUP Laboratories Fabiola Quintero-Rivera, MD, Professor, University of California Irvine (UCI) Completed 26/4/2022
EBV-positive mucocutaneous ulcer Disease GC NEW (No Prior) NEW (No Prior) NEW (No Prior) NEW (No Prior) NEW (No Prior)
Lymphomas arising in immune deficiency / dysregulation Disease FIX ISSUE! (on 5th edition page instructions say "encompassing monomorphic PTLD, classic HL PTLD, lymphomas assoc with HIV infection, among others" GC
Inborn error of immunity-associated lymphoid proliferations and lymphomas Disease FIX ISSUE! (on 5th edition page instructions say "Editor said this overview page is a match. [Immunodeficiency-Associated Lymphoproliferative Disorders] [Lymphoproliferative diseases associated with primary immune disorders]") - last link name above is not a known page in haem4 or haem5. GC
Classic Hodgkin lymphoma Disease PENDING GC Note: author needs to merge Nodular Sclerosis Classic Hodgkin Lymphoma, Lymphocyte-Rich Classic Hodgkin Lymphoma, Mixed Cellularity Classic Hodgkin Lymphoma, Lymphocyte-Depleted Classic Hodgkin Lymphoma (1) Lymphocyte-Rich Classic Hodgkin Lymphoma + (2) Nodular Sclerosis Classic Hodgkin Lymphoma + (3) Mixed Cellularity Classic Hodgkin Lymphoma + (4) Lymphocyte-Depleted Classic Hodgkin Lymphoma (1) Patricia V. Hernandez, M.D., Washington University School of Medicine and Holli Drendel + (2) Xiaolin Hu, PhD, Sema4 OpCo Inc. + (3 and 4) Patricia V. Hernandez Pending + Completed (03/21/22) Not completed for checking (1, 3 and 4) + 03/21/22 (2)
Nodular lymphocyte predominant Hodgkin lymphoma Disease GC NEW (No Prior) NEW (No Prior) NEW (No Prior) NEW (No Prior) NEW (No Prior)
Disease (5th Edition) Page Type Author (5th Edition) (Note: please indicate trainees in parentheses) Date Assigned to Author (5th Edition) Target Completion Date (5th Edition) Content Status (5th Edition)(Pending or Complete) Date Completed by Author (5th Edition) Associate Editor Date of Last Editor Review (5th Edition) Notes (5th Edition) Correlated Prior Disease Name (4th Edition) Correlated Prior Author (4th Edition) Prior Content Status (4th Edition)(Pending or Complete) Prior Date of Last Editor Review (4th Edition) Prior Notes (4th Edition)
Cold agglutinin disease Disease SG NEW (No Prior) NEW (No Prior) NEW (No Prior) NEW (No Prior) NEW (No Prior)
IgM monoclonal gammopathy of undetermined significance Disease SG NEW (No Prior) NEW (No Prior) NEW (No Prior) NEW (No Prior) NEW (No Prior)
Non-IgM monoclonal gammopathy of undetermined significance Disease SG NEW (No Prior) NEW (No Prior) NEW (No Prior) NEW (No Prior) NEW (No Prior)
Monoclonal gammopathy of renal significance Disease SG NEW (No Prior) NEW (No Prior) NEW (No Prior) NEW (No Prior) NEW (No Prior)
Immunoglobulin-related (AL) amyloidosis Disease PENDING SG Primary Amyloidosis Heather E. Williams, PhD, MS, PgD, ErCLG ?PENDING
Monoclonal immunoglobulin deposition disease Disease PENDING SG Light Chain and Heavy Chain Deposition Disease Chen Yang, MD, PhD, University of Michigan Complete 10/15/2022
Mu heavy chain disease Disease SG NEW (No Prior) NEW (No Prior) NEW (No Prior) NEW (No Prior) NEW (No Prior)
Gamma heavy chain disease Disease PENDING SG Gamma Heavy Chain Disease Manisha Brahmbhatt-Sutariya Asst. Professor, Dept. of Pathology and Human Anatomy Technical Supervisor, Clinical Genetics Laboratory Loma Linda University, Medical Center, CA Complete 5/26/2021
Alpha heavy chain disease Disease SG NEW (No Prior) NEW (No Prior) NEW (No Prior) NEW (No Prior) NEW (No Prior)
Plasmacytoma Disease PENDING SG author needs to include Solitary plasmacytoma of bone, Extraosseous plasmacytoma (extramedullary) (v4 page did not have content on ccga) NEW (No Prior) - no content on version 4 page "Plasmacytoma' originally assigned to Zhenya Tang NEW (No Prior) NEW (No Prior) NEW (No Prior) NEW (No Prior)
Disease (5th Edition) Page Type Author (5th Edition) (Note: please indicate trainees in parentheses) Date Assigned to Author (5th Edition) Target Completion Date (5th Edition) Content Status (5th Edition)(Pending or Complete) Date Completed by Author (5th Edition) Associate Editor Date of Last Editor Review (5th Edition) Notes (5th Edition) Correlated Prior Disease Name (4th Edition) Correlated Prior Author (4th Edition) Prior Content Status (4th Edition)(Pending or Complete) Prior Date of Last Editor Review (4th Edition) Prior Notes (4th Edition)
Plasma cell myeloma / multiple myeloma Disease PENDING SG Note: author needs to include Plasma_Cell_Myeloma_Variants content in this page (1) Plasma Cell Myeloma + (2) Plasma Cell Myeloma Variants (1) Huan Mo, MD, MS and Zhenya Tang, MD, PhD The University Of Texas MD Anderson Cancer Center, Department of Hematopathology, Houston, Texas + (2) Fariborz Rashid-Kolvear, PhD, FACMG, FCCMG Pending
Plasma cell neoplasms with associated paraneoplastic syndrome Disease PENDING SG Note: author needs to include POEMS, TEMPI, and look for AESOP content (1) POEMS Syndrome + (2) TEMPI Syndrome (1 and 2) Sohini Anand, MBBS Tharanga Niroshini Senaratne, PhD ?PENDING
Disease (5th Edition) Page Type Author (5th Edition) (Note: please indicate trainees in parenthesis) Date Assigned to Author (5th Edition) Target Completion Date (5th Edition) Content Status (5th Edition) (Pending or Complete) Date Completed by Author (5th Edition) Associate Editor Date of Last Editor Review (5th Edition) Notes (5th Edition) Correlated Prior Disease Name (4th Edition) Correlated Prior Author (4th Edition) Prior Content Status (4th Edition) (Pending or Complete) Prior Date of Last Editor Review (4th Edition) Prior Notes (4th Edition)

CHAPTER 5 (T-CELL AND NK-CELL LYMPHOID PROLIFERATIONS AND LYMPHOMAS)














Kikuchi-Fujimoto disease Disease Sumi Kitahara (SK) NEW (No Prior) NEW (No Prior) NEW (No Prior) NEW (No Prior) NEW (No Prior)
Autoimmune lymphoproliferative syndrome Disease Aviv Oren, MD (trainee), Karin Miller, MD 3/25/2024 SK NEW (No Prior) NEW (No Prior) NEW (No Prior) NEW (No Prior) NEW (No Prior)
Indolent T-lymphoblastic proliferation Disease SK NEW (No Prior) NEW (No Prior) NEW (No Prior) NEW (No Prior) NEW (No Prior)
T-lymphoblastic leukaemia / lymphoma, NOS Disease SK NEW (No Prior) NEW (No Prior) NEW (No Prior) NEW (No Prior) NEW (No Prior)
Early T-precursor lymphoblastic leukaemia / lymphoma Disease Fei Yang, MD Pending SK Early T-Cell Precursor Lymphoblastic Leukemia Fei Yang, MD, FACMG, Kaiser Permanente Northwest Pending
T-prolymphocytic leukaemia Disease Parastou Tizro, MD (trainee); Celeste Eno, PhD 3/17/2024 Complete 6/24/2024 SK 7/1/2024 NEW (No Prior) NEW (No Prior) NEW (No Prior) NEW (No Prior) NEW (No Prior)
Disease (5th Edition) Page Type Author (5th Edition) (Note: please indicate trainees in parentheses) Date Assigned to Author (5th Edition) Target Completion Date (5th Edition) Content Status (5th Edition)(Pending or Complete) Date Completed by Author (5th Edition) Associate Editor Date of Last Editor Review (5th Edition) Notes (5th Edition) Correlated Prior Disease Name (4th Edition) Correlated Prior Author (4th Edition) Prior Content Status (4th Edition)(Pending or Complete) Prior Date of Last Editor Review (4th Edition) Prior Notes (4th Edition)
T-large granular lymphocytic leukaemia Disease Nicolas LaScala (trainee); Michelle Don, MD, MS 3/17/2024 (trainee name added on 9/9/24 by JH) 6/30/24 Pending SK T-cell Large Granular Lymphocytic Leukemia Michelle Don, MD, MS Pending
NK-large granular lymphocytic leukaemia Disease Hailee St. Louis (trainee);

Michelle Don, MD, MS

3/17/2024 6/30/24 Pending SK Chronic Lymphoproliferative Disorder of NK Cells Michelle Don, MD Pending
Adult T-cell leukaemia/lymphoma Disease SK Adult T-cell Leukemia/Lymphoma Prasad R. Kopparapu, PhD and Ferrin C. Wheeler, PhD, FACMG Vanderbilt University Medical Center ?Pending
Sezary syndrome Disease Daynna J. Wolff, PhD 3/22/2024 SK Sézary Syndrome Madison E. Hannay, DO, Medical University of South Carolina Tingting Barrett, MD, Medical University of South Carolina Daynna J. Wolff, PhD, Medical University of South Carolina Pending
Aggressive NK-cell leukaemia Disease Rabail Aslam, MD (fellow); Shashirekha Shetty, PhD 7/1/2024 8/31/2024 Pending SK Aggressive NK-cell Leukemia Shanelle De Lancy, MD, Shashirekha Shetty, PhD ?Pending
Primary cutaneous CD4-positive small or medium T-cell lymphoproliferative disorder Disease Amanda Xu, MD/MSc, Teodora Popa (resident) 3/19/2024 Pending SK NEW (No Prior) NEW (No Prior) NEW (No Prior) NEW (No Prior) NEW (No Prior)
Primary cutaneous acral CD8-positive T-cell lymphoproliferative disorder Disease Ahmed Eladely (trainee),

Andrew Siref, MD

4/12/2024 Pending SK NEW (No Prior) NEW (No Prior) NEW (No Prior) NEW (No Prior) NEW (No Prior)
Mycosis fungoides Disease Daynna J. Wolff, PhD 3/22/2024 SK Mycosis Fungoides Jane Scribner, MD and Daynna J. Wolff, PhD Pending
Primary cutaneous CD30-positive T-cell lymphoproliferative disorder: Lymphomatoid papulosis Disease Rabail Aslam, MD (fellow); Shashirekha Shetty, PhD 7/1/2024 8/31/224 Pending SK NEW (No Prior) NEW (No Prior) NEW (No Prior) NEW (No Prior) NEW (No Prior)
Primary cutaneous CD30-positive T-cell lymphoproliferative disorder: Primary cutaneous anaplastic large cell lymphoma Disease Rabail Aslam, MD (fellow); Shashirekha Shetty, PhD 7/1/2024 8/31/2024 Pending SK Primary Cutaneous Anaplastic Large Cell Lymphoma Theresa Spivey, MD, Shashirekha Shetty, PhD Pending
Disease (5th Edition) Page Type Author (5th Edition) (Note: please indicate trainees in parentheses) Date Assigned to Author (5th Edition) Target Completion Date (5th Edition) Content Status (5th Edition)(Pending or Complete) Date Completed by Author (5th Edition) Associate Editor Date of Last Editor Review (5th Edition) Notes (5th Edition) Correlated Prior Disease Name (4th Edition) Correlated Prior Author (4th Edition) Prior Content Status (4th Edition)(Pending or Complete) Prior Date of Last Editor Review (4th Edition) Prior Notes (4th Edition)
Subcutaneous panniculitis-like T-cell lymphoma Disease Raniah Alamri (Hemepath trainee) 3/19/2024 Pending SK NEW (No Prior) NEW (No Prior) NEW (No Prior) NEW (No Prior) NEW (No Prior)
Primary cutaneous gamma/delta T-cell lymphoma Disease Mahzad Azimpouran (trainee); Sumire Kitahara, MD 6/30/2024 Pending SK NEW (No Prior) NEW (No Prior) NEW (No Prior) NEW (No Prior) NEW (No Prior)
Primary cutaneous CD8-positive aggressive epidermotropic cytotoxic T-cell lymphoma Disease Ahmed Eladely (trainee),

Andrew Siref, MD

4/12/2024 Pending SK NEW (No Prior) NEW (No Prior) NEW (No Prior) NEW (No Prior) NEW (No Prior)
Primary cutaneous peripheral T-cell lymphoma, NOS Disease SK NEW (No Prior) NEW (No Prior) NEW (No Prior) NEW (No Prior) NEW (No Prior)
Indolent T-cell lymphoma of the gastrointestinal tract Disease SK Indolent T-cell Lymphoproliferative Disorder of the Gastrointestinal Tract Derick Okwan-Duodu MD, PhD; Sumire Kitahara, MD Pending
Indolent NK-cell lymphoproliferative disorder of the gastrointestinal tract Disease SK NEW (No Prior) NEW (No Prior) NEW (No Prior) NEW (No Prior) NEW (No Prior)
Enteropathy-associated T-cell lymphoma Disease Fnu Monika, MBBS (trainee),

Andrew Siref, MD

3/20/2024 Pending SK Enteropathy-Associated T-cell Lymphoma *Derick Okwan-Duodu, MD, PhD *Sumire Kitahara, MD Complete 1/21/2021
Monomorphic epitheliotropic intestinal T-cell lymphoma Disease Fnu Monika, MBBS (trainee),

Andrew Siref, MD

3/20/2024 Pending SK Monomorphic Epitheliotropic Intestinal T-cell Lymphoma Derick Okwan-Duodu MD, PhD; Sumire Kitahara, MD Pending
Intestinal T-cell lymphoma, NOS Disease SK Intestinal T-cell Lymphoma, Not Otherwise Specified (NOS) Derick Okwan MD, PhD (Stanford Medicine, CA) Sumire Kitahara MD (Cedars-Sinai, CA) Complete 9/26/2022
Hepatosplenic T-cell lymphoma Disease Forough Sargolzaeiaval (trainee);

Michelle Don, MD, MS

3/19/2024 6/30/24 Complete 5/13/24 SK 10/18/24 Hepatosplenic T-cell Lymphoma Michelle Don, MD, MS Complete 1/21/2021
Disease (5th Edition) Page Type Author (5th Edition) (Note: please indicate trainees in parentheses) Date Assigned to Author (5th Edition) Target Completion Date (5th Edition) Content Status (5th Edition)(Pending or Complete) Date Completed by Author (5th Edition) Associate Editor Date of Last Editor Review (5th Edition) Notes (5th Edition) Correlated Prior Disease Name (4th Edition) Correlated Prior Author (4th Edition) Prior Content Status (4th Edition)(Pending or Complete) Prior Date of Last Editor Review (4th Edition) Prior Notes (4th Edition)
ALK-positive anaplastic large cell lymphoma Disease Miguel Gonzalez Mancera, MD (trainee)

Sumire Kitahara, MD

6/6/24 Pending SK Anaplastic Large Cell Lymphoma, ALK-Positive Miguel Gonzalez Mancera, MD

Sumire Kitahara, MD

Cedars-Sinai, Los Angeles, CA

Complete 09/23/2022
ALK-negative anaplastic large cell lymphoma Disease Miguel Gonzalez Mancera, MD (trainee)

Sumire Kitahara, MD

6/6/24 Pending SK Anaplastic Large Cell Lymphoma, ALK-Negative Miguel Gonzalez Mancera, MD Sumire Kitahara, MD Cedars-Sinai, Los Angeles, CA Complete 09/23/2022
Breast implant-associated anaplastic large cell lymphoma Disease Lynne Abruzzo, MD, PhD 4/1/2024 Pending SK Breast Implant-Associated Anaplastic Large Cell Lymphoma Derick Okwan-Duodu, MD, PhD; Sumire Kitahara, MD Cedars-Sinai Medical Center Pending
Nodal TFH cell lymphoma, angioimmunoblastic-type Disease Rachel Burnside, PhD 7/28/2023 Pending SK prior authors not available Angioimmunoblastic T-cell Lymphoma Sara Akhavanfard, M.D., Ph.D. and Ruthann Pfau, Ph.D., FACMG Pending
Nodal TFH cell lymphoma, follicular-type Disease Rachel Burnside, PhD 7/28/2023 Pending SK NEW (No Prior) NEW (No Prior) NEW (No Prior) NEW (No Prior) NEW (No Prior)
Nodal TFH cell lymphoma, NOS Disease SK Nodal Peripheral T-cell Lymphoma with T Follicular Helper Phenotype Hans Magne Hamnvåg, MD Kamran Mirza, MD, PhD Pending
Peripheral T-cell lymphoma, NOS Disease Bo Hong, MD 6/25/2023 SK NEW (No Prior) NEW (No Prior) NEW (No Prior) NEW (No Prior) NEW (No Prior)
EBV-positive nodal T- and NK-cell lymphoma Disease Fnu Monika, MBBS (trainee), Andrew Siref, MD 3/22/2024 Pending SK NEW (No Prior) NEW (No Prior) NEW (No Prior) NEW (No Prior) NEW (No Prior)
Extranodal NK/T-cell lymphoma Disease Amanda Xu, MD/MSc, Teodora Popa (resident) 3/19/2024 Pending SK NEW (No Prior) NEW (No Prior) NEW (No Prior) NEW (No Prior) NEW (No Prior)
Severe mosquito bite allergy Disease SK NEW (No Prior) NEW (No Prior) NEW (No Prior) NEW (No Prior) NEW (No Prior)
Disease (5th Edition) Page Type Author (5th Edition) (Note: please indicate trainees in parentheses) Date Assigned to Author (5th Edition) Target Completion Date (5th Edition) Content Status (5th Edition)(Pending or Complete) Date Completed by Author (5th Edition) Associate Editor Date of Last Editor Review (5th Edition) Notes (5th Edition) Correlated Prior Disease Name (4th Edition) Correlated Prior Author (4th Edition) Prior Content Status (4th Edition)(Pending or Complete) Prior Date of Last Editor Review (4th Edition) Prior Notes (4th Edition)
Hydroa vacciniforme lymphoproliferative disorder Disease SK NEW (No Prior) NEW (No Prior) NEW (No Prior) NEW (No Prior) NEW (No Prior)
Systemic chronic active EBV disease Disease Karin Miller, MD 3/25/2024 SK NEW (No Prior) NEW (No Prior) NEW (No Prior) NEW (No Prior) NEW (No Prior)
Systemic EBV-positive T-cell lymphoma of childhood Disease Karin Miller, MD 3/25/2024 SK prior authors not available Systemic EBV-Positive T-cell Lymphoma of Childhood Lisa A. Lansdon, PhD and Linda D. Cooley, MD, MBA Complete 11/21/2021

CHAPTER 6 (STROMA-DERIVED NEOPLASMS OF LYMPHOID TISSUES)














Follicular dendritic cell sarcoma Disease PENDING GC Follicular Dendritic Cell Sarcoma Anna Heimes Dillon, MD and Shivani Golem, PhD, FACMG ?Pending
EBV-positive inflammatory follicular dendritic cell sarcoma Disease GC NEW (No Prior) NEW (No Prior) NEW (No Prior) NEW (No Prior) NEW (No Prior)
Fibroblastic reticular cell tumour Disease GC NEW (No Prior) NEW (No Prior) NEW (No Prior) NEW (No Prior) NEW (No Prior)
Intranodal palisaded myofibroblastoma Disease GC NEW (No Prior) NEW (No Prior) NEW (No Prior) NEW (No Prior) NEW (No Prior)
Disease (5th Edition) Page Type Author (5th Edition) (Note: please indicate trainees in parentheses) Date Assigned to Author (5th Edition) Target Completion Date (5th Edition) Content Status (5th Edition)(Pending or Complete) Date Completed by Author (5th Edition) Associate Editor Date of Last Editor Review (5th Edition) Notes (5th Edition) Correlated Prior Disease Name (4th Edition) Correlated Prior Author (4th Edition) Prior Content Status (4th Edition)(Pending or Complete) Prior Date of Last Editor Review (4th Edition) Prior Notes (4th Edition)
Littoral cell angioma Disease GC NEW (No Prior) NEW (No Prior) NEW (No Prior) NEW (No Prior) NEW (No Prior)
Splenic hamartoma Disease GC NEW (No Prior) NEW (No Prior) NEW (No Prior) NEW (No Prior) NEW (No Prior)
Sclerosing angiomatoid nodular transformation (SANT) of spleen Disease GC NEW (No Prior) NEW (No Prior) NEW (No Prior) NEW (No Prior) NEW (No Prior)

CHAPTER 7 (GENETIC TUMOUR SYNDROMES)














Fanconi anaemia Disease See GTS5 volunteer sheet for authorship status N/A N/A N/A N/A N/A N/A N/A NEW (No Prior) NEW (No Prior) NEW (No Prior) NEW (No Prior) NEW (No Prior)
Bloom syndrome Disease See GTS5 volunteer sheet for authorship status N/A N/A N/A N/A N/A N/A N/A NEW (No Prior) NEW (No Prior) NEW (No Prior) NEW (No Prior) NEW (No Prior)
Ataxia-telangiectasia syndrome Disease See GTS5 volunteer sheet for authorship status N/A N/A N/A N/A N/A N/A N/A NEW (No Prior) NEW (No Prior) NEW (No Prior) NEW (No Prior) NEW (No Prior)
RASopathies Disease NA NEW (No Prior) NEW (No Prior) NEW (No Prior) NEW (No Prior) NEW (No Prior)
Retrieved from "https://ccga.io/index.php?title=HAEM5:Volunteer_Assignments_and_Opportunities&oldid=15550"